UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K

[X] Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act
of 1934

For the fiscal year ended December 31, 2004

or

[ ] Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange
Act of 1934

For the transition period from ____________ to _______________

Commission File Number 333-118568

NATIONAL PATENT DEVELOPMENT CORPORATION
(Exact name of Registrant as specified in its charter)

         Delaware                                        13-4005439
--------------------------------------------------------------------------------
(State of Incorporation)                    (I.R.S. Employer Identification No.)

777 Westchester Avenue, White Plains, NY                     10604
--------------------------------------------------------------------------------
(Address of principal executive offices)                  (Zip Code)

                                 (914) 249-9700
--------------------------------------------------------------------------------

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.01 Par Value
(Title of Class)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No____

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K/x/.

Indicate by check mark whether the registrant is an accelerated filer. Yes No X

The aggregate market value of the outstanding shares of the Registrant's Common Stock, par value $.01 per share held by non-affiliates as of December 31, 2004 was approximately $29,612,000.

The number of shares outstanding of each of the Registrant's Common Stock and Class B Stock as of March 29, 2005:

Class Outstanding

Common Stock, par value $.01 per share 17,799,945 shares

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant's definitive Proxy Statement for its 2005 Annual Meeting of Stockholders are incorporated herein by reference into Part III hereof.


                                                                           Page
PART I

Item 1. Business                                                             2

Item 2. Properties                                                          17

Item 3. Legal Proceedings                                                   17

Item 4. Submission of Matters to a Vote of Security Holders                 18

PART II

Item 5. Market for the Registrant's Common Equity and Related
        Stockholder Matters                                                 19

Item 6. Selected Financial Data                                             20

Item 7. Management's Discussion and Analysis of Financial Condition
        and Results of Operations                                           21

Item 7A. Quantitative and Qualitative Disclosures about Market Risk         33

Item 8. Financial Statements and Supplementary Data                         34

Item 9. Changes in and Disagreements with Accountants on Accounting
         and Financial Disclosure                                           73

Item 9A. Controls and Procedures                                            73

PART III

Item 10. Directors and Executive Officers of the Registrant *               73

Item 11. Executive Compensation *                                           73

Item 12. Security Ownership of Certain Beneficial Owners and Management
         and Related Stockholder Matters*                                   73

Item 13. Certain Relationships and Related Transactions*                    73

Item 14. Principal Accountant Fees and Services*                            73

PART IV

Item 15. Exhibits and Financial Statement Schedules                         74

Signatures                                                                  75

Exhibit Index                                                               76

* To be incorporated by reference from the proxy statement for the Registrant's
2005 Annual Meeting of Shareholders.


Cautionary Statement Regarding Forward-Looking Statements

The forward-looking statements contained herein reflect National Patent Development Corporation's management's current views with respect to future events and financial performance. We use words such as "expects", "intends" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including those discussed under "Factors Affecting Our Future Performance" and "Management's Discussions and Analysis of Financial Condition and Results of Operations."

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the differences could be significant. We do not undertake to update any forward-looking statements made by us.

PART I

Item 1: Business

General Development of Business

National Patent Development Corporation (the "Company", "we" or "National Patent Development") was incorporated on March 10, 1998 as a wholly-owned subsidiary of GP Strategies Corporation ("GP Strategies"). The Company common stock is quoted on the OTC Bulletin Board and is traded under the symbol NPDV.OB.

In July 2002, GP Strategies announced that it was actively considering transferring certain of its non-core assets into National Patent Development and spinning-off National Patent Development to the stockholders of GP Strategies. On November 14, 2002, GP Strategies filed a ruling request with the Internal Revenue Service with respect to the federal tax consequences of the proposed spin-off, and received a favorable ruling on March 21, 2003. On February 12, 2004, National Patent Development was recapitalized whereby the authorized capital was changed to 10,000,000 shares of preferred stock and 30,000,000 shares of common stock. On July 30, 2004, GP Strategies contributed its ownership interests in its optical plastics and home improvement distribution businesses, as well as other non-core assets, to National Patent Development in exchange for National Patent Development common stock. The separation of these businesses was accomplished through a pro-rata distribution (the "Distribution" or "spin-off") of 100% of the outstanding common stock of National Patent Development to the stockholders of GP Strategies on the record date of November 18, 2004 for the Distribution. On November 24, 2004, holders of record received one share of National Patent Development common stock for each share of GP Strategies common stock or Class B capital stock owned.

The Company owns and operates the optical plastics business through its wholly-owned subsidiary, MXL Industries, Inc. ("MXL"), the home improvement distribution business through its partially owned subsidiary Five Star Products, Inc. ("Five Star") and also owns certain other non-core assets, including an

2

investment in a publicly held company, Millennium Cell; an approximately 17.7% interest in a private company, Valera Pharmaceuticals; and certain real estate.

Company Information Available on the Internet

The Company's internet address is www.npdc.com. The Company makes available free of charge through its internet site, its annual reports on Form 10-K; quarterly reports on Form 10-Q; current reports on Form 8-K; and any amendment to those reports filed or furnished pursuant to the Securities Exchange Act of 1934, or the "Exchange Act," as soon as reasonably practicable after such material is electronically filed with, or furnished to, the U.S. Securities and Exchange Commission.

MXL Industries

General

Our wholly-owned subsidiary, MXL, is a molder and precision coater of optical plastics. MXL is a specialist in the manufacture of polycarbonate parts requiring adherence to strict optical quality specifications, and in the application of abrasion and fog resistant coatings to those parts. Polycarbonate is the most impact resistant plastic utilized in optical quality molded parts. MXL's products include shields, face masks and non-optical plastic products, produced for over 50 clients in the safety, recreation, and military industries. MXL also produces custom molded and decorated products manufactured out of acrylic. Additionally, MXL's Illinois operations, previously known as The Woodland Mold and Tool Division of MXL, have the capability to design and construct injection molds for a variety of applications (optical and non-optical).

Established over thirty years ago, MXL evolved into one of the leading coaters of polycarbonate and acrylic parts. A growing insistence on quality coating results led MXL to also establish itself as a specialist in the injection molding of optical quality polycarbonate, thus enabling MXL to control the process from start to finish. At its Lancaster, PA facility, molding machines are housed in a climate controlled clean environment designed and built by MXL. Coating lines also feature a controlled, enclosed environment and are CFC -free.

MXL's Illinois division, Woodland Mold and Tool, was acquired by MXL in 1987 as MXL's business grew to include in-house optical injection molding. Illinois' capabilities range from the production of long-life tooling for standard molding applications to the design, construction and repair and polishing of sophisticated optical molds. In the fourth quarter 2004, MXL began to explore the divestiture of its Illinois facility, as a result of a decline in production volume for the Illinois division and taking into consideration MXL's diminished real estate needs. MXL is in contract to sell the Illinois facility and lease back 10,000 square feet of the facility. Management believes the transaction will occur in 2005; however there can be no assurance that the transaction will be completed in 2005 or that it will ever occur.

In 2003, MXL acquired certain of the precision custom optical assemblies inventory, machinery and equipment of AOtec for $1,000,000 in notes (the "AOtec Notes") and $100,000 in cash. AOtec, located in the Massachusetts area, is a successor to the American Optical Corporation, one of the pioneers in optics research and development for over 160 years. MXL leased space in Massachusetts for the newly purchased equipment. In 2004, MXL exercised an option for an earlier termination without penalty of the Massachusetts facility

3

lease. MXL vacated the premises and the lease terminated as of March 31, 2005. MXL relocated the inventory, machinery and equipment purchased from AOtec and is consolidating its injection molding and precision coating operations at its Lancaster, PA facility. In addition, MXL is currently negotiating a reduction in the amounts due under the AOtec Notes with maturity dates of August 5, 2004 and 2005, resulting from a dispute over the purchase price. According to the contract of sale, the payments due pursuant to the AOtec Notes were subject to an offset and withholding by MXL. The parties are attempting to resolve this matter; however there is no guarantee that MXL will successfully negotiate the reduction of the AOtec Notes. The AOtec Notes, which amount to $550,000 in the aggregate following a repayment of $450,000 of the AOtec Notes in October 2003, are included in short-term borrowings in the consolidated December 31, 2004 balance sheet.

MXL's contracts in the military and commercial arena often require either vacuum deposited beam-splitter coatings, vacuum deposited anti-reflective coatings, laser eye protection, or a combination of these technologies in addition to MXL's historic capabilities of providing difficult and optically correct molded and coated components. Prior to the acquisition of the equipment and intellectual property assets from AOtec, MXL was required to enter into subcontracting arrangements to secure these technologies. The laser eye protection technology, vacuum deposition processing, and equipment acquired from AOtec, will enable MXL to better service purchase orders for precision pilot visors for next generation military fighter and attack aircraft, which require beam-splitter coatings, anti-reflective coatings and/or laser eye protection.

MXL has earned a reputation as a leading toolmaker, molder and coater for optical quality products in the United States by consistently meeting its customer's requirements, even in the case of the most difficult designs and compound curve optics. This expertise has allowed MXL to expand its customer base beyond the United States to Japan, the United Kingdom, Europe, the Middle East, Mexico, Canada, Australia and other locales.

MXL's net sales in the regions it does business for the years ended December 31, 2004, 2003 and 2002, based upon the customers' locations, are as follows (in thousands):

                             Year Ended December 31,
                         --------------------------------------
                         -------- --------------- -------------
                            2004            2003          2002
                            ----            ----          ----
                         -------- --------------- -------------

United States             $5,662          $6,930        $8,264
Far East                   1,288           1,230         1,266
Other                      1,291             453           466
                          ------          ------        ------
Total                     $8,241          $8,613        $9,996
                          ======          ======        ======

MXL has been continuously and actively engaged in its optical plastics business since 1968. Prior to the spin-off of National Patent Development, GP Strategies has owned all of the MXL stock since 1973.

Industry Overview and Competition

The optical quality molding business requires expertise, experience and an environment totally committed to the task. It requires the construction of a facility designed and built expressly for precision injection molding and personnel with the technical expertise to run such facility.

4

The markets for the products currently manufactured and sold by MXL are characterized by extensive competition. The principal competitive factors of MXL are its reputation for quality, service and integrity. MXL is able to provide its customers with a breadth of experience, from mold design through mold construction, to injection molding, coating, laser eye protection and/or high technology optical coating. MXL is able to accomplish the most complex projects for its customers. In addition, MXL's engineering, performance, availability and reliability are important competitive factors.

Many existing and potential competitors have greater financial, marketing and research resources than MXL.

Business Strengths

MXL has earned a reputation as one of the leading toolmakers, molders and coaters for optical quality products in the Unites States by consistently meeting its customers' requirements, even in the case of the most difficult designs and compound curve optics.

As a pioneer in the optical plastic coating business, MXL offers expertise in designing new parts and products for its customers. MXL has spent over 30 years developing and perfecting its coating technology and materials.

The market for optical injection molding, tooling and coating is focused, leading to intense competition. The following are major competitive strengths and characteristics of MXL.

o Reputation for Quality and Service. MXL's on-going commitment to quality has enabled it to meet the rigorous requirements of its most valued customers and has earned it a reputation as the premier optical injection molder in the industry. MXL has a reputation for on-time delivery, and its return rate is exceptionally low, representing less than 1% of sales volume. As these customers continue to focus on product quality, MXL's past performance and long-term improvement programs should further strengthen customer relationships.
o Superior Technical Skills and Expertise. The engineering experience of MXL's senior management has enabled MXL to take advantage of state-of-the-art injection molding technology and effectively develop cost-effective and efficient production facilities. MXL's proprietary HYDRON(R) permanent anti-fog coating absorbs moisture to form a barrier against fogging.
o ISO 9001:2000 Registration. MXL's Pennsylvania and Massachusetts facilities are ISO 9001:2000 certified-a universally accepted quality assurance designation indicating the highest quality manufacturing standards. A certification by the International Standards Organization means that a company maintains a quality system that is regularly assessed for compliance to ISO standards. Meeting the ISO standard of quality confirms MXL's commitment to manufacturing excellence.
o Integrated Plastics Business. The combination of MXL's original business and its acquired equipment and technology from AOtec, has created an integrated business which offers clients a full range of design, production and marketing services for molded and coated optical plastic products.
o Modern Automated Manufacturing. MXL's presses and coating lines, state-of-the-art for the molding business, are efficiently designed and well maintained. The equipment can be quickly reconfigured to meet specific job requirements.

5

o Well-Qualified Management Team. MXL's senior management has extensive experience in all aspects of the plastic molding and coating industry. The senior management team has on average a minimum of 10 years of direct manufacturing experience in this or related industries.
o Attractive Growth Opportunities. With the leadership of the senior management, MXL is poised to enter any plastic molding and coating business. Its acquisition of certain of the AOtec assets was a logical extension of its position as a leading provider of optical quality injection molds by allowing MXL to further expand its business into the military arena. MXL believes that the combination of its proprietary "Anti-Fog" coating, precise processing of the "Anti-Scratch" coatings, precise molding and proprietary grinding and polishing methods for its injection tools as well as its vacuum deposited anti-reflection coatings and laser eye protection technology will provide it with the opportunity to expand into related products. Strategy

MXL intends to leverage its expertise as a molder and coater of optical quality products by expanding into other markets and products. The performance of MXL in the future will depend on its ability to develop and market new products that will gain customer acceptance and loyalty, as well as its ability to adapt its product offerings to meet changing pricing conditions and other factors.

Markets and Products

MXL focuses its manufacturing capabilities in three distinct capacities: injection molding, precision coating of optical plastics, and tool and mold design and manufacture.

Injection Molding. MXL has the capability to manufacture a wide variety of custom injection molding plastics for the recreation, industrial safety and defense industries. Some of the products that MXL produces include facemasks and shields for recreation purposes and industrial safety companies. All of MXL's custom molding involves polycarbonate, which is a difficult resin to mold and has required the development of sophisticated manufacturing skills. MXL's closed-loop process control system monitors and provides quality-assurance for every critical variable from resin drying, through mold temperature and alignment, to robotic part removal. MXL's specially designed clean room environment automatically removes dust and holds temperature and humidity constant throughout the year.

MXL serves as the prime contractor for several major development programs in industry and government for precision optical systems, including medical optics; military eye wear; and custom molded and decorated products. In order to maintain its competitive position, MXL has traditionally invested in state of the art equipment, including molding presses ranging from 60 to 485 tons, automation equipment, clean room facilities, and vacuum and dip coating equipment. MXL utilizes computer aided design software to design its optical products. In addition, modern computer controlled molding machinery is used to fabricate precision optic components.

Precision Coating. MXL's two coating lines allow it to offer a wide range of coating technologies to its customers. These services include dual coating processes, urethane hard coat, silicone hard coat, permanent anti-fog, and finish application design. 80% of MXL's coating business is for abrasion resistant purposes and 20% is for anti-fog applications. MXL's two coating lines were designed and built in-house, and allow for maximum flexibility and quality

6

throughout the coating process. All functions are controlled by state-of-the-art programmable controllers and A.C. Linear drives and robotics. These highly flexible dip and spray operations can deliver a variety of coatings for parts as large as eight inches by twenty-six inches, including anti-scratch on all surfaces, anti-fog on all surfaces, one coating on one side only or dual coating with anti-scratch on one side and anti-fog on the opposite side.

Tool Manufacturing. The Illinois operations use eight tool and die makers to produce optical injection mold tools and standard injection mold tools in sizes up to 36 inches x 36 inches x 36 inches.

Manufacturing and Raw Materials

MXL's primary raw materials are plastic resin (principally polycarbonate), acrylic, silicone hard coatings and HYDRON(R) anti-fog coating. MXL is able to fulfill its requirements for plastic resin and acrylic through arrangements with various distributors and is able to fulfill its requirements for silicone hard coating from manufacturers. MXL manufactures its proprietary HYDRON(R), which is applied as a fog resistant coating to its optical products. Plastic resin is a petroleum based product, and as such, is subject to price increases (up to 40% during the year ended December 31, 2004) along with increases in crude oil prices, which have increased by over 50% during the year ended December 31, 2004.

Customers

As the market for optical injection molded plastics is relatively focused, MXL serves virtually all of the major users. The customer base of MXL includes over 50 commercial customers in 27 states and Japan, the United Kingdom, Europe, the Middle East, Mexico, Canada and Australia. These commercial customers are primarily in the recreation, safety, and security industries. MXL's largest two customers comprised approximately 16% and 13%, respectively, of its total sales in 2004.

MXL's government customers include various offices of the Department of Defense. MXL is required to comply with various federal regulations including military specifications and Federal Acquisition Regulations for military end use applications. There are no government contracts subject to renegotiation or termination at the election of the government.

Sales and Distribution

Because of the narrow niche MXL serves, its sales and marketing effort concentrates on industry trade shows, such as the Society of Plastics Engineers, and advertising in industry journals. Its senior management team, as well as four marketing and sales executives, is responsible for the sales and marketing effort. It also utilizes one sales representative to market its products.

Backlog

MXL's sales order backlog as of December 31, 2004 was approximately $1,627,000 ($1,703,000 as of December 31, 2003) and most of the orders are expected to be completed during fiscal 2005.

7

Patents, Trademarks, and other Intellectual Property

The names MXL and HYDRON are registered trademarks. In connection with the AOtec transaction, MXL entered into an exclusive, royalty-free perpetual license (with the right to grant sublicenses) to use the trademarks AOTEC(TM) and AOGUARD(TM) for military eye protection products, electro-optical systems and precision molded and coated plastic components.

Environmental Matters and Governmental Regulations

For its manufacturing work as a subcontractor in the military industry, MXL is required to comply with various federal regulations including Military Specifications and Federal Acquisition Regulations for military end use applications. In addition, MXL's activities may subject it to federal, state and local environmental laws and regulations. MXL believes that it is in compliance in all material respects with such government regulations and environmental laws.

Employees

As of December 31, 2004, MXL employed approximately 78 persons, including 46 at its Lancaster facility, 7 in its Illinois facility and 25 at its new Massachusetts facility. Of the MXL employees, 64 are in production or shipping, with the remainder serving in executive, administrative office and sales capacities. None of MXL's employees are subject to collective bargaining agreements. MXL believes its relationship with its employees is good.

Five Star Products

General

Five Star is engaged in the wholesale distribution of home decorating, hardware and finishing products. It serves over 3,500 independent retail dealers in twelve states, making Five Star one of the largest distributors of its kind in the Northeast. Five Star operates two state -of -the -art warehouse facilities, located in Newington, CT and East Hanover, NJ. All operations are coordinated from Five Star's New Jersey headquarters.

In the first quarter of 2000, Five Star expanded its sales territory with the addition of an established, dedicated sales force servicing the Mid-Atlantic States, and as far south as North Carolina. This addition to the sales force generates revenues of approximately $9 million annually. Five Star services this new territory from its 236,000 square foot East Hanover, New Jersey facility, from which it also services the Northeast, enabling Five Star to leverage its fixed costs over a broader revenue base.

Five Star offers products from leading manufacturers such as Cabot Stain, William Zinsser & Company, DAP, General Electric Corporation, American Tool, USG, Stanley Tools, Minwax and 3M Company. Five Star distributes its products to retail dealers, which include lumber yards, "do-it yourself" centers, hardware stores and paint stores principally in the northeast region. It carries an extensive inventory of the products it distributes and provides delivery, generally within 24 to 72 hours. Five Star has grown to be one of the largest independent distributors in the Northeast by providing a complete line of competitively priced products, timely delivery and attractive pricing and financing terms to its customers. Much of Five Star's success can be attributed to a continued commitment to provide customers with the highest quality service at reasonable prices.

8

As one of the largest distributors of paint sundry items in the Northeast, Five Star enjoys cost advantages and favorable supply arrangements over the smaller distributors in the industry. This enables Five Star to compete as a "low cost" provider. Five Star uses a fully computerized warehouse system to track all facets of its distribution operations. Five Star has enhanced the sophistication of its warehouse and office facilities to take full advantage of economies of scale, speed the flow of orders and to compete as a low cost distributor. Nearly all phases of the selling process from inventory management to receivable collection are automated and tracked; all operations are overseen by senior management at the New Jersey facility. Five Star is able to capitalize on manufacturer discounts by strategically timing purchases involving large quantities.

Management takes a proactive approach in coordinating all phases of Five Star's operations. For example, sales managers require all sales representatives to call on customers once every week. Each salesperson transmits his or her orders through Five Star's automated sales system, to the IBM AS/400 computer located at the New Jersey facility. The salesperson system combines the ability to scan product codes in the customers' stores and download the information to a laptop computer for final transmission. Based on the floor plan of each warehouse and the location of products therein, the computer designs a pattern for the orders to be picked. The orders are then relayed to the appropriate location and typically picked in the evening. The warehouse facilities are well-maintained and skillfully organized. A bar-coded part number attached to the racking shelves identifies the location of each of the approximately 23,000 stock keeping units (SKUs). The products are loaded onto Five Star's trucks in the evening in the order that they will be unloaded, and are delivered directly to the customers locations the following morning.

Five Star, which was then 37.5% owned by GP Strategies, purchased its business from GP Strategies in 1998 in exchange for cash and a $5,000,000 unsecured 8% note payable (the "Five Star Note"). In 2002 and 2003, GP Strategies converted $1,000,000 principal amount of the Five Star Note into 4,272,727 shares of Five Star's common stock. In 2004, Five Star, through a tender offer, repurchased approximately 2,628,000 shares of its common stock. The conversion of the Five Star Note and the tender offer increased GPS' ownership in the Company to approximately 64%. On July 30, 2004, GP Strategies contributed its ownership interest in Five Star and the Five Star Note to the Company.

Industry Overview and Competition

The paint sundry items distribution industry is closely related to the do-it-yourself retail market, which has tended to exhibit elements of counter-cyclicality. In times of recession, consumers tend to spend more on home improvements if they cannot afford to trade up to bigger homes. In times of economic strength, consumers tend to spend heavily on home improvements because they believe they can afford to complete their home improvement projects. According to the National Retail Hardware Association, total retail sales by home improvement retailers are estimated to be $236 billion in 2004 and are projected to grow at a 5.3% compound rate through 2008.

Painting is the quintessential do-it-yourself project. Painting has to be done more frequently than most remodeling jobs, and it is a relatively inexpensive way to update the appearance of a home. For these reasons, the paint and paint sundry items industry tends to be counter-cyclical and a solid growth segment of the do-it-yourself market.

9

Competition within the do-it yourself industry is intense. There are large national distributors commonly associated with national franchises such as Ace and TruServ as well as smaller regional distributors, all of whom offer similar products and services. Moreover, in some instances manufacturers will bypass the distributor and choose to sell and ship their products directly to the retail outlet. In addition, Five Star's customers face stiff competition from Home Depot, which purchases directly from manufacturers. The principal means of competition for Five Star are its strategically placed distribution centers and its extensive inventory of quality, name-brand products. Five Star will continue to focus its efforts on supplying its products to its customers at a competitive price and on a timely, consistent basis. While other paint sundry items distributors sell to the same retail networks as Five Star, they are at a distinct disadvantage due to Five Star's experience, sophistication and size.

Hardware stores that are affiliated with the large, dealer-owned distributors such as Ace also utilize Five Star's services because they are uncomfortable with relying solely on their dealer network. Most cooperative-type distributors lack the level of service and favorable credit terms that independent hardware stores enjoy with Five Star. Five Star effectively competes with the dealer-owned distributors because it provides more frequent sales calls, faster deliveries, better financing terms and a full line of vendors and products to choose from.

Business Strengths

As one of the largest distributors of paint sundry items in the Northeast, Five Star enjoys cost advantages and favorable supply arrangements over the smaller distributors in the industry. This enables Five Star to compete as a "low cost" provider. Five Star uses a fully computerized warehouse system to track all facets of its distribution operations. Five Star has enhanced the sophistication of its warehouse and office facilities to take full advantage of economies of scale, speed the flow of orders and to compete as a low cost distributor. Nearly all phases of the selling process from inventory management to receivable collection are automated and tracked; all operations are overseen by senior management at the New Jersey facility. Five Star is able to capitalize on manufacturer discounts by strategically timing large quantity purchases.

Strategy

Five Star carries an extensive inventory of the products it distributes and provides delivery, generally within 24 to 72 hours. Five Star believes that it will continue to grow its business by providing a complete line of competitively priced products, timely delivery and attractive pricing and financing terms to its customers. In the future, Five Star will attempt to acquire complementary distributors and to expand the distribution of its use of private-label products sold under the "Five Star" name. Through internal growth and acquisitions, Five Star has already captured a leading share in its principal market the Northeast. This growth-oriented acquisition strategy of acquiring complementary distributors has allowed Five Star to compete against a substantial number of its competitors.

Markets, Products and Sales

The do-it-yourself industry relies on distributors to link manufacturer's products to the various retail networks. The do-it-yourself market operates on this two-step distribution process, i.e., manufacturers deal through distributors who in turn service retailers. This occurs principally because most retailers are not equipped to carry sufficient inventory in order

10

to be cost effective in their purchases from manufacturers. Thus, distributors add significant value by effectively coordinating and transporting products to retail outlets on a timely basis. Five Star distributes and markets products from hundreds of manufacturers to all of the various types of retailers from regional paint stores, to lumber yards, to independent paint and hardware stores.

The marketing efforts are directed by regional sales managers. These individuals are responsible for designing, implementing and coordinating marketing policies. They work closely with senior management to coordinate company-wide marketing plans as well as to service Five Star's major multi-state customers. In addition, each regional sales manager is responsible for overseeing the efforts of his sales representatives.

The sales representatives, by virtue of daily contact with Five Star's customers, are the most integral part of Five Star's marketing strategy. It is their responsibility to generate revenue, ensure customer satisfaction and expand the customer base. Each representative covers an assigned geographic area. The representatives are compensated based solely on commission. Five Star has experienced low turnover in its sales force; most representatives have a minimum of five years' experience with Five Star. Many sales representatives had retail experience in the paint or hardware industry when they were hired by Five Star.

Five Star's size, solid reputation for service, large inventory and attractive financing terms provide sales representatives with tremendous advantages relative to competing sales representatives from other distributors. In addition, the representatives' efforts are strengthened by company-sponsored marketing events. For example, each year in the first quarter, Five Star invites all of its customers to special trade shows for Five Star's major suppliers, so that suppliers may display their products and innovations. Five Star also participates in advertising circular programs in the spring and the fall which contain discount specials and information concerning new product innovations.

Management Information System

All of Five Star's inventory control, purchasing, accounts payable and accounts receivable are fully automated on an IBM AS/400 computer system. In addition, Five Star's software alerts buyers to purchasing needs, and monitors payables and receivables. This system allows senior management to control closely all phases of Five Star's operations. Five Star also maintains a salesperson-order-entry system, which allows the salesperson to scan product and then download the information to a laptop. The laptop contains all product and customer information and interacts with the AS/400.

Purchasing

Five Star relies heavily upon its purchasing capabilities to gain a competitive advantage relative to its competitors. Five Star's capacity to stock the necessary products in sufficient volume and its ability to deliver them promptly upon demand is one of the strongest components of service in the distribution business, and is a major factor in Five Star's success.

Since retail outlets depend upon their distributor's ability to supply products quickly upon demand, inventory is the primary working capital investment for most distribution companies, including Five Star. Through its strategic purchasing decisions, Five Star carries large quantities of inventory relative to its competitors and thus can boast fill ratios of approximately 95%.

11

All purchasing decisions based on current inventory levels, sales projections, manufacturer discounts and recommendations from sales representatives, are made by the merchandising group, located in New Jersey, in order to coordinate effectively Five Star's activities. In addition to senior management's active involvement, regional sales managers play an extremely critical role in this day-to-day process.

Five Star has developed strong, long-term relationships with the leading suppliers since its predecessor company, J. Leven, was founded in 1912. As a major distributor of paint sundry items, suppliers rely on Five Star to introduce new products to market. Furthermore, suppliers have grown to trust Five Star's ability to penetrate the market. As a result, Five Star is often called on first by manufacturers to introduce new products into the marketplace. For example, Minwax, Bestt Liebco and Cabot Stain have utilized Five Star to introduce and distribute some of their new product innovations.

Customers

Five Star's largest customer accounted for approximately 3% of its sales in 2004. All customers are unaffiliated and Five Star does not have a long-term contractual relationship with any of them.

Backlog

Five Star does not have any significant backlog.

Patents, Trademarks, and other Intellectual Property

Except for its line of private-label products, Five Star does not have any material patents, trademarks or other intellectual property. Five Star intends to expand the distribution of its line of private-label products sold under the "Five Star" name.

Environmental Matters and Governmental Regulations

Five Star's activities may subject it to federal, state and local environmental laws and regulations and OSHA regulations. Five Star believes that it is in compliance in all material respects with such environmental and federal laws and regulations.

Employees

Five Star employed approximately 260 people as of December 31, 2004. Management-employee relations are considered good at both of Five Star's warehouse facilities. The Teamsters union represents approximately 94 union employees at the New Jersey warehouse facility. The Connecticut warehouse facility is completely non-unionized. Five Star has never experienced a labor strike at its facilities. Five Star's contract with Local No. 11, affiliated with the International Brotherhood of Teamsters expires on December 19, 2008.

Other Assets

Valera Pharmaceuticals

We own 100% of the common stock and 2,068,966 shares of the Series B convertible preferred stock of Valera Pharmaceuticals (formerly Hydro Med

12

Sciences, Inc.), which amounts to a 17.7% ownership interest assuming conversion of Valera outstanding preferred stock and exercise of stock options held by employees of Valera. Valera is a specialty pharmaceutical company focused on the acquisition, development and commercialization of novel prescription pharmaceuticals, particularly for the treatment of urological conditions and disorders. Valera intends to develop new formulations using its hydron drug delivery technology, which is a subcutaneous implant that controls the amount, timing and location of the release of drug compounds into the body.

Valera's lead product is a twelve-month implant that delivers histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH). LHRH agonists have become a mainstay in treating locally advanced and metastatic prostate cancer. On October 13, 2004, Valera announced that the FDA approved the marketing of Vantas(TM), the name for Valera's long-acting LHRH implant for treating prostate cancer.

Prior to June 2000, Valera operated as a division of GP Strategies. In connection with an offering of GP Strategies 6% Convertible Subordinated Exchangeable Notes due June 2003, Valera was incorporated as a separate company and became a wholly-owned subsidiary of GP Strategies through GP Strategies' ownership of 100% of the common stock of Valera. On July 30, 2004 GP Strategies contributed its ownership interest in Valera to National Patent Development.

In December 2001, Valera completed a $7 million private placement of Series A convertible preferred stock to certain institutional investors. As a condition of the private placement, GP Strategies contractually gave up operating control over Valera through an Investors Rights Agreement, which gave GP Strategies the right to designate one director on Valera's board of directors and gave the other stockholders the right to designate the other directors. National Patent Development is also subject to the Investors Rights Agreement. Accordingly, while we own 100% of Valera's common stock, we do not have financial and operating control of Valera.

In the second quarter of 2003, Valera completed a private placement offering pursuant to which Valera raised approximately $12 million in gross proceeds from the sale of Series B convertible preferred stock. As part of such transaction, GP Strategies was granted an option until March 31, 2004 (with a closing by June 30, 2004), to purchase up $5 million of the Series B convertible preferred stock at the offering price of $0.725 per share, which was subsequently verbally extended to June 30, 2004. On June 30, 2004, GP Strategies transferred a portion of its option to an institutional investor, which exercised such option and purchased from Valera 3,448,276 shares of Series B convertible preferred stock for $0.725 per share. The balance of the option expired unexercised. In consideration of such transfer, such institutional investor granted us an option until October 28, 2004 to purchase up to 2,068,966 shares of Series B convertible preferred stock owned by such institutional investor for prices ranging from $0.725 to $0.7685 per share. We exercised such option on October 28, 2004 at a price of $0.7685 per share, for an aggregate exercise price of $1,590,000. On November 12, 2004, we entered into an agreement to borrow approximately $1,022,000 from Bedford Oak Partners, which is controlled by Harvey P. Eisen, a director of the Company, and approximately $568,000 from Jerome I. Feldman, who is Chairman and Chief Executive Officer of the Company, to exercise our option to purchase Series B Convertible Preferred shares of Valera. The loans bear interest at 6% per annum, mature on October 31, 2009, and are secured by all shares of Valera owned by us, including the purchased shares. The loans are required to be prepaid out of the proceeds received from the sale of the purchased shares or from any additional capital contribution received by us from GP Strategies out of proceeds received by GP

13

Strategies from its claims relating to the Learning Technologies acquisition. Bedford Oak Partners and Jerome I. Feldman are entitled to receive 50% of any profit received by us from the sale of the Valera purchased shares. On January 11, 2005, we prepaid the loans, including accrued interest of approximately $16,000, to Bedford Oak Partners and Jerome I. Feldman out of such proceeds.

On August 16, 2004 Valera sold 11,600,000 shares of Series C convertible preferred stock and received gross proceeds of $11.6 million. On March 14, 2005 Valera registered with the Securities and Exchange Commission for an initial public offering of up to approximately $75 million of common stock. If the initial public offering is completed, all the convertible preferred stock outstanding at the time of the offering, including accrued dividends, will automatically convert into common stock. Assuming conversion of all of the outstanding shares of Series A, Series B and Series C convertible preferred stock and exercise of stock options held by employees of Valera at December 31, 2004, the Company would own approximately 17.7% of Valera. Such percentage will be further reduced upon successful completion of the public offering.

Millennium Cell

Millennium Cell is a publicly traded emerging technology company engaged in the business of developing innovative fuel systems for the safe storage, transportation and generation of hydrogen for use as an energy source. At December 31, 2002, we held 293,271 shares of Millennium Cell with a market value on that date of $698,000. On October 17, 2003, National Patent Development received pursuant to the repayment of a receivable from GP Strategies an additional 1,000,000 shares of common stock of Millennium Cell with a market value on that date of approximately $3,500,000. At December 31, 2003, we held 1,188,271 shares of common stock of Millennium Cell with a market value of $2,769,000. At December 31, 2004, we held 964,771 shares of common stock of Millennium Cell with a market value of $1,235,000.

Pawling Property

We own an approximately 980 acre parcel of undeveloped land in Pawling, New York, which includes an approximately 50 acre lake, Little Whaley Lake. The Boy Scouts of America operated a camp located along the western side of Little Whaley Lake, which was closed in the early 1980's, and the site is currently unoccupied. GP Strategies purchased this property in 1986. In connection with the sale of the Gabelli Notes and GP Warrants, GP Strategies mortgaged this property to the holders of the Gabelli Notes, and GP Strategies transferred it to us subject to that mortgage.

Factors Affecting Our Future Performance

Risks Related to the Distribution

We will have increased expenses as an independent public company. This could impair our profitability.

We do not have an operating history as an independent company. Our business has historically relied on GP Strategies for various financial, managerial and administrative services and has been able to benefit from the earnings, assets and cash flows of GP Strategies' other businesses. GP

14

Strategies will not be obligated to provide assistance or services to National Patent Development after the spin-off, except as provided in an agreement by GP Strategies to provide certain management services to National Patent Development. We also may not be able to develop our own management after the termination of the agreement under which GP Strategies will provide management services.

Following the spin-off, we will incur the costs and expenses associated with the management of a public company. The spin-off may result in some temporary disruption to the business operation, as well as to the organization and personnel structure, of National Patent Development, which may reduce our net income and working capital.

Our historical consolidated financial information may not be representative of our historical results as an independent company; therefore, it may not be reliable as an indicator of historical or future results.

Our historical consolidated financial information may not reflect what our financial condition, results of operations and cash flows would have been on a historical basis had we operated our business as an independent company during the periods presented or what our financial condition, results of operations and cash flows will be in the future. This is because our historical consolidated financial statements include allocations for services provided or procured by GP Strategies, which we may not be able to procure or provide ourselves on the same basis. In addition, we have not made adjustments to our historical consolidated financial information to reflect other changes that will occur in our cost structure, financing and operations as a result of the spin-off. These changes could potentially include increased costs associated with reduced economies of scale and a higher cost of capital, and also changes in how we fund our operations and development and pursue our strategic objectives. Therefore, our historical consolidated financial statements may not be indicative of our future performance as an independent company.

Risks Related to our Business

MXL's revenue and net income could decline as a result of a loss of business from significant customers.

For the years ended December 31, 2004, 2003 and 2002, revenue from MXL's three largest customers represented approximately 38%, 37%, and 52% of MXL's revenue, respectively. MXL's revenue has declined over the past three years, partly due to the loss of business from its most significant customers. MXL has no significant long-term supply contracts and therefore its operations are dependent on its clients' continued satisfaction with its services and their continued willingness to engage MXL, rather than its competitors, to deliver such services.

MXL's source of raw materials may be limited and failure to obtain raw materials with cost efficiency and on a timely basis may cause a disruption in MXL's operations.

MXL's primary raw material is plastic resin (principally polycarbonate). In the past, MXL primarily relied on one supplier for its primary raw material. Due to new entrants in the market to supply plastic resin, MXL currently uses two primary suppliers and could choose from one or more other suppliers for plastic resin. However, if the number of suppliers again declined to past levels, MXL would be dependent on limited sources of supply for its raw

15

materials, and the failure of MXL to fulfill its raw material requirement could disrupt its business and result in a decrease in net income.

In addition, plastic resin is a petroleum based product, and as such, is subject to price increases (20% to 40% during the year ended December 31, 2004, depending on grade and type) along with increases in crude oil prices (over 50% during the year ended December 31, 2004). There is no guarantee that MXL will be able to fully recover from its customers its cost increases associated with increases in the price of plastic resin.

If our subsidiaries are unable to compete successfully, our revenues may be adversely affected.

Competition in the optical plastics industry is vigorous. MXL's customers require state-of-the-art technology. In order to keep pace with MXL's customers' needs, MXL is required to constantly develop and improve its technology, facilities and production equipment and methods. MXL's future success will depend upon its ability to gain expertise in technological advances rapidly and respond quickly to evolving industry trends and client needs.

Competition within the do-it-yourself industry is intense. There are large national distributors commonly associated with national franchises such as Ace and TruServ as well as smaller regional distributors, all of whom offer products and services similar to those offered by Five Star. Moreover, in some instances, manufacturers will bypass distributors and choose to sell and ship their products directly to retail outlets. In addition, Five Star's customers face stiff competition from Home Depot, which purchases directly from manufacturers, and national franchises such as Ace and TruServ. Five Star competes principally through its strategically placed distribution centers and its extensive inventory of quality, name-brand products. Five Star will continue to focus its efforts on supplying its products to its customers at a competitive price and on a timely, consistent basis.

Our subsidiaries' inability to compete successfully would materially decrease our results of operations and working capital.

Risks Related to Our Stock

We have agreed to restrictions and adopted policies that could have possible anti-takeover effects and reduce the value of our stock.

We have agreed to certain restrictions on our future actions to assure that the spin-off will be tax-free, including restrictions with respect to an acquisition of shares of National Patent Development common stock. If we fail to abide by these restrictions, and, as a result, the spin-off fails to qualify as a tax-free reorganization, National Patent Development will be obligated to indemnify GP Strategies for any resulting tax liability. The potential tax liability that could arise from an acquisition of shares of National Patent Development common stock, together with our related indemnification obligations, could have the effect of delaying, deferring or preventing a change in control of National Patent Development.

Several provisions of our Certificate of Incorporation and Bylaws could deter or delay unsolicited changes in control of National Patent Development. These include limiting the stockholders' powers to amend the Bylaws or remove directors, and prohibiting the stockholders from increasing the size of the Board of Directors or acting by written consent instead of at a stockholders'

16

meeting. Our Board of Directors has the authority, without further action by the stockholders to fix the rights and preferences of and issue preferred stock. These provisions and others that could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in control or management of National Patent Development, including transactions in which stockholders might otherwise receive a premium for their shares over then current market prices. These provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests.

Item 2. Properties

The following information describes the material physical properties owned or leased by us and our subsidiaries. We lease approximately 10,000 square feet of space for our White Plains, New York principal executive offices.

MXL owns 50,200 square feet of warehouse and office space in Lancaster, PA and 55,000 square feet of warehouse and office space in Downer's Grove, IL, both of which are subject to mortgages. Due to a decline in production volume for the Illinois division and considering MXL's diminished real estate requirements, MXL is in contract to sell the Illinois facility and lease back 10,000 square feet of the facility. In September 2003, MXL entered into a three-year lease for a 55,000 square foot storage and manufacturing facility in Southbridge, Massachusetts for its newly purchased equipment from AOtec. In 2004, MXL exercised an option for an earlier termination without penalty of the Massachusetts facility lease. MXL vacated the premises and the lease terminated as of March 31, 2005.

Five Star leases 236,000 square feet in New Jersey, 111,000 square feet in Connecticut, 1,300 square feet of sales offices in New York and 800 square feet in Maryland. Five Star's operating lease for the New Jersey facility expires in March, 2007 and the operating lease for the Connecticut facility expires in February, 2007.

The facilities owned or leased by us are considered to be suitable and adequate for their intended uses and are considered to be well maintained and in good condition.

Item 3. Legal Proceedings

Claims Relating to Learning Technologies Acquisition

On July 30, 2004 GP Strategies agreed to make an additional capital contribution to National Patent Development, in an amount equal to the first $5 million of any proceeds (net of litigation expenses and taxes incurred, if any), and 50% of any proceeds (net of litigation expenses and taxes incurred, if any) in excess of $15 million, received with respect to the claims described below. GPS has received $13.7 million of net proceeds from such claims and, pursuant to such agreement, in January 2005 GPS made a $5 million additional capital contribution to National Patent Development

On January 3, 2001, GP Strategies commenced an action alleging that MCI Communications Corporation, ("MCI") MCI's Systemhouse subsidiaries ("Systemhouse"), and Electronic Data Systems Corporation, as successor to Systemhouse, ("EDS") committed fraud in connection with GP Strategies's 1998 acquisition of Learning Technologies from the defendants for $24,300,000. GP Strategies seeks actual damages in the amount of $117,900,000 plus interest,

17

punitive damages in an amount to be determined at trial, and costs. Such damages are subject to reduction by the amount recovered in the arbitration.

The complaint, which is pending in the New York State Supreme Court, alleges that the defendants fraudulently induced GP Strategies to acquire Learning Technologies by concealing the poor performance of Learning Technologies' United Kingdom operation. The complaint also alleges that the defendants represented that Learning Technologies would continue to receive new business from Systemhouse even though the defendants knew that the sale of Systemhouse to EDS was imminent and that such new business would cease after such sale. In February 2001, the defendants filed answers denying liability. No counterclaims against the plaintiffs have been asserted. Although discovery had not yet been completed, defendants made a motion for summary judgment, which was submitted in April 2002. The motion was denied by the court due to the MCI bankruptcy, but with leave to the other defendants to renew, as described below.

The defendants other than MCI then made an application to the court to stay the fraud action until a later-commenced arbitration, alleging breach of the acquisition agreement and of a separate agreement to refer business to General Physics on a preferred provider basis and seeking actual damages in the amount of $17,600,000 plus interest, are concluded. In a decision dated May 9, 2003, the court granted the motion and stayed the fraud action pending the outcome of the arbitration.

The arbitration hearings began on May 17, 2004 and concluded on May 24, 2004 before JAMS, a private dispute resolution firm. On September 10, 2004, the arbitrator issued an interim award in which she found that the sellers of Learning Technologies breached certain representations and warranties contained in the acquisition agreement. In a final award dated November 29, 2004, the arbitrator awarded GP Strategies $12,273,575 in damages and $6,016,109 in interest. On December 30, 2004, EDS made a payment of $18,427,684, which included $138,000 of accrued interest, to GP Strategies to satisfy its obligation under the arbitration award. The arbitration settlement, net of legal fees and expenses was held in escrow as of December 31, 2004. EDS subsequently agreed that the arbitration award is final and binding and that it will take no steps of any kind to vacate or otherwise challenge the award.

As a result of the conclusion of the arbitration, the state court has lifted the stay of the fraud claim against EDS. GP Strategies is now proceeding with the fraud claim against EDS. On February 14, 2005, EDS filed a new motion for summary judgment dismissing GP Strategies' fraud claim. GP Strategies responded to the motion by March 17, 2005 and the motion was argued by the parties on April 4, 2005. The fraud action against MCI had been stayed as a result of the bankruptcy of MCI. In February 2004, the Bankruptcy Court lifted the stay so that the state court could rule on the merits of MCI's summary judgment motion. MCI has stated that it intends to ask the Bankruptcy Court to reinstate the stay.

MXL and Five Star are from time to time subject to litigation or other legal proceedings arising in the ordinary course of business. National Patent Development believes that the outcome of such proceedings will not have a material adverse effect on its financial condition, results of operations, and cash flows.

Item 4: Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of security holders during the fourth quarter of the fiscal year covered by this report.

18

PART II

Item 5: Market for the Registrant's Common Equity and Related Stockholder Matters

The Company's Common Stock, $.01 par value, is quoted on the OTC Bulletin Board. The high and low market prices since regular trading began on November 26, 2004 were $2.50 and $1.50, respectively.

The number of shareholders of record of the Common Stock as of March 29, 2005 was 1,967 and the closing price on the OTC Bulletin Board on that date was $2.75.

The Company has not declared or paid any cash dividends on its Common Stock in 2004. The Company currently intends to retain future earnings to finance the growth and development of its business

Equity Compensation Plan information as of December 31, 2004:

                                                                                                  2003 Incentive Stock
Plan category                                                                                             Plan
Equity compensation plans not approved by security holders:
(a)  Number of securities to be issued upon exercise
       of outstanding options (1)                                                                                  -
(b)  Weighted average exercise price of outstanding options (1)                                                    -
(c)  Number of securities remaining available for future issuance under
       equity compensation plans (excluding securities reflected in row (a)) (2)                                   -

Equity compensation plans approved by security holders:
(a)  Number of securities to be issued upon exercise
       of outstanding options (1)                                                                                  -
(b)  Weighted average exercise price of outstanding options (1)                                                    -
(c)   Number of securities remaining available for future issuance under
        equity compensation plans (excluding securities reflected in row (a)) (2)                          1,750,000

(1)    Does not include warrants to purchase 1,423,887 shares issued and sold to
       four Gabelli funds in conjunction with GP Strategies 6% Conditional
       Subordinated Notes due 2008 at an exercise price of $3.57 per share.
(2)    Does not include shares of Common Stock that may be issued to directors of the Company as director's fees.

For a description of the material terms of the Company's 2003 Incentive Stock Plan, see Note 11 to the notes to the Consolidated Financial Statements.

Directors of the Company who are not employees of the Company or its subsidiaries receive an annual fee of $5,000, payable quarterly. At the option of each director up to one-half of the annual fee could be paid in Common Stock. In addition, the directors receive $1,000 for each meeting of the Board of Directors attended, and generally do not receive any additional compensation for service on the committees of the Board of Directors. Employees of the Company or its subsidiaries do not receive additional compensation for serving as directors.

19

Item 6: Selected Consolidated Financial Data (in thousands, except per share
data):

The selected financial data presented below should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and the notes thereto included elsewhere in this report. Before the spin-off and the related corporate restructuring transactions, we operated as part of GP Strategies. Because the data reflect periods during which we did not operate as an independent company, the historical data may not reflect the results of operations or the financial condition that would have resulted if we had operated as a separate, independent company during the periods shown.

----------------------------------------- --------------------------------------------------------------------
Consolidated Statement of
Operations Data (1)                                                  Year Ended December 31,
                                               2004           2003          2002        2001         2000
                                               ----           ----          ----        ----         ----
----------------------------------------- --------------- -------------- ----------- ------------ ------------

Sales                                         $  110,223     $103,698      $9,996      $11,184      $10,998
Gross Margin                                      20,069       19,582       2,099        2,816        2,888
Interest expense                                   1,098          864         208          169          102
Income (loss) before income taxes and
minority interest                                 (3,111)         383         292          764       (1,468)
Net income (loss)                                 (4,529)        (104)        147          369         (960)
Net income (loss)
per share:
Basic and diluted                              $    (.25)      $    (.01) $   .01      $   .03    $   (.08)

Consolidated Balance Sheet Data (1)                                      December 31,
                                            2004          2003         2002         2001        2000
                                            ----          ----         ----         ----        ----
--------------------------------------- -------------- ------------ ------------ ----------- ------------
--------------------------------------- -------------- ------------ ------------ ----------- ------------
Cash and cash equivalents                 $  2,087        $    602      $   562   $   536       $   627
Short-term borrowings                       18,784          16,960            -         -             -
Working capital                             14,028          10,565        3,954    14,139        10,866
Total assets                                60,474          53,638       29,870    30,836        29,441
Long-term debt                               1,395           3,203        2,670     2,875            59
Stockholders' equity                        19,760          17,236       25,451    26,025        26,580

(1) On October 8, 2003, the Company increased its ownership interest in Five Star's outstanding common stock from 48% to 54%, resulting in a controlling financial interest in Five Star and accordingly commenced consolidating Five Star's financial statements with those of the Company. Five Star's results of operations are included in the 2003 consolidated statement of operations as though a controlling financial interest had been acquired by the Company at the beginning of such year and, accordingly, Five Star's sales, cost of sales and expenses are included for the twelve months ended December 31, 2003. The acquisition of a controlling financial interest was accounted for as a purchase transaction.

As a result of an issuer tender offer by Five Star, approximately 2,628,000 shares of Five Star common stock were tendered and acquired by Five Star effective March 31, 2004 at a cost of $657,000. The effect of such tender offer was to increase our ownership in Five Star to approximately 64% at March 31, 2004.

20

Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations:

Results of Operations

General Overview

National Patent Development was incorporated on March 10, 1998 as a wholly-owned subsidiary of GP Strategies Corporation. In July 2002, GP Strategies announced that it was actively considering transferring certain of its non-core assets into National Patent Development and spinning-off National Patent Development to the stockholders of GP Strategies. On November 14, 2002, GP Strategies filed a ruling request with the Internal Revenue Service with respect to the federal tax consequences of the proposed spin-off, and received a favorable ruling on March 21, 2003. On February 12, 2004, National Patent Development was recapitalized whereby the authorized capital was changed to 10,000,000 shares of preferred stock and 30,000,000 shares of common stock. On July 30, 2004 GP Strategies transferred to National Patent Development its optical plastics business through its wholly-owned subsidiary, MXL; the home improvement distribution business through its partially owned subsidiary Five Star; and certain other non-core assets. The separation of these businesses was accomplished through a pro-rata distribution (the "Distribution" or "spin-off") of 100% of the outstanding common stock of National Patent Development to the stockholders of GP Strategies on the record date of November 18, 2004 for the Distribution. On November 24, 2004, holders of record received one share of National Patent Development common stock for each share of GP Strategies common stock or Class B capital stock owned.

The Company operates in two segments: MXL, which was formerly called the Optical Plastics segment, and Five Star, which was formerly called the Home Improvement Distribution segment. The Company also owns certain other non-core assets, including an investment in a publicly held company, Millennium Cell; an approximately 17.7% interest in a private company, Valera Pharmaceuticals; and certain real estate. National Patent Development monitors Millennium Cell for progress in the commercialization of Millennium Cell's emerging technology and monitors Valera Pharmaceuticals for progress in the FDA approval process.

MXL Overview

The primary business of MXL is the manufacture of polycarbonate parts requiring adherence to strict optical quality specifications, and the application of abrasion and fog resistant coatings to those parts. MXL also designs and constructs injection molds for a variety of applications. Some of the products that MXL produces include:

o facemasks and shields for recreation purposes and industrial safety companies,

o precision optical systems, including medical optics, military eye wear and custom molded and decorated products, and

o tools, including optical injection mold tools and standard injection mold tools.

MXL's manufactures and sells its products to various commercial and government customers, who utilize MXL's parts to manufacture products that will be ultimately delivered to the end-user. MXL's government customers include various offices of the Department of Defense, while MXL's commercial customers are primarily in the recreation, safety, and security industries. MXL's commitments to its customers, consisting of unfilled sales orders or backlog, amounted to approximately $1.6 million as of December 31, 2004. Some of MXL's

21

consumer based products are considered to be at the high-end of their respective markets. As a result, sales of MXL's products may decline together with a decline in discretionary consumer spending; therefore a key performance indicator that the Company's management uses to manage the business is the level of discretionary spending in key markets, specifically the United States and Japan. Other key performance measures used by the Company's management to run the business include:

o consumer confidence indices in key markets,

o sales levels of complementary items in the recreational vehicle market, such as motorcycles, RV's and snowmobiles,

o levels of defense spending, and

o new OSHA safety standards.

MXL believes that the principal strengths of its business are its state-of-the-art injection molding equipment, advanced production technology, high quality standards, and on time deliveries. However, due to the focused nature of the market, MXL has a limited customer base and tends to be adversely affected by a loss in business from its significant customers. As a result of losses of business from certain of its key customers, MXL sales and operating profits for the past three years have shown a declining trend, reflecting a loss in market share. To reverse the declining sales trend, a new management team with significant sales and marketing experience has been established in 2004. To further grow, MXL not only intends to regain market share in its existing market, but to leverage its expertise as a molder and coater of optical quality products by expanding into other markets and products. However, due to the spin-off, MXL may have less financial resources at its disposal with which to support and grow the business, as National Patent Development will have a smaller market capitalization and less access to capital markets than GP Strategies.

Five Star Overview

Five Star is a publicly held company that is a leading distributor in the United States of home decorating, hardware, and finishing products. Five Star offers products from leading manufacturers in the home improvement industry and distributes those products to retail dealers, which include lumber yards, "do-it yourself" centers, hardware stores and paint stores. Five Star has grown to be one of the largest independent distributors in the Northeast United Stated by providing a complete line of competitively priced products, timely delivery and attractive pricing and financing terms to its customers.

The following key factors affect Five Star's financial and operation performance:

o its ability to negotiate the lowest prices from its suppliers,

o its ability to increase revenue by obtaining new customers, while maintaining a level fixed cost structure by utilizing its existing warehouses,

o the housing market in general,

o consumers' confidence in the economy,

o consumers' willingness to invest in their homes, and

o weather conditions that are conducive to home improvement projects.

22

The following key performance measures are utilized by the Company's management to run Five Star's business:

o new U.S. housing starts,

o sales of existing homes,

o sales of high margin products to its customers,

o purchases from each vendor, and

o performance benchmarks used by Home Depot and Lowe's, such as number of stores and square footage, as well as financial benchmarks.

Five Star operates in the Home Improvement market, which has grown in recent years and for which the National Retail Hardware Association predicts average annual industry growth of approximately 5% for the next several years. Nonetheless, Five Star faces intense competition from large national distributors, smaller regional distributors, and manufacturers that bypass the distributor and sell directly to the retail outlet. The principal means of competition for Five Star are its strategically placed distribution centers and its extensive inventory of quality, name-brand products. In addition, Five Star's customers face stiff competition from Home Depot and Lowe's, which purchase directly from manufacturers. As a result of such competition, while the Home Improvement market has expanded significantly in recent years, Five Star's revenue has not increased at the same rate, and such revenue would have declined if Five Star had not entered into new geographic sales territories as described below. In spite of this, the independent retailers that are Five Star's customers remain a viable alternative to Home Depot and Lowe's, due to the shopping preferences of and the retailer's geographic convenience for some consumers.

Five Star has continued to expand its sales territory with an addition of a sales force servicing the Mid-Atlantic States, and as far south as North Carolina, which has generated additional annual revenues of approximately $9 million since 2000. Five Star services this territory from its existing New Jersey warehouse, enabling Five Star to leverage its fixed costs over a broader revenue base. To further expand, Five Star will attempt to grow its revenue base in the Mid-Atlantic States, to acquire complementary distributors and to expand the distribution of its use of private-label products sold under the "Five Star" name. However, due to the spin-off, Five Star may have less financial resources at its disposal with which to support and grow the business, as National Patent Development will have a smaller market capitalization and less access to capital markets than GP Strategies.

Consolidated Results of Operations

Year Ended December 31, 2004 compared to Year Ended December 31, 2003

National Patent Development had losses before income taxes and minority interest of $3,111,000 for the year ended December 31, 2004 as compared to income before income taxes and minority interest of $383,000 for the year ended December 31, 2003. The decrease in profitability of $3,494,000 is primarily related to the following factors: (i) increased selling, general and administrative expenses of $1,695,000, partly due to higher allocation of expenses from GP Strategies, higher MXL selling, general and administrative expenses (ii) a loss on the write-down of the Illinois facility of $872,000 and
(iii) a decrease in investment and other income of $1,180,000, primarily due to an impairment loss due to a decline in market value considered other-than

23

temporary of $1,081,000 on the National Patent Development investment in Millennium Cell stock, in addition to a net loss on sales of stock of Millennium Cell. The decrease was partially offset by a higher gross margin of $487,000 which increased in proportion with the increase in Five Star revenue.

Sales. For the year ended December 31, 2004, sales increased by $6,525,000 from $103,698,000 for the year ended December 31, 2003 to $110,223,000, due to increased Five Star sales of $6,897,000. The increase was primarily a result of increased sales to Five Star's existing customer base. Sales to existing customers have increased mainly due to Five Star offering more product lines for the retailers to stock, as well as Five Star conducting small local trade shows for its customers to create additional sales. Sales were favorably affected by clement weather in the Northeast during the year ended December 31, 2004, causing an increase in home improvement projects.

The decrease in MXL sales of $372,000 was a result of a decrease in sales from the Illinois and Lancaster facilities, primarily a result of market fluctuations on tool purchases, lower levels of purchases from several key customers and a discontinuance of a product line associated with diabetes treatment produced by one of MXL's most significant customers following the first quarter of 2003. The decreases were offset by increased sales from MXL's Massachusetts facility, which was purchased in September 2003.

Gross margin. For the year ended December 31, 2004, gross margin increased by $487,000, or 2%, from $19,582,000, or 18.9% of sales, for the year ended December 31, 2003 to $20,069,000, or 18.2% of sales, due to an increase in Five Star gross margin, offset by a decrease in MXL gross margin.

The increase of $1,671,000, or 9%, in Five Star gross margin dollars from $17,719,000 for the year ended December 31, 2003 to $19,389,000 for the year ended December 31, 2004 was the result of increased sales and increased gross margin percentage, offset in part by higher costs on purchases for the period. Five Star gross margin as a percentage of sales increased from 18.6 % for the year ended December 31, 2003 to 19.0% for the year ended December 31, 2004, mainly due to a favorable shift in the product mix sold, offset by an increase in warehousing costs. Five Star includes warehousing expenses as part of cost of goods sold.

MXL gross margin of $680,000 or 8.3% of sales, for the year ended December 31, 2004 declined by $1,183,000, or 63%, from gross margin of $1,863,000, or 21.6% of sales, for the year ended December 31, 2003. The decrease in gross margin dollars and percentage is due to the following factors:
(i) the Massachusetts facility, which MXL has exited as of March 31, 2005, experienced higher levels of manufacturing overhead, (ii) the Illinois facility incurred certain cost associated with write-downs of inventory and equipment, and (iii) the Lancaster facility experienced an increase in raw material costs.

Selling, general and administrative. For the year ended December 31, 2004, selling, general and administrative expenses increased by $1,695,000, or 9%, from $18,274,000 for the year ended December 31, 2003 to $19,969,000 partially due to increased allocations of GP Strategies corporate selling, general and administrative expenses of $906,000. Five Star's selling, general and administrative expenses increased by $494,000 primarily due to increased

24

delivery expenses, salesmen commissions, medical expenses and legal and professional fees. MXL's selling, general and administrative expenses increased by $307,000 primarily due to increased salaries and employee benefits, as well as rent associated with MXL's Massachusetts facility.

Loss on write-down of the Illinois facility. In the fourth quarter 2004, MXL began to explore the divestiture of its Illinois facility as a result of a decline in production volume for the Illinois division and taking into consideration MXL's diminished real estate needs. In accordance with SFAS 144, Accounting for the Impairment or Disposal of Long-Lived Assets, assets held for sale are reported at the lower of the carrying amount or fair value, less costs to sell. The Company recognized a charge of $872,000 to record the Illinois facility assets at fair value of $1,595,000, based upon the expected net proceeds from the sale of the Illinois facility.

Investment (loss) and other income, net. National Patent Development incurred investment and other losses of $1,241,000 for the year ended December 31, 2004 mainly due an impairment loss due to a decline in market value considered other-than temporary of $1,081,000 on National Patent Development investment in Millennium Cell stock, as well as to a net loss of $131,000 on sales of Millennium and HEB stock, as compared to other loss of $61,000 for the year ended December 31, 2003, mainly due to a net loss on sales of Millennium and HEB stock.

Income taxes. National Patent Development had an effective tax rate of 31.6% and 46% for the year ended December 31, 2004 and December 31, 2003, respectively. The rate was primarily due to operating losses of MXL unable to be utilized on a stand-alone basis in 2004, non-deductible expenses and impairment and realized losses for equity investments for which no benefit had been provided.

Year Ended December 31, 2003 compared to Year Ended December 31, 2002

National Patent Development had income before income taxes and minority interest of $383,000 for the year ended December 31, 2003 as compared to income before income taxes and minority interest of $292,000 for the year ended December 31, 2002. The increase in profitability of $91,000 is primarily related to an increase in operating profit of $2,068,000 from the consolidation of Five Star following the Five Star Majority Ownership. The increase in profitability was partially offset by the following factors: (i) increased interest expense of $656,000 mainly due to the consolidation of Five Star following the Five Star Majority Ownership, (ii) a decrease in income from equity investee and investment income of $509,000, from a gain of $448,000 mainly due to Five Star income from equity investee, to a loss of $61,000 mainly due to a net loss on sales of Millennium and HEB stock and (iii) a decrease in operating profit at MXL of $460,000, due to lower sales and increased selling, general and administrative expenses.

Sales. For the year ended December 31, 2003, sales increased by $93,702,000 from $9,996,000 for the year ended December 31, 2002 to $103,698,000 mainly due to the consolidation of Five Star's revenue of $95,085,000 into National Patent Development's financial statements as a result of the Five Star Majority Ownership. Five Star's revenue was essentially flat from 2002, increasing by approximately $9 million due to Five Star's expansion of its sales territory with an addition of a sales force servicing the Mid-Atlantic States, offset by a loss in revenue of approximately $8 million from its existing customer base concentrated in the Northeast. The decrease in MXL's revenue of $1,383,000 was primarily due to a discontinuance of a product line associated with diabetes treatment produced by one of MXL's most significant customers, which accounted for a loss in revenue of $1,196,000. The remainder of the

25

decline was due to less significant losses in revenue from MXL's other top ten customers, mainly due to a decline in the overall economy, which caused a reduction in discretionary spending for high-end products which MXL manufactures.

Gross margin. For the year ended December 31, 2003, gross margin increased by $17,483,000 from $2,099,000 for the year ended December 31, 2002 to $19,582,000 mainly due to the consolidation of Five Star gross margin of $17,719,000 into National Patent Development's financial statements as a result of the Five Star Majority Ownership. Five Star's gross margin increased by $1,106,000 from 2002 mainly due to increased revenue and a reduction in cost of goods sold, mainly due to improved purchasing efficiencies from Five Star's vendors. The purchasing efficiencies, including quantity and other discounts, were the primary reason for the increase in gross margin percentage from 17.6% in 2002 to 18.6% in 2003. The increase in Five Star gross margin was partially offset by increased warehousing costs, with increases in payroll and related expenses, rent and utilities, and repairs and maintenance expenses. The increase in gross margin was offset by a decrease in MXL's gross margin of $236,000, mainly due to the decline in MXL revenue. MXL's gross margin percentage rose slightly from 21% in 2002 to 21.6% in 2003 due to the discontinued product line which traditionally caused lower gross margin percentages to MXL.

Selling, general and administrative. For the year ended December 31, 2003, selling, general and administrative expenses increased by $16,227,000 from $2,047,000 for the year ended December 31, 2002 to $18,274,000 mainly due to the consolidation of Five Star's selling, general and administrative expenses of $15,598,000 into National Patent Development's financial statements as a result of the Five Star Majority Ownership. Five Star's selling, general and administrative expenses increased by $933,000 from 2002 due to increases in salary and bonuses, sales personnel and expenses incurred for business development, sales territory expansion and computer system upgrades. Corporate selling, general and administrative expenses increased by $445,000, mainly due to increased allocations of GP Strategies corporate selling, general and administrative expenses. MXL's selling, general and administrative expenses increased by $184,000 primarily due to increases in employee benefits, bad debt expense, general insurance and rent.

Investment (loss) and other income, net and income (loss) related to equity investee. For the year ended December 31, 2003, National Patent Development had zero income related to equity investee due to the consolidation of Five Star into National Patent Development's financial statements as a result of the Five Star Majority Ownership, as compared to income related to equity investee of $439,000 for the year ended December 31, 2002. In addition, National Patent Development incurred investment and other losses of $61,000 in 2003 mainly due to a net loss on sales of Millennium and HEB stock, a decrease of $70,000 from investment income of $9,000 in 2002.

Income taxes. National Patent Development had an effective tax rate of 46.0% and 49.7% for the years ended December 31, 2003 and December 31, 2002, respectively. The rate was primarily due to state and local taxes, non-deductible expenses and impairment and realized losses for equity investments for which no benefit had been provided.

26

Liquidity and Capital Resources

At December 31, 2004, National Patent Development had cash and cash equivalents totaling $2,087,000, 964,771 shares of common stock of Millennium Cell with a market value of $1,235,000 and a receivable from GP Strategies of $5,000,000, which was collected in January 2005. National Patent Development believes the aforementioned resources, together with the cash received from the sale of other assets, will be sufficient to fund the working capital and other requirements of National Patent Development for at least the next twelve months. From time to time National Patent Development may attempt to raise capital with potential equity financings, although no such equity financings are currently anticipated.

For the year ended December 31, 2004, National Patent Development's working capital increased by $3,463,000 to $14,028,000 from $10,565,000 as of December 31, 2003. The working capital increase was primarily a result of capital contributions from GP Strategies; offset by a net loss for the period, additions to property, plant and equipment, and repayment of long term debt.

The increase in cash and cash equivalents of $1,485,000 for the year ended December 31, 2004 resulted from net cash used in operations of $641,000; cash used in investing activities of $1,542,000, consisting of additions to property, plant and equipment of $458,000, acquisition of minority interest in Five Star Products pursuant to the tender offer of $657,000 and additions to investments of $1,590,000, offset by proceeds on sale of investments of $1,013,000 and cash repayment of the receivable from GPS of $150,000; and cash provided by financing activities of $3,668,000, consisting of capital contributions from GPS of $1,951,000, proceeds of borrowings of $3,139,000, offset by repayments of long-term debt of $414,000 and distributions to GP Strategies of $1,008,000.

On March 8, 2001, MXL entered into a loan in the amount of $1,680,000, secured by a mortgage covering the real estate and fixtures on its property in Pennsylvania. At December 31, 2004, $1,305,000 of such loan was outstanding. The loan requires monthly repayments of $8,333 plus interest at 2.5% above the one month LIBOR rate and matures on March 8, 2011, when the remaining amount outstanding of approximately $680,000 is due in full. The loan is guaranteed by GP Strategies. The proceeds of the loan were used to repay a portion of the GP Strategies' short-term borrowings under its prior credit agreement.

On July 3, 2001, MXL entered into a loan in the amount of $1,250,000, secured by a mortgage covering the real estate and fixtures on its property in Illinois. At December 31, 2004, $1,155,000 of such loan was outstanding. The loan requires monthly payments of principal and interest in the amount of $11,046 with interest at a fixed rate of 8.75% per annum, and matures on June 26, 2006, when the remaining amount outstanding of approximately $1,100,000 is due in full. The loan is guaranteed by GP Strategies. The proceeds of the loan were used to repay a portion of the GP Strategies' short-term borrowings under its prior credit agreement. As of December 31, 2004, the mortgage has been classified separately in the balance sheet as a current liability, as a result of the classification of the Illinois property as held for sale.

On September 15, 2003, MXL purchased machinery, equipment and inventory from AOtec, located in the Massachusetts area, for a purchase price of $1,100,000, subject to adjustment. On August 1, 2003, MXL paid $100,000 of the purchase price and issued three notes, in the amounts of $450,000, $275,000 and

27

$275,000, due October 1, 2003, August 5, 2004 and August 5, 2005, respectively (collectively, the "AOtec Notes"). The AOtec Notes bear interest on the unpaid principal amount at the rate of 4% per annum. On October 1, 2003, MXL borrowed $700,000, or the AOtec Debt, from a bank to finance the purchase price and used the proceeds to pay the $450,000 Note. The AOtec Debt is payable monthly for three-years and is secured by the machinery and equipment purchased from AOtec. GP Strategies guaranteed the AOtec Debt. MXL is currently negotiating a reduction in the amounts due under the AOtec Notes with maturity dates of August 5, 2004 and 2005, resulting from a dispute over the purchase price. According to the contract of sale, the payments due pursuant to the AOtec Notes were subject to an offset and withholding by MXL. The parties are attempting to resolve this matter; however there is no guarantee that MXL will successfully negotiate the reduction of the AOtec notes. The AOtec Notes, which amount to $550,000 in the aggregate following a repayment of $450,000 of the AOtec Notes in October 2003, are included in short-term borrowings in the consolidated December 31, 2004 balance sheet.

On June 20, 2003, Five Star obtained a Loan and Security Agreement (the "Loan Agreement") with Bank of America (formerly Fleet Capital Corporation) (the "Lender"). The Loan Agreement has a five-year term, with a maturity date of June 30, 2008. The Loan Agreement, as amended on May 28, 2004, provides for a $28,000,000 revolving credit facility, which allows Five Star to borrow based upon a formula of up to 55% of eligible inventory and 80% of eligible accounts receivable, as defined therein. The interest rates under the Loan Agreement consist of LIBOR plus a credit spread of 2% (4.28% at December 31, 2004) for borrowings not to exceed $15,000,000 and the prime rate (5.25% at December 31, 2004) for borrowings in excess of the above-mentioned LIBOR-based borrowings. The credit spreads can be reduced in the event that Five Star achieves and maintains certain performance benchmarks. At December 31, 2004, approximately $18,234,000 was outstanding under the Loan Agreement and approximately $434,000 was available to be borrowed.

In March 2005, Five Star amended the Loan Agreement to allow it to increase the maximum amount that can be borrowed under the revolving credit facility to $30,000,000 through June 30, 2005; reverting back to a maximum of $28,000,000 on July 1, 2005.

In connection with the Loan Agreement, Five Star also entered into a derivative transaction with the Lender on June 20, 2003. The derivative transaction is an interest rate swap and has been designated as a cash flow hedge. Effective July 1, 2004 through June 30, 2008, Five Star will pay a fixed interest rate of 3.38% to the Lender on notional principal of $12,000,000. In return, the Lender will pay to Five Star a floating rate, namely, LIBOR, on the same notional principal amount. The credit spread under the new Loan Agreement is not included in, and will be paid in addition to this fixed interest rate of 3.38%.

On June 17, 2004, Five Star has also entered into a derivative interest rate collar transaction during the period from July 1, 2004 through June 30, 2008 on notional principal of $12,000,000. The transaction consists of an interest rate floor of 2.25%, whereas if LIBOR is below 2.25%, the Lender will pay to Five Star the difference between LIBOR and 2.25%, on the same notional principal amount. The transaction also consists of an interest rate cap of 5.75%, whereas if LIBOR is above 5.75%, Five Star will pay to the Lender the difference between LIBOR and 5.75%, on the same notional principal amount.

As of December 31, 2003 MXL provided security for General Physics' Financing and Security Agreement. The Financing and Security Agreement provides

28

for a maximum outstanding balance of $25 million and was secured by certain of the assets of General Physics and the accounts receivable of MXL. The Financing and Security Agreement is also guaranteed by GP Strategies. MXL provided a limited guaranty up to the value of its account receivable collateral securing the Financing and Security Agreement. For the continuation of the bank's security interest in MXL's accounts receivable and the continuation of its limited guarantee after the spin-off, General Physics paid MXL a guarantee fee of 2% of the value of the borrowing base collateral attributable to MXL, calculated monthly. At General Physics' option, General Physics could eliminate MXL's accounts receivable from the borrowing base under the Financing and Security Agreement, provided that General Physics made a mandatory prepayment under the Financing and Security Agreement to eliminate any borrowing base deficiency. At such point, all obligations of MXL relating to the Financing and Security Agreement terminated, MXL's limited guaranty of the Financing and Security Agreement became void, and General Physics was no longer required to pay to MXL the guarantee fee. In March 2004 General Physics eliminated MXL's accounts receivable from the borrowing base, no mandatory prepayment was required by General Physics, and the guarantee fee was eliminated.

Pursuant to a Note and Warrant Purchase Agreement dated August 8, 2003, GP Strategies issued and sold to four Gabelli funds $7,500,000 aggregate principal amount of 6% Conditional Subordinated Notes due 2008 (the "Notes") and 937,500 warrants ("GP Warrants"), each entitling the holder thereof to purchase (subject to adjustment) one share of GP Strategies' common stock. The aggregate purchase price for the Notes and GP Warrants was $7,500,000. GP Strategies agreed to allocate to National Patent Development $1,875,000 of the $7,500,000 received for the Notes and Warrants (the "Gabelli Allocation"). National Patent Development received the funds pursuant to the Gabelli Allocation prior to the spin-off.

The Notes are secured by a non-recourse mortgage on the property located in Pawling, New York (the "Property") which was transferred to MXL. MXL has no liability for repayment of the Notes or any other obligations of GP Strategies under the Note and Warrant Purchase Agreement (other than foreclosure on such property). If there is a foreclosure on the mortgage for payment of the Notes, GP Strategies has agreed to indemnify MXL for loss of the value of the Property.

The Note and Warrant Purchase Agreement provided that, on completion of the spin-off, National Patent Development would issue warrants ("National Patent Development Warrants") to the holders of the GP Warrants. The National Patent Development Warrants entitle the holders to purchase, in the aggregate, a number of shares of National Patent Development common stock equal to 8% of the number of shares of such stock outstanding at completion of the spin-off. An aggregate of 1,423,887 National Patent Development Warrants were issued to the holders of the GP Warrants on December 4, 2004, and allocated among them pro-rata based on the respective number of GP Warrants held by them on such date.

The exercise price of the National Patent Development Warrants is $3.57, which represents 160% of the average closing price of the National Patent Development common stock over the 20 consecutive trading days commencing on the record date of the spin-off. The National Patent Development Warrants are exercisable at any time through August 2008. The National Patent Development Warrants will have anti-dilution provisions similar to those of the GP Warrants. National Patent Development has agreed to provide the holders of the National Patent Development Warrants with registration rights similar to those provided by GP Strategies to the holders of the GP Warrants.

29

GP Strategies has guaranteed the leases for Five Star's New Jersey and Connecticut warehouses, totaling approximately $1,589,000 per year through the first quarter of 2007. GP Strategies' guarantee of such leases was in effect when Five Star was a wholly-owned subsidiary of GP Strategies. In 1998, GP Strategies sold substantially all of the operating assets of the Five Star business to the predecessor corporation of Five Star. As part of this transaction, the landlord of the New Jersey and Connecticut facilities and the lessor of the equipment did not consent to the release of GP Strategies' guarantee.

On March 1, 2005, MXL obtained a Line of Credit Loan (the "MXL Line") from M&T Bank with a one year term, maturing on March 1, 2006. The MXL Line provides for a $1,000,000 revolving credit facility, which is secured by MXL's eligible accounts receivable, inventory and a secondary claim on the Lancaster, PA property. The interest rates under the MXL Line consist of LIBOR plus a credit spread of 3% or the prime rate plus a credit spread of 0.25%. The MXL Line is subject to an unused commitment fee of 0.25% of the average daily unused balance of the line payable quarterly. National Patent Development has guaranteed the MXL Line.

Contractual Obligations and Commitments

The following table summarizes operating lease commitments and employment agreements as of December 31, 2004 (in thousands):

                                                                     Payments due in
                                             2005        2006-2007     2008-2009      After 2009        Total
                                             ----        ---------     ---------      ----------        -----

Operating lease commitments                    2,267         2,955            340             -            5,562
Employment agreements                            938           150              -             -            1,088
                                             -------      --------    -----------       -------          -------

Total                                        $ 3,205       $ 3,105           $340       $     -           $6,650

Management discussion of critical accounting policies

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our estimates, judgments and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.

Certain of our accounting policies require higher degrees of judgment than others in their application. These include valuation of accounts receivable, accounting for investments, and impairment of long-lived assets which are summarized below. In addition, Note 2 to the Consolidated Financial Statements, includes further discussion of our significant accounting policies.

30

Revenue recognition

Revenue on product sales is recognized at the point in time when the product has been shipped, title and risk of loss has been transferred to the customer, and the following conditions are met: persuasive evidence of an arrangement exists, the price is fixed and determinable, and collectibility of the resulting receivable is reasonably assured. Allowances for estimated returns and allowances are recognized when sales are recorded.

Valuation of accounts receivable

Provisions for allowance for doubtful accounts are made based on historical loss experience adjusted for specific credit risks. Measurement of such losses requires consideration of National Patent Development's historical loss experience, judgments about customer credit risk, and the need to adjust for current economic conditions. The allowance for doubtful accounts as a percentage of total gross trade receivables was 2.6% and 6.3% at December 31, 2004 and December 31, 2003, respectively.

Impairment of long-lived tangible assets

Impairment of long-lived tangible assets with finite lives results in a charge to operations whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived tangible assets to be held and used is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by determining the amount by which the carrying amount of the assets exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of their carrying amount or fair value less cost of sale.

The measurement of the future net cash flows to be generated is subject to management's reasonable expectations with respect to National Patent Development's future operations and future economic conditions which may affect those cash flows.

As of December 31, 2004, National Patent Development holds undeveloped land in Pawling, New York with a carrying amount of approximately $2.5 million and in East Killingly, Connecticut with a carrying amount of approximately $0.4 million, which management believes is less than its fair value, less cost of sale.

Accounting for investments

National Patent Development's investment in marketable securities are classified as available-for-sale and recorded at their market value with unrealized gains and losses recorded as a separate component of stockholders' equity. A decline in market value of any available-for-sale security below cost that is deemed to be other than temporary, results in an impairment loss, which is charged to earnings. National Patent Development has recorded an impairment loss of $1,081,000 in 2004 on its marketable security investment in Millennium Cell. Management determined the loss to be other than a temporary decline.

On October 8, 2003 National Patent Development acquired additional shares of Five Star, bringing its ownership to 54%. Five Star is consolidated

31

into National Patent Development's consolidated financial statements and is no longer accounted for as an equity investment effective as of that date.

Determination of whether an investment is impaired and whether an impairment is other than temporary requires management to evaluate evidence as to whether an investment's carrying amount is recoverable within a reasonable period of time considering factors which include the length of time that an investment's market value is below its carrying amount and the ability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

On October 17, 2003, National Patent Development received GP Strategies' shares of Valera Pharmaceuticals pursuant to the Repayment and recorded such shares at zero representing their carrying amount to GP Strategies after reflecting Valera losses. National Patent Development currently owns 100% of Valera's common stock and 2,068,966 shares of the Series B convertible preferred stock (a17.7% ownership interest, assuming conversion of Valera outstanding preferred stock and exercise of stock options held by employees of Valera) but no longer has financial and operating control of Valera. As a condition of a private placement of preferred stock in December 2001, GP Strategies contractually gave up operating control over Valera through an Investors Rights Agreement. National Patent Development accounts for its investment in Valera's Series B convertible preferred stock under the cost method.

Recent accounting pronouncements

During December 2004, the Financial Accounting Standards Board ("FASB") issued a new standard entitled Statement of Financial Accounting Standards ("SFAS") 123R, Share-Based Payment, which would revise SFAS No. 123, Accounting for Stock Based Compensation, and amend SFAS No. 95, Statement of Cash Flows. Among other items, the new standard would require the expensing, in the financial statements, of stock options issued by the Company. The new standard will be effective July 1, 2005, for calendar year companies. The Company is currently evaluating the method of adoption of SFAS No. 123R, including the valuation methods and assumptions that underlie the valuation of the awards. As permitted under SFAS No. 123 the Company currently accounts for share-based payments to employees using Accounting Principles Board ("APB") Opinion No. 25 intrinsic value method, and as such, recognizes no compensation cost for employee stock options. Accordingly the adoption of SFAS No. 123R fair value method could have a significant impact on the Company's results of operations, although it will have no impact on the Company's overall financial position. The impact of adoption of SFAS No. 123R cannot be predicted at this time, because it will depend on levels of share-based payments in the future. However had the Company adopted SFAS No. 123R in prior periods, the impact of that statement would have approximated the impact of SFAS No. 123 as described in the disclosure of pro forma net income and earnings per share shown in Note 2 under "Stock based compensation"

In November 2004, the FASB issued SFAS No. 151, Inventory Costs, an amendment to ARB No. 43, Chapter 4 (FAS 151). FAS 151 amends Accounting Research Bulleting No. 43, to clarify that abnormal amounts of idle facility expense, freight, handling costs and wasted material (spoilage) should be recognized as current period charges. In addition, FAS 151 requires that allocation of fixed production overhead to inventory be based on the normal capacity of the production facilities. The Company is required to adopt FAS 151 beginning January 1, 2006. The Company is currently assessing the impact that FAS 151 will have on its results of operations, financial position or cash flows.

32

Item 7a: Quantitative and Qualitative Disclosures About Market Risk

National Patent Development is exposed to the impact of interest rate, market risks and currency fluctuations. In the normal course of business, National Patent Development employs internal processes to manage its exposure to interest rate, market risks and currency fluctuations. National Patent Development's objective in managing its interest rate risk is to limit the impact of interest rate changes on earnings and cash flows and to lower its overall borrowing costs. National Patent Development is exposed to the impact of currency fluctuations because of its sales to customers in foreign countries.

As of December 31, 2004, the Company had approximately $7.5 million of variable rate borrowings. The Company estimates that for every 1% fluctuation in general interest rates, assuming debt levels at December 31, 2004, interest expense would vary by $75,000.

Five Star is a party to an interest rate swap agreement designated as a cash flow hedge whereby changes in the cash flows of the swap will offset changes in the interest rate payments on Five Star's variable-rate revolving loan, thereby reducing Five Star's exposure to fluctuations in LIBOR. Changes in the fair value of the interest rate swap are recognized in accumulated other comprehensive income, net of income taxes.

Effective July 1, 2004 through June 30, 2008, Five Star will pay a fixed interest rate of 3.38% to the Lender on notional principal of $12,000,000. In return, the Lender will pay to Five Star a floating rate, namely, LIBOR, on the same notional principal amount. The credit spread under the new Loan Agreement is not included in, and will be paid in addition to this fixed interest rate of 3.38%.

On June 17, 2004, Five Star has also entered into a derivative interest rate collar transaction during the period from July 1, 2004 through June 30, 2008 on notional principal of $12,000,000. The transaction consists of an interest rate floor of 2.25%, whereas if LIBOR is below 2.25%, the Lender will pay to Five Star the difference between LIBOR and 2.25%, on the same notional principal amount. The transaction also consists of an interest rate cap of 5.75%, whereas if LIBOR is above 5.75%, Five Star will pay to the Lender the difference between LIBOR and 5.75%, on the same notional principal amount.

33

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

National Patent Development Corporation
                                                                         Page

Report of Independent Registered Public Accounting Firm                   35

Consolidated Statements of Operations - Years ended December 31,
2004, 2003 and 2002                                                       36

Consolidated Statements of Comprehensive Income (Loss) - Years
ended December 31, 2004, 2003 and 2002                                    36

Consolidated Balance Sheets - December 31, 2004 and 2003                  37

Consolidated Statements of Cash Flows - Years ended December 31,
2004, 2003 and 2002                                                       38

Consolidated Statements of Changes in Stockholders' Equity - Years
ended December 31, 2004, 2003 and 2002                                    40

Notes to Consolidated Financial Statements                                42

34

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders of National Patent Development Corporation:

We have audited the accompanying consolidated balance sheets of National Patent Development Corporation and subsidiaries (the "Company") as of December 31, 2004 and 2003 and the related consolidated statements of operations, comprehensive loss, cash flows and stockholders' equity for each of the years in the three year period ended December 31, 2004. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of National Patent Development Corporation and subsidiaries as of December 31, 2004 and 2003, and the consolidated results of their operations and their cash flows for each of the years in the three year period ended December 31, 2004, in conformity with accounting principles generally accepted in the Unites States of America.

EISNER LLP
New York, New York
March 22, 2005

35

NATIONAL PATENT DEVELOPMENT CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

                                                                  Year Ended December 31,
                                                              2004            2003          2002
----------------------------------------------------- ---------------- --------------- ---------------

Sales                                                     $110,223         $103,698       $  9,996
Cost of sales                                               90,154           84,116          7,897
----------------------------------------------------- ---------------- --------------- ---------------
Gross margin                                                20,069           19,582          2,099
----------------------------------------------------- ---------------- --------------- ---------------
Selling, general and administrative expenses               (19,969)         (18,274)        (2,047)
Loss on write-down of Illinois property                       (872)               -              -
Income related to equity investee                                -                -            439
----------------------------------------------------- ---------------- --------------- ---------------
Operating  profit (loss)                                      (772)           1,308            491
----------------------------------------------------- ---------------- --------------- ---------------
Interest expense                                            (1,098)            (864)          (208)
Investment and other income (loss)                          (1,241)             (61)             9
----------------------------------------------------- ---------------- --------------- ---------------
Income (loss) before income taxes                           (3,111)             383            292
and minority interest
----------------------------------------------------- ---------------- --------------- ---------------
Income tax expense                                             982              176            145
----------------------------------------------------- ---------------- --------------- ---------------
Income (loss) before minority interest                      (4,093)             207            147
----------------------------------------------------- ---------------- --------------- ---------------
Minority interest                                             (436)            (311)
----------------------------------------------------- ---------------- --------------- ---------------
Net  income (loss)                                          (4,529)        $   (104)       $   147
----------------------------------------------------- ---------------- --------------- ---------------
Net income (loss) per share
Basic and diluted                                         $   (.25)          $    (.01)   $    .01

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

                              (in thousands)

                                                                       Year Ended December 31,
                                                                     2004           2003           2002
------------------------------------------------------------ --------------- -------------- -------------
------------------------------------------------------------ --------------- -------------- -------------

Net income (loss)                                                $ (4,529)        $  (104)       $  147
Other comprehensive income (loss), before tax:
Net unrealized loss on available-for-sale-securities
                                                                   (1,067)           (902)         (833)
Reclassification adjustment for loss on securities sold
included in net loss                                                  173               -             -
Reclassification adjustment for impairment loss on
securities included in net loss                                     1,081               -             -
Net unrealized gain on interest rate swap, net of minority
interest                                                               31              43
------------------------------------------------------------ --------------- -------------- -------------
------------------------------------------------------------ --------------- -------------- -------------
Comprehensive loss before tax                                      (4,311)           (963)         (686)
------------------------------------------------------------ --------------- -------------- -------------
------------------------------------------------------------ --------------- -------------- -------------
Income tax benefit (expense) related to  items of other
comprehensive loss                                                    (19)            116           325
------------------------------------------------------------ --------------- -------------- -------------
------------------------------------------------------------ --------------- -------------- -------------
Comprehensive loss                                                $(4,330)          $(847)       $ (361)
------------------------------------------------------------ --------------- -------------- -------------

See accompanying notes to consolidated financial statements.

36

NATIONAL PATENT DEVELOPMENT CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands)

                                                                                        December 31,
                                                                              2004               2003
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
Assets
Current assets
Cash and cash equivalents                                                $     2,087        $       602
Accounts and other receivables, less allowance
 for doubtful accounts of $306 and $739                                       11,410             11,082
Inventories                                                                   30,698             28,300
Receivable from GP Strategies Corporation                                      5,000                709
Deferred tax asset                                                               172                 80
Prepaid expenses and other current assets                                        358                845
Property held for sale                                                         1,595
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
Total current assets                                                           51,320            41,618
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
Marketable securities available for sale                                        1,416             2,981
Investment in Valera                                                            1,590              -
Property, plant and equipment, net                                              2,876             5,725
Goodwill                                                                          182               182
Other assets                                                                    3,090             3,132
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
Total assets                                                                  $60,474           $53,638
--------------------------------------------------------------------------- ------------------ ------------------

Liabilities and stockholders' equity
Current liabilities
Current maturities of long-term debt                                      $     1,967         $     389
Short term borrowings                                                          18,784            16,960
Accounts payable and accrued expenses                                          15,386            13,704
Mortgage collateralized by property held for sale                              1,155
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
Total current liabilities                                                      37,292             31,053
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
Long-term debt less current maturities                                          1,395              3,203
Deferred tax liability                                                            239                102
Interest rate collar, at market                                                    19                 -

Minority interest                                                               1,769              2,044

Stockholders' equity
Preferred stock, par value $0.01 per share
  authorized 10,000,000 shares; issued none                                     -                  -
Common stock, par value $0.01 per share
  authorized 30,000,000 shares; issued 17,798,585 shares                          178                178
Additional paid-in capital                                                     24,761             17,946
Accumulated deficit                                                            (4,843)              (353)
Accumulated other comprehensive loss                                             (336)              (535)
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
Total stockholders' equity                                                      19,760             17,236
--------------------------------------------------------------------------- ------------------ ------------------
--------------------------------------------------------------------------- ------------------ ------------------
                                                                               $60,474            $53,638
--------------------------------------------------------------------------- ------------------ ------------------

See accompanying notes to consolidated financial statements.

37

NATIONAL PATENT DEVELOPMENT CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

                                                                            Year ended December 31,
                                                                        2004          2003          2002
------------------------------------------------------------------- ------------- ------------- -------------
------------------------------------------------------------------- ------------- ------------- -------------
Cash flows from operations:
Net income (loss)                                                    $(4,529)        $(104)         $147
Adjustments to reconcile net income (loss) to
 net cash provided by (used in) operating activities:
Depreciation and amortization                                            726           593           510
Minority Interest                                                        436            48             -
Income related to equity investee, prior to acquiring a
controlling financial interest                                             -          (256)          (55)
Net loss on marketable securities                                        131            36             -
Impairment charge on securities                                        1,081
Loss on write-off of equipment                                            83             -             -
Loss on write-down of Illinois property                                  872             -             -
Deferred income taxes                                                     53          (296)           77
Allocation of expenses and taxes from GP Strategies                    1,470         1,150           593
Changes in other operating items:
   Accounts and other receivables                                       (328)        4,730          (293)
   Inventories                                                        (2,398)       (6,348)          354
   Prepaid expenses and other assets                                      80           225           (69)
   Accounts payable and accrued expenses                               1,682         2,917           147
------------------------------------------------------------------- ------------- ------------- -------------
Net cash provided by (used in) operations                               (641)        2,695        $1,411
------------------------------------------------------------------- ------------- ------------- -------------
Cash flows from investing activities:
Additions to property, plant and equipment, net                         (458)         (525)        $(368)
Proceeds from sales of fixed assets                                        -           203             -
Proceeds from sale of investments                                      1,013           521             -
Advances to GP Strategies                                               (882)       (1,310)         (400)
Repayment of receivable from GP Strategies                             1,032             -             -
Additions to investments                                              (1,590)            -             -
Payments for acquisition of AOtec assets, net of
   cash ($6) acquired in Five Star acquisition                             -          (544)            -
Acquisition of minority interest in Five Star Products pursuant
to the tender offer                                                     (657)            -             -
Repayment of note from Five Star Products                                  -         1,000             -
Recovery of investment in Five Star Products                               -           475            33
------------------------------------------------------------------- ------------- ------------- -------------
Net cash used in investing activities                                 (1,542)         (180)        $(735)
------------------------------------------------------------------- ------------- ------------- -------------

See accompanying notes to consolidated financial statements.

38

NATIONAL PATENT DEVELOPMENT CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

                                                                            Year ended December 31,
                                                                        2004          2003           2002
------------------------------------------------------------------- ------------- -------------- ------------
------------------------------------------------------------------- ------------- -------------- ------------
Cash flows from financing activities:
Distributions to GP Strategies                                         (1,008)       (1,985)         (360)
Contribution from GP Strategies                                         1,951             -             -
Proceeds from issuance of long-term debt                                1,590           700             -
Proceeds from (repayment of)
short-term borrowings                                                   1,549          (932)            -
Repayment of long-term debt                                              (414)         (258)         (290)
------------------------------------------------------------------- ------------- -------------- ------------
------------------------------------------------------------------- ------------- -------------- ------------
Net cash (used in) provided by financing activities                     3,668        (2,475)         (650)
------------------------------------------------------------------- ------------- -------------- ------------
------------------------------------------------------------------- ------------- -------------- ------------
Net increase in cash and cash equivalents                               1,485            40            26
Cash and cash equivalents at beginning of period                          602           562           536
------------------------------------------------------------------- ------------- -------------- ------------
Cash and cash equivalents at end of period                             $2,087          $602          $562
------------------------------------------------------------------- ------------- -------------- ------------

Supplemental disclosures of cash flow information:

Cash paid during the period for:
Interest                                                              $ 1,190         $ 398         $ 208
Income taxes                                                              524           201             2

Non-cash investing activities:
Conversion of Five Star Products Note Receivable
 into common stock of Five Star Products                                                500           500
Repayment of receivable from GP Strategies
with marketable and other securities                                                 10,000
Contribution of HEB shares from GP Strategies                                           550

Non-cash financing activities:
Capital contribution receivable from GP Strategies                      5,000

Purchase of certain assets from AOtec:
   Fixed assets                                                                        $900
   Inventory                                                                            350
   Accrued expenses                                                                    (150)
   Issuance of notes (exclusive of $450,000 note
   paid in 2003)                                                                       (550)
                                                                                     ------
   Cash paid                                                                        $   550
                                                                                    =======

See accompanying notes to consolidated financial statements.

39

NATIONAL PATENT DEVELOPMENT CORPORATION
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 2004, 2003, AND 2002
(in thousands)

                                                                                                   Accumulated
                                                   Common         Additional      Retained            other               Total
                                                   Stock           paid-in        earnings        comprehensive       stockholders'
                                                 $(.01 Par)        capital        (deficit)       income (loss)           equity
----------------------------------------------- ------------- ------------------- ------------- ------------------- ----------------
Balance at December 31, 2001                           $178           $18,432         $6,699            $716             $26,025
----------------------------------------------- ------------- ------------------- ------------- ------------------- ----------------
Net unrealized loss on available
   for sale securities, net of tax                                                                      (508)               (508)
Net income                                                                               147                                 147
Allocation of expenses from
   GP Strategies                                                           81                                                 81
Reclassification (a)                                                      168           (168)
Income tax provision deemed
   contributed by GP Strategies                                            66                                                 66
Distributions to GP Strategies                                           (360)                                              (360)
----------------------------------------------- ------------- ------------------- ------------- ------------------- ----------------
Balance at December 31, 2002                           $178           $18,387         $6,678            $208             $25,451
----------------------------------------------- ------------- ------------------- ------------- ------------------- ----------------
Net unrealized loss on available
   for sale securities, net of tax                                                                      (769)                (769)
Net unrealized gain on interest rate
   swap, net of tax and minority
   interest                                                                                               26                   26
Net loss                                                                                 (104)                               (104)
Allocation of expenses from GP
   Strategies                                                             449                                                 449
Reclassification (a)                                                      427            (427)
Balance of receivable from GP Strategies in
  excess of carryover basis of assets received
  in repayment                                                                         (6,500)                             (6,500)
Income tax benefit deemed
  distributed to GP Strategies                                            (16)                                                (16)
Capital contribution by GP
  Strategies                                                              550                                                 550
Distributions to GP Strategies                                         (1,985)                                             (1,985)
Other                                                                     134                                                 134
----------------------------------------------- ------------- ------------------- ------------- ------------------- ----------------
Balance at December 31, 2003                           $178           $17,946           $(353)         $(535)             $17,236
----------------------------------------------- ------------- ------------------- ------------- ------------------- ----------------

(a) Principally represents net income (loss) attributable to non-core assets not operated as separate entities.

See accompanying notes to consolidated financial statements.

40

(Continued)

NATIONAL PATENT DEVELOPMENT CORPORATION
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 2004, 2003, AND 2002
(in thousands)

                                                                                                     Accumulated
                                                 Common         Additional                              other             Total
                                                  Stock           paid-in         Accumulated       comprehensive      stockholders'
                                               $(.01 Par)         capital           deficit         income (loss)         equity
-------------------------------------------- ---------------- ---------------- ------------------ ------------------- --------------
Balance at December 31, 2003                          $178          $17,946          $(353)               $(535)            $17,236
-------------------------------------------- ---------------- ---------------- ------------------ ------------------- --------------

Net unrealized loss on available
   for sale securities                                                                                   (1,067)             (1,067)
Reclassification adjustment for

   loss on securities sold included
   in net loss, net of tax                                                                                  173                 173
Net unrealized gain on interest
   rate swap, net of tax
   and minority interest                                                                                     12                  12
Reclassification adjustment for
   impairment loss on securities
   included in net loss                                                                                   1,081               1,081
Net loss                                                                            (4,529)                                  (4,529)
Allocation of expenses
   from GP Strategies                                                   911                                                     911
Reclassification (a)                                                    (39)            39                                        -
Distributions to GP Strategies                                       (1,008)                                                 (1,008)
Contributions from GP Strategies                                      6,951                                                   6,951
-------------------------------------------- ---------------- ---------------- ------------------ ------------------- --------------
Balance at December 31, 2004                          $178          $24,761        $(4,843)               $(336)            $19,760
-------------------------------------------- ---------------- ---------------- ------------------ ------------------- --------------

(a) Principally represents net income (loss) attributable to non-core assets not operated as separate entities.

See accompanying notes to consolidated financial statements.

41

NATIONAL PATENT DEVELOPMENT CORPORATION

Notes to Consolidated Financial Statements

1. The Company and basis of presentation

National Patent Development Corporation ("National Patent Development" or the "Company") was incorporated on March 10, 1998 as a wholly-owned subsidiary of GP Strategies Corporation ("GPS" or "GP Strategies"). In July 2002, the Board of Directors of GPS approved a spin-off of certain of its non-core assets into National Patent Development and a pro-rata distribution (the "Distribution" or "spin-off") of 100% of the outstanding common stock of National Patent Development to the stockholders of GPS. On March 21, 2003, the Internal Revenue Service issued a favorable tax ruling which would enable the Distribution to be tax-free.

On February 12, 2004, National Patent Development was recapitalized whereby the authorized capital was changed to 10,000,000 shares of preferred stock and 30,000,000 shares of common stock. On July 30, 2004, GPS contributed the following non-core assets to National Patent Development in exchange for 17,769,919 shares of common stock:

1. 100% of the outstanding common stock of MXL Industries, Inc. ("MXL").

2. 9,133,417 common shares of Five Star Products, Inc. ("Five Star") (a publicly traded corporation) representing an approximately 64% ownership interest (see Notes 4 and 6).

3. 293,271 common shares of Millennium Cell Inc. (a publicly traded corporation) (see Note 5).

4. 1,067,900 common shares of Avenue Entertainment Group, Inc. (a publicly traded corporation) (see Note 5).

5. 100% of the common stock of JL Distributors, Inc. whose sole asset is a $2,800,000 senior unsecured 8% note from Five Star due June 30, 2005, as amended (see Note 4).

6. An option to acquire 500,000 shares of common stock (an approximate 4% interest) of Red Storm Scientific Inc., a privately held company (see Note 14(c)).

7. Approximately 1,000 acres of undeveloped real property located in Pawling, New York (see Note 2).

8. 100% of the common stock of Chestnut Hill Reservoir Company whose sole asset is certain undeveloped property located in East Killingly, Connecticut (see Note 2).

National Patent Development then transferred all of the above assets other than the MXL stock to MXL for additional MXL stock. Prior to the contribution, National Patent Development was inactive and had no operations.

In addition to the above, in 2004 GPS made a capital contribution to National Patent Development, which in turn transferred to MXL, $1,875,000 in cash, representing an allocation of the proceeds received by GPS when it issued and sold to four Gabelli funds $7,500,000 aggregate principal amount of 6%

42

Conditional Subordinated Notes due 2008 (see Note 16(b)). On July 30, 2004 GPS also agreed to make an additional capital contribution to National Patent Development out of certain proceeds of pending litigation and arbitration claims (see Note 15).

As a result of the contribution, the Company owns and operates the optical plastics business through its wholly-owned subsidiary, MXL, the home improvement distribution business through its partially owned subsidiary Five Star and also owns certain other non-core assets. GP Strategies continues to own and operate its wholly-owned subsidiary, General Physics Corporation, and retains a 58% interest in GSE Systems Inc. The separation of these businesses was accomplished through the Distribution on November 24, 2004 of 17,798,585 common shares of National Patent Development, representing 100% of the outstanding common stock of National Patent Development to the stockholders of GPS on the record date of November 18, 2004 on the basis of one share of National Patent Development common stock for each share of GP Strategies common stock or Class B capital stock owned. The shares distributed reflect 28,666 additional common shares issued by National Patent Development to GPS in connection with the exchange based on an increase in outstanding common stock of GPS between the date of the exchange and the record date.

The contribution of assets from GPS to the Company represents a transfer of assets between entities under common control and accordingly has been accounted for at the carryover basis to GPS of the transferred assets as if the transfer occurred at the beginning of the periods presented. Accordingly, the accompanying consolidated financial statements present the historical results of operations, cash flows, assets, liabilities and changes in stockholders' equity of MXL combined with the non-core assets and their effect on results of operations and cash flows for the periods presented. Commencing in 2003, as a result of the acquisition of a controlling financial interest in Five Star, its accounts have been consolidated in the accompanying financial statements as described below. In 2002, the investment in Five Star was accounted for by the equity method. Results of operations reflect charges for allocations of corporate expense incurred by GPS (see Note 14(a)). All significant intercompany balances and transactions have been eliminated. Reference to National Patent Development or the Company in the notes refers to MXL, Five Star and the non-core assets contributed to National Patent Development.

On October 8, 2003, GPS exchanged $500,000 principal amount of the $3,500,000 Senior Unsecured 8% Note due June 30, 2005, as amended, of Five Star for 2,000,000 shares of Five Star common stock, increasing GPS's ownership in Five Star from approximately 48% to approximately 54% of the then outstanding Five Star common stock and obtained a controlling financial interest. As a result, commencing as of such date the accounts of Five Star have been consolidated in the Company's financial statements. As permitted by Accounting Research Bulletin No. 51 "Consolidated Financial Statements", Five Star's results of operations are included in the 2003 consolidated statement of operations as though a controlling financial interest had been acquired by the Company at the beginning of such year and, accordingly, Five Star's sales, cost of sales and expenses are included for the twelve months ended December 31, 2003. Minority interest in earnings includes, in addition to the 46% interest in Five Star not owned by the Company, pre acquisition earnings attributable to the acquired 6% interest. This method presents results which are more indicative of the current status of the Company, and facilitates future comparison with subsequent years. The minority interest balance as of December 31, 2004 and December 31, 2003 reflected in the

43

consolidated balance sheets is comprised of the 36 percent (after completion of the tender offer described in Note 6) and the 46 percent minority share in Five Star which the Company did not own, respectively.

The Company owns 100% of the common stock and 2,068,966 shares of Series B convertible preferred stock of Valera Pharmaceuticals, Inc. ("Valera") (which amounts to a 17.7% ownership interest assuming conversion of Valera outstanding preferred stock and exercise of stock options held by employees of Valera); however, it no longer has financial and operating control of the entity. Accordingly, the Company accounts for its investment in Valera under the cost method (see Note 4).

The financial statements included herein may not necessarily be indicative of the results of operations, financial position and cash flows of National Patent Development in the future or had it operated as a separate, independent company during the periods presented.

2. Description of business and a summary of significant accounting policies

Description of business. MXL is a specialist in the manufacture of polycarbonate parts requiring strict adherence to optical quality specifications, and in the application of abrasion and fog resistant coating to these parts. Products include shields and face masks and non-optical plastic products. Five Star is engaged in the wholesale distribution of home decorating, hardware and finishing products to independent retail dealers in twelve states in the Northeast. Products distributed include paint sundry items, interior and exterior stains, brushes, rollers, caulking compounds and hardware products

Cash and cash equivalents. Cash and cash equivalents consist of cash and highly liquid debt instruments with original maturities of three months or less.

Marketable securities. Marketable securities consist of U.S. corporate equity securities. The Company classifies its marketable securities as trading or available-for-sale investments. Trading and available-for-sale securities are recorded at their fair value. Trading securities are held principally for the purpose of selling them in the near term. Unrealized holding gains and losses on trading securities are included in earnings. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of stockholders' equity in accumulated other comprehensive income, net of the related tax effect, until realized. A decline in the market value of any available-for-sale security below cost, that is deemed to be other than temporary, results in a reduction in carrying amount to fair value. The impairment is charged to earnings, and a new cost basis is established. Realized gains and losses are derived using the average cost method for determining the cost of securities sold. Available-for-sale securities consist of the common stock of Millennium Cell Inc. and Avenue Entertainment Group, Inc. Trading securities, which consisted of the common stock of Hemispherx Biopharma, Inc., were included in other current assets at December 31, 2003. National Patent Development fully disposed of its trading securities in the year ended December 31, 2004.

Inventories. Inventories are valued at the lower of cost or market, using the first-in, first-out method.

44

Revenue recognition. Revenue on product sales is recognized at the point in time when the product has been shipped, title and risk of loss has been transferred to the customer, and the following conditions are met: persuasive evidence of an arrangement exists, the price is fixed and determinable, and collectibility of the resulting receivable is reasonably assured. Allowances for estimated returns and allowances are recognized when sales are recorded.

Reclassifications. Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to 2004 classifications.

Shipping and handling costs. Shipping and handling costs, which are included as a part of selling, general and administrative expense, amounted to $4,840,000, $4,514,000 and $82,000 for the years ended December 31, 2004, 2003 and 2002, respectively.

Property, plant and equipment. Property, plant and equipment are carried at cost. Major additions and improvements are capitalized while maintenance and repairs which do not extend the lives of the assets are expensed as incurred. Gain or loss on the disposition of property, plant and equipment is recognized in operations when realized.

Depreciation. The Company provides for depreciation of property, plant and equipment primarily on a straight-line basis over estimated useful lives of 5 to 40 years for buildings and improvements and 3 to 7 years for machinery, equipment and furniture and fixtures.

Long-Lived Assets. The recoverability of long-lived assets, other than goodwill, is assessed whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment is measured by determining the amount by which the carrying value of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

The Company has investments in land in Pawling, New York with a carrying value of $2.5 million and in East Killingly, Connecticut with a carrying value of $0.4 million, which are included in other assets in the Consolidated Balance Sheets (see Note 16(b)). Management believes the fair value of these investments exceed their carrying value.

Fair value of financial instruments. The carrying value of cash and cash equivalents, accounts receivable and accounts payable approximate estimated fair values because of short maturities. The carrying value of the receivable from GPS approximates estimated fair value (see Note 14(b)). The carrying value of short term borrowings approximates estimated fair value because borrowings accrue interest which fluctuates with changes in LIBOR or prime. The carrying value for the Company's long-term debt, certain of which have variable interest rates, approximates fair value.

Marketable securities, other than those accounted for on the equity basis, are carried at fair value based upon quoted market prices. Derivative instruments are carried at fair value representing the amount the Company would receive or pay to terminate the derivative.

45

Derivatives and hedging activities. The interest rate swap and interest rate collar entered into by the Five Star in connection with its loan agreement (see Note 9) is being accounted for under SFAS No. 133, as amended, "Accounting for Derivative Instruments and Hedging Activities." SFAS No. 133 requires all derivatives to be recognized in the balance sheet at fair value. Derivatives that are not hedges must be adjusted to fair value through earnings. If the derivative is a cash flow hedge, changes in the fair value of the derivative are recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative's change in fair value is immediately recognized in earnings. Changes in the fair value of the interest rate swap, which has been designated as a cash flow hedge, were recognized in other comprehensive income. Changes in the fair value of the interest rate collar are recognized in earnings. Such change from June 17, 2004, the date the interest rate collar was entered into, through December 31, 2004 amount to approximately $19,000, which has been charged to earnings during the year ended December 31, 2004.

Recent Accounting Pronouncements. During December 2004, the Financial Accounting Standards Board ("FASB") issued a new standard entitled Statement of Financial Accounting Standards ("SFAS") 123R, Share-Based Payment, which would revise SFAS No. 123, Accounting for Stock Based Compensation, and amend SFAS No. 95, Statement of Cash Flows. Among other items, the new standard would require the expensing, in the financial statements, of stock options issued by the Company. The new standard will be effective July 1, 2005, for calendar year companies. The Company is currently evaluating the method of adoption of SFAS No. 123R, including the valuation methods and assumptions that underlie the valuation of the awards. As permitted under SFAS No. 123 the Company currently accounts for share-based payments to employees using Accounting Principles Board ("APB") Opinion No. 25 intrinsic value method, and as such, recognizes no compensation cost for employee stock options. Accordingly the adoption of SFAS No. 123R's fair value method could have a significant impact on the Company's results of operations, although it will have no impact on the Company's overall financial position. The impact of adoption of SFAS No. 123R cannot be predicted at this time, because it will depend on levels of share-based payments in the future. However had the Company adopted SFAS No. 123R in prior periods, the impact of that statement would have approximated the impact of SFAS No. 123 as described in the disclosure of pro forma net income and earnings per share shown below under "Stock based compensation"

In November 2004, the FASB issued SFAS No. 151, Inventory Costs, an amendment to ARB No. 43, Chapter 4 (FAS 151). FAS 151 amends Accounting Research Bulleting No. 43, to clarify that abnormal amounts of idle facility expense, freight, handling costs and wasted material (spoilage) should be recognized as current period charges. In addition, FAS 151 requires that allocation of fixed production overhead to inventory be based on the normal capacity of the production facilities. The Company is required to adopt FAS 151 beginning January 1, 2006. The Company is currently assessing the impact that FAS 151 will have on its results of operations, financial position or cash flows.

Stock based compensation. The Company applies the intrinsic value-based method of accounting prescribed by Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations, in accounting for options to be granted under its own plan as well as options to acquire GP Strategies common stock granted to MXL employees under the GP Strategies stock option plan. As such, compensation expense would be recorded on

46

the date of grant only if the current market price of the underlying stock exceeded the exercise price. The difference between the quoted market price as of the date of the grant and the contractual purchase price of shares is charged to operations over the vesting period. SFAS No. 123, "Accounting for Stock-Based Compensation," established accounting and disclosure requirements using a fair value-based method of accounting for stock-based employee compensation plans. As allowed by SFAS No. 123, the Company has elected to continue to apply the intrinsic value-based method of accounting described above, and has adopted the disclosure requirements of SFAS No. 123.

As of December 31, 2004, no options have been granted under the Company's plan. Pro forma net income (loss) and earnings (loss) per share disclosures as if the Company recorded compensation expense based upon the fair value of the GPS stock-based awards pursuant to SFAS No. 123 has not been presented since no options have been granted to MXL employees during the periods presented and previously granted options to MXL employees vested immediately.

Pro forma net loss and loss per share disclosures as if compensation expense was recorded based on the fair value of options granted under the Five Star plan (see Note 11) have been presented in accordance with the provisions of SFAS No. 123, is as follows for the years December 31, 2004 and 2003 (in thousands, except per share amounts):

                                                                        Year ended December 31,
                                                                      2004                    2003
------------------------------------------------------------ ------------------------ ---------------------
Net loss - As reported                                               $(4,529)                  $(104)
Compensation expense, net of tax
                          Five Star stock options                         (7)  (1)               (10)  (1)
------------------------- ---------------------------------- ------------------------ ---------------------
                          Pro forma net loss                         $(4,536)                 $ (114)

Basic and diluted loss per share
                          As reported                                 $(.25)                $   (.01)
                          Pro forma                                   $(.25)                $   (.01)

(1) Expense relates to option grants made by Five Star prior to the acquisition of a controlling interest in Five Star by the Company.

Per share data. Basic and diluted income (loss) per share is based upon the 17,798,585 common shares of National Patent Development issued in 2004 and distributed in the spin-off described in Note 1, which are treated as outstanding for all periods presented.

Outstanding warrants to acquire 1,423,887 common shares issued in December 2004 (see Note 16 (b) were not included in the 2004 diluted computation as their effect would be anti-dilutive.

47

Income (loss) per share for the years ended December 31, 2004, 2003 and 2002 is as follows (in thousands, except per share amounts):

                                                    Year ended December 31,
                                                    2003          2003       2002
-------------------------------------------- -------------- ------------- ----------
Basic and Diluted EPS
Net income (loss)                                $(4,529)        $(104)      $147
Weighted average shares
  outstanding, basic and diluted                  17,798        17,798     17,798
Basic and diluted income (loss) per share           $(.25)       $(.01)      $.01

Comprehensive income. Comprehensive income consists of net income (loss) and net unrealized gains (losses) on available-for-sale securities and the interest rate swap.

Income taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date (see Note 10).

Use of estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Concentrations of credit risk. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash investments, accounts receivable from customers and the receivable from GP Strategies. The Company places its cash investments with high quality financial institutions and limits the amount of credit exposure to any one institution. See Note 14(b) with respect to the repayment of the receivable from GP Strategies.

48

Accumulated other comprehensive loss. The components of accumulated other comprehensive loss are as follows (in thousands):

                                                                        December 31,
                                                               2004                   2003
--------------------------------------------------------- ---------------------- -------------------
--------------------------------------------------------- ---------------------- -------------------
Net unrealized loss on
available-for-sale-securities                                     $  (375)            $   (567)
Net unrealized gain on interest rate swap                              67                    46
--------------------------------------------------------- ---------------------- -------------------
--------------------------------------------------------- ---------------------- -------------------
Accumulated other comprehensive
 loss before tax                                                     (308)                 (521)
--------------------------------------------------------- ---------------------- -------------------
--------------------------------------------------------- ---------------------- -------------------
Accumulated income tax expense
related to items of other comprehensive loss                          (28)                  (14)
--------------------------------------------------------- ---------------------- -------------------
--------------------------------------------------------- ---------------------- -------------------
Accumulated other comprehensive
loss, net of tax                                                  $  (336)            $   (535)

3. Inventories

Inventories are comprised of the following (in thousands):

                                              December 31,
                                        2004                2003
----------------------------- ------------------- ------------------
Raw materials                            753                 921
Work in process                          277                 383
Finished goods                        29,668              26,996
----------------------------- ------------------- ------------------
----------------------------- ------------------- ------------------
                                     $30,698             $28,300

4. Investment in Valera Pharmaceuticals, Inc. ("Valera")

Valera is a specialty pharmaceutical company engaged in the development and commercialization of prescription pharmaceuticals principally utilizing Valera's patented Hydron drug delivery technology.

Valera's lead product is a twelve-month implant that delivers histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH). LHRH agonists have become a mainstay in treating locally advanced and metastatic prostate cancer. On October 13, 2004, Valera announced that the FDA approved the marketing of Vantas(TM), the name for Valera's long-acting LHRH implant for treating prostate cancer. Prior to June 2000, Valera operated as a division of GP Strategies. In connection with an offering of GP Strategies 6% Convertible Subordinated Exchangeable Notes due June 2003, Valera was incorporated as a separate company and became a wholly-owned subsidiary of GP Strategies through GP Strategies' ownership of 100% of the common stock of Valera.

In December 2001, Valera completed a $7 million private placement of Series A convertible preferred stock to certain institutional investors. As a condition of the private placement, GP Strategies contractually gave up operating control over Valera through an Investors Rights Agreement, which gave GP Strategies' the right to designate one director on Valera's board of directors and gave the

49

other stockholders the right to designate the other directors, and subsequent thereto accounted for the investment under the equity method. As a result of Valera operating losses, GP Strategies investment was written down to zero.

In 2003, Valera completed a private placement offering pursuant to which Valera raised approximately $13.5 million in gross proceeds from the sale of Series B convertible preferred stock. As part of such transaction, GP Strategies was granted an option until March 31, 2004, to purchase up to $5 million of the Series B convertible preferred stock at the offering price of $0.725 per share, which was subsequently verbally extended to June 30, 2004. On June 30, 2004, GP Strategies transferred a portion of its option to an institutional investor, who exercised such option and purchased from Valera 3,448,276 shares of Series B convertible preferred stock for $0.725 per share. The balance of the option expired unexercised. In consideration of such transfer, such institutional investor granted National Patent Development an option until October 28, 2004 to purchase up to 2,068,966 shares of Series B convertible preferred stock owned by such institutional investor for prices ranging from $0.725 to $0.7685 per share. The Company exercised such option on October 28, 2004 at a price of $0.7685 per share, for an aggregate exercise price of $1,590,000. On November 12, 2004 the Company obtained the funds necessary to pay the exercise price (see Note 14(d)). On August 16, 2004 Valera sold 11,600,000 shares of Series C convertible preferred stock and received gross proceeds of $11.6 million. On March 14, 2005 Valera registered with the Securities and Exchange Commission for an initial public offering of up to approximately $75 million of common stock.

The Series A preferred stock, Series B preferred stock and Series C preferred stock, which are convertible into Valera's common stock at any time, have voting rights on an as-converted basis on all matters submitted to the stockholders and are also entitled to receive dividends on an as-converted basis with shares of common stock when, as and if declared by the Board of Directors. In addition the Series A, B and C preferred stock accrue cumulative dividends at the rate of 6%, 10% and 6%, respectively, of the stated value, payable when and as declared by the Board of Directors. In the event of liquidation, the holders of the preferred stock shall be entitled to receive preferential distributions before any payment shall be made in respect of the common stock. If the initial public offering is completed under the terms presently anticipated, all the convertible preferred stock outstanding at the time of the offering, including accrued dividends, will automatically convert into common stock. Assuming conversion of all of the outstanding shares of Series A, Series B and Series C convertible preferred stock and exercise of stock options held by employees of Valera at December 31, 2004, the Company would own approximately 17.7% of Valera. Such percentage will be further reduced upon successful completion of the public offering.

As described in Note 14(b), on October 17, 2003, MXL received from GPS in partial payment of a note receivable the common shares of Valera and recorded such shares at zero representing their carrying amount to GPS. As a result of the Investors Rights Agreement referred to above, the Company was accounting for its investment in Valera under the equity method. However as the Company had not guaranteed obligations of Valera and had not otherwise committed to provide further support for Valera, it had discontinued recognizing additional losses of Valera.

As described above, the Company's investment in voting stock of Valera has declined below 20% and is anticipated to decrease further upon completion of Valera's initial public offering. In addition, at December 31, 2004 Valera's

50

board of directors consists of nine directors only one of which has been designated by the Company. Accordingly the Company believes that it no longer has the ability to exercise significant influence over operating and financial policies of Valera and will no longer account for its investment in Valera by the equity method. As a result thereof, the investment in Valera's Series B convertible preferred stock is being accounted for at cost.

5. Marketable securities

Marketable securities, which are carried at market value, were comprised of the following (in thousands):

Available-for-sale securities

                                                                December 31,
                                                            2004         2003
        --------------------------------------------- ------------- ------------
        Millennium Cell Inc.                               $1,235       $2,769
        Avenue Entertainment Group, Inc.                      181          212
                                                         --------     --------
                                  $1,416 $2,981

Millennium Cell Inc. ("Millennium")

Millennium is a publicly traded emerging technology company engaged in the business of developing innovative fuel systems for the safe storage, transportation and generation of hydrogen for use as an energy source. At December 31, 2002 and 2001, Company held 293,271 shares of Millennium with a market value of $698,000 and $1,531,000, respectively, and unrealized gains of $341,000 and $1,174,000, respectively. On October 17, 2003, the Company received from GP Strategies in partial payment of a receivable an additional 1,000,000 shares of common stock of Millennium with a market value on that date of approximately $3,500,000. From October 17, 2003 through December 31, 2003 the Company sold 105,000 of such Millennium shares for $272,000 and recognized a loss of $95,000, which is included in Investment and other income (loss). At December 31, 2003 the Company held 1,188,271 shares of common stock of Millennium with a market value of $2,769,000 and an unrealized loss of $721,000, which resulted from reductions in market value during the year ended December 31, 2003. During the year ended December 31, 2004, the Company sold 223,500 shares of Millennium shares received in October 2003 for $609,000 and recognized a loss of $173,000, which is included in Investment and other income (loss). At December 31, 2004, the Company held 964,771 shares of common stock of Millennium with a market value of $1,235,000, representing approximately a 3% ownership interest, and an unrealized loss of $499,000 reflecting further unrealized losses during the year ended December 31, 2004, after recognition of an impairment loss described below.

At December 31, 2003 the Company believed that the reduction in market value of Millennium correlated with the general trend of the market for emerging technology companies and reflected the volatility of Millennium's stock price. The Company had evaluated the near-term prospects of Millennium in relation to the severity and duration of the impairment. Based on that evaluation and the Company's ability and intent to hold this investment for a reasonable period of

51

time sufficient for a forecasted recovery of fair value, the Company did not consider its investment in Millennium to be other-than-temporarily impaired. However, at June 30, 2004, based on the increase in the severity and duration of the impairment and the absence of sufficient evidence to support a recovery of fair value within a reasonable period of time, the Company considered the investment in the 671,500 remaining shares acquired in October 2003 to be other-than-temporarily impaired and accordingly has recorded an impairment loss of $1,081,000 related to such shares in Investment and other income (loss) in the year ended December 31, 2004.

As of March 22, 2005, the market value of the 964,771 shares of Millennium common stock was approximately $2,007,000, representing a recovery of the unrealized loss at December 31, 2004.

Avenue Entertainment Group, Inc ("Avenue")

The Company owns 1,067,900 shares of Avenue, which is an independent entertainment company that produces feature films, series for television, made for television/cable movies and one hour profiles of Hollywood stars. As of December 31, 2004 and 2003 the market value of Avenue approximated $181,000 and $212,000, respectively, resulting in an unrealized gain of $124,000 and $154,000, respectively.

Trading securities

Hemispherx Biopharma Inc. ("HEB")

In the fourth quarter of 2003, MXL received a capital contribution of 267,296 shares of HEB from GP Strategies with a market value of $550,000 and subsequently sold 107,700 of the shares for $249,000. For the year ended December 31, 2003, the Company realized a gain of $27,000 on the sale of these shares and unrealized holding gains of $32,000 on the remainder of the shares, which are both included in Investment and other income (loss). The approximately 160,000 shares remaining at December 31, 2003 were classified as trading securities. These shares had a fair value of approximately $361,000 at December 31, 2003 and were sold in the first quarter of 2004 for $404,000. For the year ended December 31, 2004 the Company recorded a realized gain of $43,000 on the sale of these shares, which is included in Investment and other income (loss).

6. Five Star acquisition

On September 30, 1998, GP Strategies sold substantially all of the operating assets of the Five Star business to American Drug, an entity which was then 37.5% owned by GP Strategies, and received cash and a five-year 8% unsecured senior note in the original principal amount of $5,000,000 (the "Five Star Note") as partial consideration. American Drug then changed its name to Five Star Products, Inc.

On August 31, 1998, GP Strategies entered into a voting agreement with Five Star (the "Voting Agreement") pursuant to which GP Strategies agreed that for a period of three years it would vote its shares of Five Star common stock (i) such that not more than 50% of Five Star's directors would be officers or directors of GP Strategies and (ii) on all matters presented to a vote of stockholders, other than the election of directors, in the same manner and in

52

the same proportion as the remaining stockholders of Five Star vote. On June 30, 2002, GP Strategies and Five Star extended the Voting Agreement until June 30, 2004.

The Five Star Note was amended in November 2001 to provide for the extension of its maturity date until September 30, 2004, and on March 31, 2004 the maturity date of the Five Star Note was further extended until June 30, 2005. Under a separate Subordination Agreement between GP Strategies and the banks providing Five Star's $25,000,000 revolving loan, Five Star may make annual cash payments of principal to GP Strategies provided Five Star achieves certain financial performance benchmarks.

On August 2, 2002 GP Strategies exchanged $500,000 principal amount of the Five Star Note for 2,272,727 shares of Five Star's common stock, reducing the outstanding principal amount of the Five Star Note to $4,500,000 and increasing GP Strategies ownership of the Five Star common stock to 7,133,417 shares, approximately 48% of the then outstanding shares. The transaction valued the Five Star common stock at $0.22 a share, which was at a premium to the market value at that time.

Pursuant to the provisions of the Subordination Agreement, in 2003 Five Star made principal payments on the Five Star Note to GP Strategies in the amounts of $1,000,000 prior to the exchange referred to below and $200,000 after such exchange. On October 8, 2003, GP Strategies exchanged $500,000 principal amount of the Five Star Note for 2,000,000 shares of Five Star common stock, reducing the outstanding principal balance of the Five Star Note to $3,000,000 and increasing GP Strategies' ownership of Five Star's common stock to 9,133,417 shares, approximately 54% of the then outstanding shares. In consideration for GP Strategies agreeing to exchange at a price of $0.25 per share, which was at a significant premium to the market price of the Five Star common stock on the day prior to approval of the transaction, Five Star agreed to terminate the Voting Agreement and thereby GP Strategies obtained a controlling financial interest in Five Star. Accordingly, as described in Note 1, Five Star's financial statements have been consolidated with those of the Company commencing as of such date. On July 30, 2004, GP Strategies transferred the Five Star Note with an outstanding balance of $2,800,000 to National Patent Development (see Note 1); accordingly the Five Star Note has been eliminated from the consolidated balance sheet as of December 31, 2004 and December 31, 2003 as an intercompany balance.

The Company accounted for its investment in Five Star using the equity method prior to obtaining a controlling financial interest. In 2003 and 2002, the Company received $475,000 and $33,000, respectively, representing a recovery of a portion of its investment in Five Star.

Information relating to the Company's investment in Five Star for the year ended December 31, 2002 is as follows (in thousands):

                                                              2002
        Interest income on note (1)                         $  384
        Equity interest in net income (2)                   $   55


(1)      Included in income related to equity investee.

53

(2) Net of depreciation of property, plant and equipment (attributable to excess of the carrying value of investment in Five Star over underlying equity in its net assets) of $107,000. Effective January 1, 2002, upon adoption of FASB Statement No. 142, amortization of goodwill ceased (see Note 8).

Condensed financial information for Five Star for the year ended December 31, 2002 is as follows (in thousands):

                                                             2002
                                                             ----
 Sales                                                    $94,074
Gross profit                                               16,613
Net income                                                    391

As described above, on October 8, 2003, the Company increased its ownership interest in Five Star's outstanding common stock from 48% to 54%, obtained a controlling financial interest in Five Star and accordingly commenced consolidating Five Star's financial statements with those of the Company. The increase in ownership occurred because the Company believed that the common stock of Five Star represented an attractive investment opportunity based on its valuation at that time. Five Star is a separate segment of the Company, formerly called the Home Improvement Distribution Segment.

The acquisition of a controlling financial interest was accounted for as a purchase transaction, and accordingly, the net assets acquired were recorded at their fair value at the date of the acquisition. The excess of the net assets acquired over carrying value of the Company's investment in Five Star was recorded as a reduction to property, plant and equipment.

The components of the net assets at date of acquisition, minority interest and the Company's cost of its acquired interest were as follows (in thousands):

Accounts receivable                                             $13,267
Inventory                                                        20,222
Property, plant & equipment and other assets                      1,228
------------------------------------------------------------ -------------
Total assets                                                     34,717
------------------------------------------------------------ -------------
Short term borrowings                                            17,616
Accounts payable and accrued expenses                            10,063
Debt to GP Strategies                                             3,000
------------------------------------------------------------ -------------
------------------------------------------------------------ -------------
Total liabilities assumed                                        30,679
------------------------------------------------------------ -------------
------------------------------------------------------------ -------------
Five Star net assets                                              4,038
------------------------------------------------------------ -------------
------------------------------------------------------------ -------------
Less minority interest in net assets                              1,996
------------------------------------------------------------ -------------
------------------------------------------------------------ -------------
Cost of net assets acquired                                      $2,042
------------------------------------------------------------ -------------

54

The following table represents the Company's unaudited pro forma consolidated statements of operations for the years ended December 31, 2003 and 2002, as if the acquisition of a controlling financial interest in Five Star had been completed at the beginning of each period. The pro forma information is presented for comparative purposes only and does not purport to be indicative of what would have occurred had the acquisition actually been made at such dates, nor is it necessarily indicative of future operating results (in thousands, except per share data):

----------------------------------------- ----------------- -----------------
Years ended December 31,                            2003              2002
----------------------------------------- ----------------- -----------------
----------------------------------------- ----------------- -----------------
Sales                                           $103,698          $104,070
Income before minority interest                       61               585
Minority interest                                   (319)             (180)
Net income                                      $     32          $    405
Net income per share
Basic and diluted                               $    .00          $    .03
----------------------------------------- ----------------- -----------------

On February 6, 2004, Five Star announced that it would repurchase up to 5,000,000 shares, or approximately 30% of its common stock currently outstanding, through a tender offer for the shares at $0.21 per share, originally set to expire on March 16, 2004. On March 17, 2004 Five Star announced that it had increased the price it was offering to pay for the shares in the tender offer to $0.25 per share and extended the offer to March 31, 2004. Effective as of such date, approximately 2,627,790 shares of common stock were tendered and acquired by Five Star at a cost of $657,000. The effect of the tender offer increased the Company's ownership in Five Star to approximately 64%. The minority interest in Five Star has been adjusted to reflect the tender offer in the accompanying balance sheet at December 31, 2004.

7. Property, plant and equipment

Property, plant and equipment consist of the following (in thousands):

                                                                     December 31,
                                                                2004               2003
-------------------------------------------------------- ------------------ -------------------
Land                                                         $    90              $  915
Buildings and improvements                                     2,383               4,228
Machinery and equipment                                        7,910               7,755
Furniture and fixtures                                         1,294               1,071
                                                         ------------------ -------------------
                                                         ------------------ -------------------
                                                              11,677              13,969
                                                         ------------------ -------------------
                                                         ------------------ -------------------
Accumulated depreciation and amortization                     (8,801)             (8,244)
                                                         ------------------ -------------------
                                                         ------------------ -------------------
                                                             $ 2,876             $ 5,725

Depreciation and amortization expense for the years ended December 31, 2004, 2003 and 2002 amounted was $726,000, $593,000 and $510,000, respectively.

In the fourth quarter 2004, management decided to sell MXL's Illinois facility as a result of a decline in production volume for the Illinois division and taking into consideration MXL's diminished real estate needs. On March 16, 2005, MXL entered into a contract to sell the Illinois facility for $1,750,000, and lease back a portion of the facility. Management believes the transaction will

55

close in 2005. Accordingly, the carrying value of the land and building has been written down by $872,000 to $1,595,000, representing its estimated fair value less costs to sell.

8. Goodwill

Goodwill, which represents the excess of cost over the fair value of the identifiable net assets of a business acquired by MXL, was being amortized through December 31, 2001 on a straight line basis over 20 years.

Effective January 1, 2002, the Company adopted FASB Statement No. 142, Goodwill and Other Intangible Assets. Statement No. 142 requires that goodwill no longer be amortized but instead tested for impairment at least annually in accordance with the provisions of Statement No. 142. The Company did not recognize any impairment as a result of the adoption of this statement. In addition, Statement 142 requires that upon adoption, the excess of cost over the underlying equity in net assets of an investee accounted for using the equity method that has been recognized as goodwill no longer be amortized. For the years ended December 31, 2004, 2003 and 2002 the Company performed a test for potential impairment of goodwill and determined that there was no impairment. The Company will continue to perform such impairment tests on an annual basis with the date of assessment being December 31. The Company's carrying amount of goodwill was $182,000 as of December 31, 2004 and 2003.

9. Long-term debt and short term borrowings

Long-term debt is comprised of the following (in thousands):

                                                                  December 31,
                                                                2004           2003
---------------------------------------------------------- -------------- ------------
MXL Pennsylvania Mortgage (a)                                 $1,305         $1,405
MXL Illinois Mortgage (b)                                          -          1,185
AOtec Debt and Notes (c)                                         421            922
Valera stock acquisition debt (see Note 14(d))                 1,590              -
Capital lease obligations                                         46             80
---------------------------------------------------------- -------------- ------------
---------------------------------------------------------- -------------- ------------
                                                               3,362          3,592
Less current maturities                                       (1,967)          (389)
---------------------------------------------------------- -------------- ------------
---------------------------------------------------------- -------------- ------------
                                                              $1,395         $3,203

(a) On March 8, 2001, MXL mortgaged its real estate and fixtures on its property in Pennsylvania for $1,680,000. The loan requires monthly repayments of $8,333 plus interest at 2.5% above the one month LIBOR rate and matures on March 8, 2011, when the remaining amount outstanding of approximately $680,000 is due in full. The loan is guaranteed by GPS.

(b) On July 3, 2001, MXL mortgaged its real estate and fixtures on its property in Illinois for $1,250,000. The loan requires monthly payments of principal and interest in the amount of $11,046 with interest at a fixed rate of 8.75% per annum, and matures on June 26, 2006, when the remaining amount outstanding of approximately $1,100,000 is due in full. The loan is guaranteed by GPS. As of December 31, 2004, the mortgage has been classified separately in the balance

56

sheet as a current liability, as a result of the classification of the Illinois property as held for sale.

(c) In September 2003, MXL purchased machinery, equipment and inventory from AOtec LLC ("AOtec"), located in the Massachusetts area, for $1,100,000, subject to adjustment. In connection with this purchase, the Company valued the machinery and equipment at approximately $900,000, the inventory at approximately $350,000 and recorded an accrued expense of $150,000. MXL paid $100,000 of the purchase price in cash and issued three notes, in the amount of $450,000, $275,000 and $275,000 each, due October 1, 2003, August 5, 2004 and August 5, 2005, respectively (collectively, the "AOtec Notes"). The AOtec Notes bear interest on the unpaid principal amount at the rate of 4% per annum. On October 1, 2003, MXL borrowed $700,000 from a bank under an agreement to finance the purchase price (the "AOtec Debt") and used a portion of the proceeds to pay the $450,000 note. The AOtec Debt bears interest at the rate of 5.89 % per annum, is payable monthly for three-years and is secured by the machinery and equipment purchased from AOtec. GPS guaranteed the AOtec Debt. The AOtec Notes amounting to $550,000 and $275,000 as of December 31, 2004 and 2003, respectively, are classified as short term borrowings on the Company's Consolidated Balance Sheets and are not included in the table above. MXL is currently negotiating a reduction in the amounts due under the AOtec Notes with maturity dates of August 5, 2004 and 2005, resulting from a dispute over the purchase price. According to the contract of sale, the payments due pursuant to the AOtec Notes were subject to an offset and withholding by MXL. The parties are attempting to resolve this matter; however there is no guarantee that MXL will successfully negotiate the reduction of the AOtec Notes.

Aggregate annual maturities of long-term debt at December 31, 2004 are as follows (in thousands):

                  2005                     $ 1,967
                  2006                         289
                  2007                         101
                  2008                         100
                  2009                         100
                  Thereafter                   805
                  --------------------------------
                  Total                     $3,362

Short-term borrowings

Five Star

In 2003, Five Star obtained a Loan and Security Agreement (the "Loan Agreement") with Bank of America Business Capital (formerly Fleet Capital Corporation) (the "Lender"). The Loan Agreement has a five-year term, with a maturity date of June 30, 2008. The Loan Agreement, as amended on May 28, 2004 provides for a $28,000,000 revolving credit facility, which allows Five Star to borrow based upon specified percentages of eligible inventory and eligible accounts receivable, as defined therein. The interest rates under the Loan Agreement are LIBOR plus a credit spread of 2% (4.28% at December 31, 2004) for borrowings not to exceed $15,000,000 and the prime rate (5.25% at December 31, 2004) for borrowings in excess of the above-mentioned LIBOR-based borrowings. The credit

57

spreads can be reduced in the event that Five Star achieves and maintains certain performance benchmarks. At December 31, 2004 and 2003, approximately $18,234,000 and $16,685,000 was outstanding under the Loan Agreement and approximately $434,000 and $480,000 was available to be borrowed, respectively. Substantially all of Five Star's assets (with a carrying amount of $40,277,000 at December 31, 2004) are pledged as collateral for the outstanding borrowings. Under the Loan Agreement, Five Star is subject to covenants requiring minimum net worth, limitations on losses, if any, and minimum or maximum values for certain financial ratios. As of December 31, 2004 Five Star was in compliance with all required covenants.

In March 2005, Five Star amended the Loan Agreement to allow it to increase the maximum amount that can be borrowed under the revolving credit facility to $30,000,000 through June 30, 2005; reverting back to a maximum of $28,000,000 on July 1, 2005.

In connection with the Loan Agreement, Five Star also entered into a derivative transaction with the Lender on June 20, 2003. The derivative transaction is an interest rate swap which has been designated as a cash flow hedge. Effective July 1, 2004 through June 30, 2008, Five Star will pay a fixed interest rate of 3.38% to the Lender on notional principal of $12,000,000. In return, the Lender will pay to Five Star a floating rate, namely, LIBOR, on the same notional principal amount. The credit spread under the Loan Agreement is not included in and will be paid in addition to this fixed interest rate of 3.38%. At December 31, 2004 and 2003, the interest rate swap had a fair value of $105,000 and $122,000, respectively, which is included in other assets in the accompanying balance sheets. On June 17, 2004, Five Star has also entered into a derivative interest rate collar transaction during the period from July 1, 2004 through June 30, 2008 on notional principal of $12,000,000. The transaction consists of an interest rate floor of 2.25%, whereas if LIBOR is below 2.25%, the Lender will pay to Five Star the difference between LIBOR and 2.25%, on the same notional principal amount. The transaction also consists of an interest rate cap of 5.75%, whereas if LIBOR is above 5.75%, Five Star will pay to the Lender the difference between LIBOR and 5.75%, on the same notional principal amount. The interest rate collar is shown as a non-current liability in the Company's Consolidated Balance Sheet as of December 31, 2004.

MXL

On March 1, 2005, MXL obtained a Line of Credit Loan (the "MXL Line") from M&T Bank with a one year term, maturing on March 1, 2006. The MXL Line provides for a $1,000,000 revolving credit facility, which is secured by MXL's eligible accounts receivable, inventory and a secondary claim on the Lancaster, PA property. The interest rates under the MXL Line consist of LIBOR plus a credit spread of 3% or the prime rate plus a credit spread of 0.25%. The MXL Line is subject to an unused commitment fee of 0.25% of the average daily unused balance of the line payable quarterly. National Patent Development has guaranteed the MXL Line.

58

10. Income taxes

Commencing November 24, 2004, the date of the spin-off, the Company will file a consolidated federal income tax return with its subsidiaries, except for Five Star which is less than 80% owned and files its own separate consolidated federal income tax return. Prior to the spin-off, MXL's operating results together with those of the non-core assets historically have been included in consolidated federal income tax returns filed by GPS. In addition, MXL files separate state income tax returns in Pennsylvania and Illinois. Income tax expense (benefit) in the accompanying financial statements for the periods prior to the spin-off has been computed as if MXL filed its own separate federal and state income tax returns including transactions related to the non-core assets. As GPS did not own 80% of its common stock, Five Star filed its own separate consolidated federal income tax return, as well as separate state and local income tax returns.

Prior to the spin-off National Patent Development and GPS entered into a Tax Sharing Agreement. The Tax Sharing Agreement, which was effective as of January 1, 2004, provides for tax sharing payments between National Patent Development and GPS for the period prior to the spin-off, so that National Patent Development is generally responsible for tax expense attributable to its lines of business and entities comprising it, and GPS is generally responsible for the tax expense attributable to its lines of business and entities comprising it. From January 1, 2004 through November 24, 2004, the date of the spin-off, no amounts were charged to National Patent Development under the Tax Sharing Agreement, as no tax expense was incurred by National Patent Development for this period. Prior to the tax sharing agreement being in effect, no amounts were charged or credited to MXL as if it filed its own separate federal income tax return. In addition, no amount was credited to MXL for utilization by GPS of MXL's 2004 loss for the period prior to the spin-off. Accordingly, the expense (benefit) for current federal income taxes (exclusive of amounts pertaining to Five Star for 2004 and 2003) for such periods and current state and local income taxes related to the results of non-core assets has been accounted for as an adjustment to stockholders' equity.

The components of income tax expense (benefit) are as follows (in thousands):

                                          Year Ended December 31,
                                        2004           2003          2002
-------------------------------- -------------- ------------- -------------
Current
Federal                               $703           $359           $57
State and local                        226            113            11
-------------------------------- -------------- ------------- -------------
-------------------------------- -------------- ------------- -------------
Total current                          929            472            68
-------------------------------- -------------- ------------- -------------
-------------------------------- -------------- ------------- -------------
Deferred
Federal                                 53           (246)           64
State and local                          -            (53)           13
-------------------------------- -------------- ------------- -------------
-------------------------------- -------------- ------------- -------------
Total deferred                          53           (296)           77
-------------------------------- -------------- ------------- -------------
-------------------------------- -------------- ------------- -------------
Total income tax expense              $982           $176          $145

The deferred expense (benefit) excludes activity in the net deferred tax liability relating to tax on appreciation (depreciation) in available-for-sale securities and the interest rate swap, which is recorded directly to stockholders' equity.

59

The difference between the expense (benefit) for income taxes computed at the statutory rate and the reported amount of tax expense (benefit) is as follows:

                                                                                  Year Ended December 31,
                                                                              2004          2003         2002
------------------------------------------------------------------------- ------------- ------------ -------------
Federal income tax rate                                                        (35.0)%        35.0%      35.0%
State and local taxes, net of federal benefit                                   4.7           7.0         5.2
Non-deductible expenses                                                         0.4           9.3         7.6
Impairment and realized losses for investment in marketable securities
for which no benefit has been provided                                         15.2           3.4         -
Loss on write-down of Illinois property for which no benefit has been
provided                                                                       10.9           -           -
Net operating loss of MXL for period prior to spin-off unable to be
utilized on a stand-alone basis for which no benefit has been provided         15.1           -           -
Net operating loss of the Company for period subsequent to spin-off for
which no benefit has been provided                                             24.6           -           -
Other                                                                          (4.3)         (8.7)        1.9
------------------------------------------------------------------------- ------------- ------------ -------------
------------------------------------------------------------------------- ------------- ------------ -------------
Effective tax rate expense (benefit)                                            31.6%         46.0%      49.7%

The tax effects of temporary differences between the financial reporting and tax bases of assets and liabilities that are included in the net deferred tax (liability) asset are summarized as follows:

                                                December 31,
                                                     2004          2003
----------------------------------------------- ------------- -----------
Deferred tax assets:
Property and equipment                            $   425        $  176
Allowance for doubtful accounts                        98            78
Accrued liabilities                                    42            45
Marketable securities                                 491           187
Other investments                                   2,256         2,256
Net operating loss carryforward                     1,801             -
Interest rate collar                                    8             -
Inventory                                             122            47
Capital loss carryforward                              65            14
----------------------------------------------- ------------- -----------
Deferred tax assets                                 5,308         2,803
----------------------------------------------- ------------- -----------
Deferred tax liabilities:
Interest rate swap                                     44            51
----------------------------------------------- ------------- -----------
Deferred tax liabilities                               44            51
----------------------------------------------- ------------- -----------
----------------------------------------------- ------------- -----------
Net deferred tax assets                             5,264         2,752
----------------------------------------------- ------------- -----------
----------------------------------------------- ------------- -----------
Less valuation allowance                           (5,331)       (2,774)
----------------------------------------------- ------------- -----------
Net deferred tax liabilities                       $  (67)       $  (22)
----------------------------------------------- ------------- -----------

60

As of December 31, 2004 National Patent Development has a net operating loss carryforward of $4,618,000, representing a loss incurred subsequent to the spin-off and losses incurred by MXL prior to the spin-off, which expire from 2017 to 2024. In addition, National Patent Development has a capital loss carryforward of $166,000, which expires in 2009.

Under the Internal Revenue Code's consolidated return regulations, each member of GP Strategies consolidated group (including MXL) is jointly and severally liable for the consolidated federal income tax liabilities. GPS, National Patent Development and their respective subsidiaries entered into a Tax Sharing Agreement that defines the parties' rights and obligations with respect to deficiencies and refunds of federal, state and other taxes relating to the National Patent Development business for tax years prior to the spin-off and with respect to certain tax attributes of National Patent Development after the spin-off. In general, GPS will be responsible for filing consolidated federal tax returns and paying any associated taxes for periods through the date of the spin-off (the "Distribution Date"). National Patent Development will be required to pay GPS an amount equivalent to federal taxes relating to National Patent Development and its subsidiaries allocated taxable income includable in GPS's consolidated federal income tax return for the taxable period that ends on the Distribution Date. National Patent Development is responsible for filing its own tax returns and paying taxes for periods beginning on or after the Distribution Date. GPS and National Patent Development agreed to cooperate with each other and to share information in preparing such tax returns and in dealing with other tax matters. GPS and National Patent Development will be responsible for their own taxes other than those described above.

National Patent Development has agreed not to take any actions or enter into any transactions that would cause the spin-off not to qualify as tax-free. National Patent Development also has agreed to indemnify GPS to the extent that any action National Patent Development takes gives rise to a tax incurred by GPS with respect to the spin-off.

If National Patent Development increases its ownership to at least 80% of Five Star's common stock, Five Star would become, for federal tax purposes, part of the affiliated group of which National Patent Development is the common parent. As a member of such affiliated group, Five Star would be included in National Patent Development's consolidated federal income tax returns, Five Star's income or loss would be included as part of the income or loss of the affiliated group and any of Five Star's income so included might be offset by the consolidated net operating losses, if any, of the affiliated group. Five Star has entered into a tax sharing agreement with GP Strategies (which was assigned to National Patent Development as part of the spin-off) pursuant to which Five Star will make tax sharing payments to National Patent Development once Five Star becomes a member of the consolidated group equal to 80% of the amount of taxes Five Star would pay if Five Star were to file separate consolidated tax returns but did not pay as a result of being included in National Patent Development affiliated group.

11. Capital Stock, stock option and employee benefit plans

The Board of Directors without any vote or action by the holders of common stock is authorized to issue preferred stock from time to time in one or more series and to determine the number of shares and to fix the powers, designations, preferences and relative, participating, optional or other special rights of any series of preferred stock.

61

Under GPS's non-qualified stock option plan, employees of MXL were granted options to purchase shares of common stock of GPS. Although the plan permits options to be granted at a price not less than 85% of the fair market value, the plan options primarily are granted at the fair market value of the common stock at the date of the grant and are exercisable over periods not exceeding ten years from the date of grant. Changes in options outstanding granted to MXL employees during the years ended December 31, 2002, 2003 and 2004 are as follows:

                                                                  Number           Number             Weighted Average
                                              Price Range       Of Options       Of Options       Exercise         Years
                                               Per share        Outstanding     Exercisable        Price         Remaining
------------------------------------------ ------------------ ---------------- --------------- --------------- ---------------
------------------------------------------ ------------------ ---------------- --------------- --------------- ---------------
December 31, 2001                           $  9.98               1,250            1,250         $  9.98       1 year
------------------------------------------ ------------------ ---------------- --------------- --------------- ---------------
------------------------------------------ ------------------ ---------------- --------------- --------------- ---------------
Expired                                     $  9.98              (1,250)                         $  9.98
------------------------------------------ ------------------ ---------------- --------------- --------------- ---------------
------------------------------------------ ------------------ ---------------- --------------- --------------- ---------------
December 31, 2002, 2003 and 2004               -                   -                -               -              -
------------------------------------------ ------------------ ---------------- --------------- --------------- ---------------

On November 3, 2003, GPS and the Board of Directors of National Patent Development adopted an Incentive Stock Plan under which 1,750,000 shares of common stock are available for grant to employees, directors and outside service providers. The plan permits awards of incentive stock options, nonqualified stock options, restricted stock, stock units, performance shares, performance units and other incentives payable in cash or in shares of National Patent Development's common stock. As of December 31, 2004, no awards have been granted under the plan.

Five Star Stock Option plan

On January 1, 1994, Five Star's Board of Directors adopted the Five Star Products, Inc. 1994 Five Star Plan (the "Five Star Plan"), which became effective August 5, 1994. On January 1, 2002, the Board of Directors amended the Five Star Plan increasing the total number of shares of common stock to 4,000,000 shares reserved for issuance, subject to adjustment in the event of stock splits, stock dividends, recapitalizations, reclassifications or other capital adjustments. Unless designated as "incentive stock options" intended to qualify under Section 422 of the Internal Revenue Code, options granted under the Five Star Plan are intended to be nonqualified options. Options may be granted to any director, officer or other key employee of Five Star and its subsidiaries, and to consultants and other individuals providing services to Five Star.

The term of any option granted under the Five Star Plan will not exceed ten years from the date of the grant of the option and, in the case of incentive stock options granted to a 10% or greater holder in the total voting stock of Five Star, three years from the date of grant. The exercise price of any option will not be less than the fair market value of the Common Stock on the date of grant or, in the case of incentive stock options granted to a 10% or greater holder in the total voting stock, 110% of such fair market value. Options granted vest 20% on date of grant with the balance vesting in equal annual installments over four years.

62

Activity relating to stock options granted by Five Star commencing at the date the Company acquired a controlling financial interest follows:

                                                                   Number of          Weighted Average
Options Outstanding                                                   Shares           Exercise Price
-------------------------------------------------------------- ------------------- ------------------------
October 8, 2003                                                    2,930,000                   $.16
-------------------------------------------------------------- ------------------- ------------------------
Granted                                                                    -                      -
Exercised                                                                  -                      -
Terminated                                                        (1,400,000)                   .13
-------------------------------------------------------------- ------------------- ------------------------
December 31, 2003                                                  1,530,000                    .19
-------------------------------------------------------------- ------------------- ------------------------
Granted                                                                    -                      -
Exercised                                                                  -                      -
Terminated                                                          (430,000)                   .30
-------------------------------------------------------------- ------------------- ------------------------
December 31, 2004                                                  1,100,000                   $.14
-------------------------------------------------------------- ------------------- ------------------------

-------------------------------------------------------------- ------------------- ------------------------
Options Exercisable at December 31, 2004                             770,000                   $.14
-------------------------------------------------------------- ------------------- ------------------------

The following table summarizes information about the Five Star Plan's options at December 31, 2004:

                                        Weighted                             Weighted
                                        Average                               Average
  Exercise            Number             Years             Number              Years
    Price          Outstanding         Remaining         Exercisable         Remaining
-------------- --------------------- --------------- -------------------- ----------------
-------------- --------------------- --------------- -------------------- ----------------
     $.14              900,000             2.0              630,000               1.9
      .15               50,000             2.3               50,000               2.3
      .16              150,000             2.6               90,000               2.6
-------------- --------------------- --------------- -------------------- ----------------
-------------- --------------------- --------------- -------------------- ----------------
                     1,100,000             2.1              770,000               2.0

Five Star Employee Benefit Plan

Five Star maintains a 401(k) Savings Plan for employees who have completed one year of service. The Savings Plan permits pre-tax contributions to the plan of 2% to 50% of compensation by participants pursuant to Section 401(k) of the Internal Revenue Code. Five Star matches 40% of the participants' first 6% of compensation contributed, not to exceed an amount equivalent to 2.4% of that participant's compensation. Five Star's contribution to the plan was approximately $123,000 and $125,000 for the years ended December 31, 2004 and 2003, respectively.

12. Commitments

Five Star has several noncancellable leases for real property and machinery and equipment. In addition MXL has a noncancellable lease for real property and several noncancellable leases for machinery and equipment. Such leases expire at various dates with, in some cases, options to extend their terms.

63

As of December 31, 2004, minimum rentals under long-term operating leases are as follows (in thousands):

                           Real            Machinery &
                         property           equipment          Total
-------------------- ------------------ ------------------ --------------
2005                       $  1,829          $   438        $  2,267
2006                          1,779              374           2,153
2007                            436              366             802
2008                              -              302             302
2009                              -               38              38
Thereafter                        -                -               -
-------------------- ------------------ ------------------ --------------
-------------------- ------------------ ------------------ --------------
Total                        $4,044          $1,518           $5,562
-------------------- ------------------ ------------------ --------------

Several of the leases contain provisions for rent escalation based primarily on increases in real estate taxes and operating costs incurred by the lessor. Rent expense was approximately $3,147,000, $3,037,000, and $81,000 for the years ended December 31, 2004, 2003 and 2002, respectively. GPS has guaranteed the leases for Five Star's New Jersey and Connecticut warehouses, having annual rentals of $1,589,000 and expiring in the first quarter of 2007.

13. Segment Information

The operations of the Company currently consist of the following two business segments, by which the Company is managed.

The MXL Segment, formerly called the Optical Plastics Segment, manufactures precision coated and molded optical plastic products. MXL is a specialist in the manufacture of polycarbonate parts requiring adherence to strict optical quality specifications, and in the application of abrasion and fog resistant coatings to those parts.

The Five Star Segment, formerly called the Home Improvement Distribution Segment, distributes paint sundry items, interior and exterior stains, brushes, rollers, caulking compounds and hardware products on a regional basis. The Company acquired additional shares of Five Star in fourth quarter of 2003, bringing its ownership to 54% (see Note 4). Five Star's operations are consolidated in the Company's financial statements commencing January 1, 2003.

64

The following tables set forth the sales and operating profit attributable to each line of business (in thousands):

                                                         Year Ended December 31,
                                                      2004           2003           2002
-------------------------------------------- ---------------- ---------------- --------------
Sales
MXL                                             $    8,241      $   8,613          $9,996
Five Star                                          101,982         95,085               -
-------------------------------------------- ---------------- ---------------- --------------
                                                  $110,223       $103,698          $9,996
-------------------------------------------- ---------------- ---------------- --------------
Operating profit (loss)
MXL                                               $ (2,593)     $    (280)         $  180
Five Star                                            3,244          2,068             439(a)
Corporate and other                                 (1,423)          (480)           (128)
-------------------------------------------- ---------------- ---------------- --------------
                                                $     (772)      $  1,308          $  491
-------------------------------------------- ---------------- ---------------- --------------

(a) Income related to equity in net income of Five Star

Additional information relating to the Company's business segments is as follows (in thousands):

                                                          December 31,
                                                        2004           2003
------------------------------------------------- -------------- --------------

Total assets
MXL                                                   $13,621        $14,261
Five Star                                              40,277         36,622
Corporate and other                                     6,576          2,755
------------------------------------------------- -------------- --------------
                                                      $60,474        $53,638
------------------------------------------------- -------------- --------------

                                                           Year Ended December 31,
                                                       2004         2003            2002
------------------------------------------------- ------------ ---------------- ------------

Additions to property,
plant, and equipment
MXL                                                    $ 183      $ 1,135 (a)        $368
Five Star                                                275          159               -
------------------------------------------------- ------------ ---------------- ------------
                                                        $458       $1,294            $368
------------------------------------------------- ------------ ---------------- ------------

Depreciation and amortization
MXL                                                   $ 616        $ 565             $510
Five Star                                               110           28
------------------------------------------------- ------------ ---------------- ------------
                                                      $ 726        $ 593             $510
------------------------------------------------- ------------ ---------------- ------------

65

(a) Includes property, plant and equipment acquired from AOtec.

For the years ended December 31, 2004 and 2003, no customer accounted for 10% or more of the Company's sales. The Company's major customers of the MXL Segment accounted for the following percentage of total sales for the year ended December 31, 2002:

                               2002
--------------------- --- ---------------
--------------------- --- ---------------
A                              23%
B                              21%
C                               8%
--------------------- --- ---------------
--------------------- --- ---------------
Total                          52%

Information about the Company's net sales in different regions, which are attributable to countries based upon location of customers, is as follows (in thousands):

                                        Year Ended December 31,
                                    2004          2003         2002
------------------------------ ------------- ------------- --------------
------------------------------ ------------- ------------- --------------
United States                      $107,644      $102,015        $8,264
Far East                              1,288         1,230         1,266
Other                                 1,291           453           466
------------------------------ ------------- ------------- --------------
------------------------------ ------------- ------------- --------------
                                   $110,223      $103,698        $9,996

All assets of the Company are in the United States.

14. Related party transactions

(a) GPS provided certain administrative services to National Patent Development, including but not limited to tax and financial accounting, legal, human resources, employee benefits and insurance. The costs of these services were allocated to National Patent Development based on specific identification and, to the extent that such identification was not practical, on the basis of sales or other method which management believes to be a reasonable reflection of the utilization of services provided or the benefit received by National Patent Development. These allocations resulted in charges of $911,000, $680,000 and $321,000 being recorded in selling, general and administrative expenses in the accompanying consolidated statements of operations for the years ended December 31, 2004, 2003 and 2002, respectively. Allocated expenses in excess of amounts which reduced the receivable balance due from GPS (see (b) below) have been recorded as a capital contribution resulting in an increase in additional paid-in capital. The expenses allocated to National Patent Development for these services are not necessarily indicative of the expenses that would have been incurred if National Patent Development had been a separate, independent entity and had otherwise managed these functions.

GPS also provided legal, tax, business development, insurance and employee benefit administration services to Five Star pursuant to a management services agreement for a fee of up to $10,000 per month. The agreement is automatically renewable for successive one-year terms unless one of the parties notifies the other in writing at least six months prior to the end of any renewal thereof. The agreement was renewed for 2005. The management fee increased to $25,000 per month effective October 1, 2004. In addition Five Star agreed to reimburse GPS for $16,666 per month for Mr. Feldman's (GPS' Chief Executive Officer) service

66

to the Company effective October 1, 2004. Prior to the Distribution, GPS transferred to National Patent Development the rights and obligations under the management services agreement with Five Star. Fees paid by Five Star to GPS under this agreement, which are included in selling, general and administrative expenses, totaled $132,000 and $100,000 for the years ended December 31, 2004 and 2003, respectively. At December 31, 2003 fees due to GPS, which are included in accounts payable and accrued expenses, amounted to $257,000.

GPS and National Patent Development have entered into contracts described below that will govern certain relationships between them. GPS and National Patent Development believe that these agreements are at fair market value and are on terms comparable to those that would have been reached in arm's-length negotiations had the parties been unaffiliated at the time of the negotiations.

Certain of National Patent Development's executive officers are also executive officers of GPS and will remain on GPS's payroll. The executive officers will not receive any salary from National Patent Development; however, they will provide National Patent Development with management services under a management agreement between GPS and National Patent Development. GPS charges National Patent Development a management fee to cover an allocable portion of the compensation of these officers, based on the time they spend providing services to National Patent Development, in addition to an allocable portion of certain other corporate expenses. Such fee amounted to $107,000 for the period subsequent to the spin-off through December 31, 2004.

In connection with the spin-off, National Patent Development entered into a separate management agreement with GPS pursuant to which National Patent Development will provide certain general corporate services to GPS. Under this management agreement, National Patent Development will charge GPS a management fee to cover an allocable portion of the compensation of its employees, based on the time they spend providing services to GPS, in addition to an allocable portion of corporate overhead related to services performed for GPS and its subsidiaries. Such fee amounted to $17,000 for the period subsequent to the spin-off through December 31, 2004.

Both management fees will be paid quarterly. Any disagreements over the amount of such fees will be subject to arbitration. Each of the management agreements will each have an initial term of three years, and after two years, will be terminable by both GPS and National Patent Development, upon six months prior written notice.

National Patent Development was included in GPS's consolidated income tax group and National Patent Development's tax liability was included in the consolidated federal income tax liability of GPS until the time of the spin-off. The Tax Sharing Agreement provides for tax sharing payments between GPS and National Patent Development for periods prior to the spin-off, so that National Patent Development will be generally responsible for the taxes attributable to its lines of business and entities comprising it and GPS will be generally responsible for the taxes attributable to its lines of business and the entities comprising it.

GPS and National Patent Development agreed that taxes related to intercompany transactions that are triggered by the National Patent Development spin-off will be generally allocated to GPS. GPS and National Patent Development agreed that

67

joint non-income tax liabilities will generally be allocated between GPS and National Patent Development based on the amount of such taxes attributable to each group's line of business. If the line of business with respect to which the liability is appropriately associated cannot be readily determined, the tax liability will be allocated to GPS.

Under the distribution agreement that governed the spin-off of National Patent Development from GPS, GPS and National Patent Development each agreed that neither would take any action that might cause the spin-off of National Patent Development to not qualify as a tax-free distribution. Should one party take an action which causes the spin-off not to so qualify, then that party would be liable to the other for any taxes incurred by the other from the failure of the spin-off to qualify as a tax-free distribution.

(b) The receivable from GPS, which, except for the balance due at December 31, 2004, arose principally from cash advances by MXL, is non-interest bearing. Transactions affecting the receivable, together with the average balances, follow (in thousands):

                                                            Year Ended December 31,
                                                ------------- -- -------------- -- --------------
                                                    2004             2003              2002
                                                -------------    --------------    --------------

Balance at beginning of period                     $    709          $10,116           $10,162
Management fee and
other charges from GPS (1)                             (559)            (717)             (446)
Repayments                                           (1,032)         (10,000)
Advances                                                882            1,310               400

Contribution receivable from GPS                      5,000
----------------------------------------------- ------------- -- -------------- -- --------------
Balance at end of period                            $ 5,000         $    709          $ 10,116
----------------------------------------------- ------------- -- -------------- -- --------------
Average balance                                       $ 897          $ 7,734          $ 10,096

(1) Includes a management fee paid to GPS by MXL of $140,000 for the year ended December 31, 2004 and $240,000 for each of the fiscal years ended December 31, 2003 and 2002, respectively.

On October 17, 2003, GPS transferred 100% of the outstanding common stock in Valera (formerly Hydro Med Sciences, Inc.) valued at $6.5 million (based on an independent valuation) and 1,000,000 shares of common stock of Millennium with a quoted market price of $3.50 per share to MXL in repayment of $10 million of the receivable. MXL recorded the Valera investment at zero and the Millennium common shares at $3,500,000, representing their carrying amounts to GPS, and accounted for the excess of the $10,000,000 balance of the receivable over such carrying amounts as a distribution to GPS with a corresponding reduction of $6,500,000 in stockholders' equity.

The receivable from GPS was zero following the spin-off. In December 2004 GPS received certain proceeds of litigation and arbitration claims, out of which it had agreed on July 30, 2004 to make an additional capital contribution to National Patent Development (see Note 15). GPS made the capital contribution to National Patent Development in January 2005 to settle the receivable.

68

(c) In 2002, GPS and Redstorm Scientific, Inc. ("RSS") entered into an agreement pursuant to which GPS agreed to provide general business and administrative support to RSS. RSS is a privately held computational drug design company focused on utilizing bio-informatics and computer aided molecular design to assist pharmaceutical and biotechnology companies. GPS performed and completed all necessary services for RSS during the third quarter of 2002. In consideration for such services, RSS agreed to grant GPS a five-year option to purchase 500,000 shares of RSS common stock (an approximate 4% interest) at $1 per share. GPS also has an option to purchase additional equity in RSS upon the occurrence of certain events. GPS ascribed no value to the options, due to the adverse financial condition of RSS at that time. Michael Feldman is the Chief Executive Officer of RSS and owns approximately 25.5% of the outstanding common stock of RSS. Michael Feldman is the son of Jerome Feldman, Chief Executive Officer and a director of the Company and GPS.

In addition, Roald Hoffmann, a director of the Company and GPS, is also a director of RSS and has options to purchase shares of RSS common stock.

(d) On November 12, 2004, the Company entered into an agreement to borrow approximately $1,022,000 from Bedford Oak Partners, which is controlled by Harvey P. Eisen, a director of the Company, and approximately $568,000 from Jerome I. Feldman, who is Chairman and Chief Executive Officer of the Company, to exercise the option to purchase Series B Convertible Preferred shares of Valera. The loans bear interest at 6% per annum, mature on October 31, 2009, and are secured by all shares of Valera owned by the Company, including the purchased shares. The loans are required to be prepaid out of the proceeds received from the sale of the purchased shares or from any additional capital contribution received by the Company from GP Strategies out of proceeds received by GP Strategies from its claims relating to the Learning Technologies acquisition (see Note 15). Bedford Oak Partners and Jerome I. Feldman are entitled to receive 50% of any profit received by the Company from the sale of the Valera purchased shares.

In connection with the Spin-off, GP Strategies agreed to make an additional capital contribution to the Company in an amount equal to the first $5 million of any proceeds (net of litigation expenses and taxes incurred, if any), and 50% of any proceeds (net of litigation expenses and taxes incurred, if any) in excess of $15 million, received by GP Strategies from its claims relating to the Learning Technologies acquisition. Pursuant to such agreement, GP Strategies made a $5 million additional capital contribution to the Company on January 6, 2005. On January 11, 2005, the Company prepaid the loans, including accrued interest of approximately $16,000, to Bedford Oak Partners and Jerome I. Feldman out of such proceeds.

(e) Jerome I. Feldman, the Company's Chairman and Chief Executive Officer is also Chairman and Chief Executive Officer of GPS. Scott N. Greenberg, the Company's director and Chief Financial Officer is the President and the Chief Financial Officer of GPS. Andrea D. Kantor, the Company's Vice President and General Counsel, is the Vice President and General Counsel of GPS. Harvey P. Eisen, a director of the Company, is also a director of GPS.

69

15. Litigation

On July 30, 2004, GPS agreed to make an additional capital contribution to National Patent Development, in an amount equal to the first $5 million of any proceeds (net of litigation expenses and taxes incurred, if any), and 50% of any proceeds (net of litigation expenses and taxes incurred, if any) in excess of $15 million, received with respect to the claims described below. GPS has received $13.7 million of net proceeds from such claims and, pursuant to such agreement, in January 2005 GPS made a $5 million additional capital contribution to National Patent Development.

On January 3, 2001, GPS commenced an action alleging that MCI Communications Corporation, ("MCI") MCI's Systemhouse subsidiaries ("Systemhouse"), and Electronic Data Systems Corporation, as successor to Systemhouse, ("EDS") committed fraud in connection with GPS's 1998 acquisition of Learning Technologies from the defendants for $24,300,000. GPS seeks actual damages in the amount of $117,900,000 plus interest, punitive damages in an amount to be determined at trial, and costs. Such damages are subject to reduction by the amount recovered in the arbitration.

The complaint, which is pending in the New York State Supreme Court, alleges that the defendants fraudulently induced GPS to acquire Learning Technologies by concealing the poor performance of Learning Technologies' United Kingdom operation. The complaint also alleges that the defendants represented that Learning Technologies would continue to receive new business from Systemhouse even though the defendants knew that the sale of Systemhouse to EDS was imminent and that such new business would cease after such sale. In February 2001, the defendants filed answers denying liability. No counterclaims against the plaintiffs have been asserted. Although discovery had not yet been completed, defendants made a motion for summary judgment, which was submitted in April 2002. The motion was denied by the court due to the MCI bankruptcy, but with leave to the other defendants to renew, as described below.

The defendants other than MCI then made an application to the court to stay the fraud action until a later-commenced arbitration, alleging breach of the acquisition agreement and of a separate agreement to refer business to General Physics on a preferred provider basis and seeking actual damages in the amount of $17,600,000 plus interest, is concluded. In a decision dated May 9, 2003, the court granted the motion and stayed the fraud action pending the outcome of the arbitration.

The arbitration hearings began on May 17, 2004 and concluded on May 24, 2004 before JAMS, a private dispute resolution firm. On September 10, 2004, the arbitrator issued an interim award in which she found that the sellers of Learning Technologies breached certain representations and warranties contained in the acquisition agreement. In a final award dated November 29, 2004, the arbitrator awarded GPS $12,273,575 in damages and $6,016,109 in interest. On December 30, 2004, EDS made a payment of $18,427,684, which included $138,000 of accrued interest, to GPS to satisfy its obligation under the arbitration award. The arbitration settlement, net of legal fees and expenses was held in escrow as of December 31, 2004. EDS subsequently agreed that the arbitration award is final and binding and that it will take no steps of any kind to vacate or otherwise challenge the award.

70

As a result of the conclusion of the arbitration, the state court has lifted the stay of the fraud claim against EDS. GPS is now proceeding with the fraud claim against EDS. On February 14, 2005, EDS filed a new motion for summary judgment dismissing GPS's fraud claim. GPS responded to the motion by March 17, 2005 and the motion was argued by the parties on April 4, 2005. The fraud action against MCI had been stayed as a result of the bankruptcy of MCI. In February 2004, the Bankruptcy Court lifted the stay so that the state court could rule on the merits of MCI's summary judgment motion. MCI has stated that it intends to ask the Bankruptcy Court to reinstate the stay.

National Patent Development is not a party to any legal proceeding, the outcome of which is believed by management to have a reasonable likelihood of having a material adverse effect upon the financial condition of National Patent Development.

16. GPS borrowings

(a) As of December 31, 2002, the stock of MXL and its assets together with all of the non-core assets collateralized the outstanding bank debt under the GPS credit facility. In addition, MXL was a guarantor of the bank debt. In August 2003, GPS entered into a new credit facility which replaced the existing facility and in connection therewith the security interests of the banks were terminated and MXL was released from its guarantee under the previous credit facility. MXL provided a limited guarantee of the bank debt under the new credit facility of up to $1.5 million of its accounts receivable, which were pledged as collateral for the new bank debt. However, the guarantee was released in March 2004 as MXL's accounts receivable were no longer needed in the borrowing base.

(b) Pursuant to a Note and Warrant Purchase Agreement dated August 8, 2003, GPS issued and sold to four Gabelli funds $7,500,000 aggregate principal amount of 6% Conditional Subordinated Notes due 2008 (the "Notes") and 937,500 warrants ("GP Warrants"), each entitling the holder thereof to purchase (subject to adjustment) one share of GPS's common stock. The aggregate purchase price for the Notes and GP Warrants was $7,500,000. GP Strategies and National Patent Development agreed to allocate to National Patent Development $1,875,000 of the $7,500,000 received for the Notes and Warrants. National Patent Development received the funds prior to the spin-off.

The Notes are secured by a non-recourse mortgage on the property located in Pawling, New York (the "Property") which was transferred to MXL. MXL has no liability for repayment of the Notes or any other obligations of GPS under the Note and Warrant Purchase Agreement (other than foreclosure on such property). If there is a foreclosure on the mortgage for payment of the Notes, GPS has agreed to indemnify MXL for loss of the value of the Property.

At any time that less than $1,875,000 principal amount of Notes are outstanding, GPS may defease the obligations secured by the mortgage and obtain a release of the lien of the mortgage by depositing with an agent for the Noteholders bonds or government securities with an investment grade rating by a nationally recognized rating agency which, without reinvestment, will provide cash on the maturity date of the Notes in an amount not less than the outstanding principal amount of the Notes.

71

The Note and Warrant Purchase Agreement provided that, on completion of the spin-off, National Patent Development would issue warrants ("National Patent Development Warrants") to the holders of the GP Warrants. The National Patent Development Warrants entitle the holders to purchase, in the aggregate, a number of shares of National Patent Development common stock equal to 8% of the number of shares of such stock outstanding at completion of the spin-off. An aggregate of 1,423,887 National Patent Development Warrants were issued to the holders of the GP Warrants on December 4, 2004, and allocated among them pro-rata based on the respective number of GP Warrants held by them on such date.

The exercise price of the National Patent Development Warrants is $3.57, which represents 160% of the average closing price of the National Patent Development common stock over the 20 consecutive trading days commencing on the record date of the spin-off. The National Patent Development Warrants are exercisable at any time through August 2008. The National Patent Development Warrants have anti-dilution provisions similar to those of the GP Warrants. National Patent Development provided the holders of the National Patent Development Warrants with registration rights similar to those provided by GPS to the holders of the GP Warrant.

As the National Patent Development Warrants relate to a capital contribution by GPS, their issuance has been accounted for as an offsetting charge and credit to additional paid-in capital for $883,000, representing the estimated fair value of the warrants.

17. Accounts payable and accrued expenses

Accounts payable and accrued expenses are comprised of the following at December 31, 2004 and 2003 (in thousands):

                                           December 31,
                                     2004         2003
------------------------------------ ------------ ------------
------------------------------------ ------------ ------------
Accounts payable                        $12,193      $11,983
Accrued expenses                          1,634        1,152
Due to GPS                                    -          257
Other                                     1,559          312
------------------------------------ ------------ ------------
------------------------------------ ------------ ------------
                                        $15,386      $13,704

72

NATIONAL PATENT DEVELOPMENT CORPORATION

Notes to Consolidated Financial Statements

73

18. Valuation and Qualifying Accounts

The following is a summary of the allowance for doubtful accounts related to accounts receivable for the years ended December 31 (in thousands):

                                                                                 Additions
                                              Balance at       Additional       Charged to
                                             Beginning of       Allowance         Costs &                       Balance at
                                                Period        Acquired (a)       Expenses      Deductions (b)  End of Period
------------------------------------------ ----------------- ---------------- ---------------- --------------- --------------
Year ended December 31, 2004:
Allowance for doubtful accounts                   739                 -               253            (686)            306
------------------------------------------ ----------------- ---------------- ---------------- --------------- --------------

Year ended December 31, 2003:
Allowance for doubtful accounts                    37               700               163            (161)            739
------------------------------------------ ----------------- ---------------- ---------------- --------------- --------------

Year ended December 31, 2002:
Allowance for doubtful accounts                    99                 -                16             (78)             37
------------------------------------------ ----------------- ---------------- ---------------- --------------- --------------

(a) Represents the allowance for doubtful accounts of Five Star at date of consolidation.

(b) Write-off of uncollectible accounts, net of recoveries.

19. Selected Quarterly Financial Data

(Unaudited)                                              (in thousands, except per share data)
-------------------------------------- -----------------------------------------------------------------------
                                                                 Three months ended
                                         March 31,       June 30,         September 30,       December. 31,
                                              2004         2004               2004                2004
-------------------------------------- -------------- ---------------- -------------------- ------------------

Sales                                      $29,121        $29,604            $28,738              $22,760
Gross margin                                 4,765          5,405              4,955                4,944
-------------------------------------- -------------- ---------------- -------------------- ------------------
Net loss                                $     (297)      $ (1,366)       $      (548)        $     (2,318)
-------------------------------------- -------------- ---------------- -------------------- ------------------
Net loss per share:
Basic and Diluted                      $     (.01)    $      (.08)        $    (.03)           $    (.13)
                                       -----------    ------------        ----------           ----------


-------------------------------------- ----------------------------------------------------------------------

                                                                Three months ended
                                         March 31,       June 30,       September 30,       December. 31,
                                              2003         2003              2003                2003
-------------------------------------- -------------- --------------- ------------------- -------------------

Sales                                      $27,431        $26,494           $27,310             $22,463
Gross margin                                 4,671          4,552             5,267               5,092
-------------------------------------- -------------- --------------- ------------------- -------------------
Net income (loss)                        $     (48)     $     (35)        $      50           $     (71)
-------------------------------------- -------------- --------------- ------------------- -------------------
Net income (loss) per share:
Basic and Diluted                       $     .00      $      .00         $    .00           $    (.01)
                                        ---------      ----------         --------           ----------

73

80

ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None

ITEM 9A. Controls and Procedures

"Disclosure controls and procedures" are the controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports filed or submitted by it under the Securities Exchange Act of 1934, as amended (the "Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. These controls and procedures are designed to ensure that information required to be disclosed by an issuer in its Exchange Act reports is accumulated and communicated to the issuer's management, including its principal executive and financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to the Exchange Act Rule 13a-15(e). Based upon the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective as of the end of the period covered by this report.

During the year ended December 31, 2004, there were no changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting.

PART III

The Company has adopted a Code of Ethics for directors, officers, and employees of the Company and its subsidiaries, including but not limited to the principal executive officer, the principal financial officer, the principal accounting officer or controller, or persons performing similar functions for the Company and its subsidiaries. The Code of Ethics and Conduct of Business Policy is available on the Company's website at www.npdc.com. A copy of this Code of Business Conduct and Ethics is also incorporated by reference into this report as Exhibit 14.1. If the Company makes any substantive amendment to the Code of Ethics or grants any waiver from a provision of the Code of Ethics for its executive officers or directors, the Company will disclose the nature of such amendment or waiver on its website at www.npdc.com. The Company will also provide a copy of such Code of Ethics and Code of Business Policy to any person upon written request made to the Company's Secretary in writing to the following address: National Patent Development Corporation, Attn: Secretary, 777 Westchester Avenue, White Plains, NY 10604, with a copy to National Patent Development Corporation, General Counsel at the same address.

All other information required by Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K is incorporated herein by reference to the information under the captions "Directors and Executive Officers of the Registrant", "Executive Compensation", "Security Ownership of Certain Beneficial

74

Owners and Management and Related Stockholder Matters", "Certain Relationships and Related Transactions" and "Principal Accountant Fees and Services" in the Proxy Statement for the Company's 2005 Annual Meeting of Shareholders.

PART IV

Item 15: Exhibits and Financial Statement Schedules

(a)(1) The following financial statements are included in Part II, Item 8. Financial Statements and Supplementary Data:

Financial Statements of National Patent Development Corporation and Subsidiaries:

                                                                 Page

Report of Independent Registered Public Accounting Firm            35

Consolidated Statements of Operations - Years ended December
31, 2004, 2003 and 2002                                            36

Consolidated Statements of Comprehensive Income (Loss) -
Years ended December 31, 2004, 2003 and 2002                       36

Consolidated Balance Sheets - December 31, 2004 and 2003           37

Consolidated Statements of Cash Flows - Years ended December
31, 2004, 2003 and 2002                                            38

Consolidated Statements of Changes in Stockholders' Equity -
Years ended December 31, 2004, 2003 and 2002                       40

Notes to Consolidated Financial Statements                         42

(a)(2) Schedules have been omitted because they are not required or are not applicable, or the required information has been included in the financial statements or the notes thereto.

(a)(3) See accompanying Index to Exhibits

75

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NATIONAL PATENT DEVELOPMENT CORPORATION

Dated: April 14, 2005 Jerome I. Feldman Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signatures Title

Date:    April 14, 2005           Jerome I. Feldman
                                  Chairman and Chief Executive Officer
                                 (Principal Executive Officer)


Date:    April 14, 2005           Scott N. Greenberg
                                  Chief Financial Officer and Director
                                  (Principal Financial and Accounting Officer)


Date:    April 14, 2005           Harvey P. Eisen
                                  Director


Date:    April 14, 2005           Roald Hoffmann
                                  Director


Date:    April 14, 2005           Ellen Havdala
                                  Director


Date:    April 14, 2005           Thomas C. Kinnear
                                  Director


Date:    April 14, 2005           Talton R. Embry
                                  Director

76

EXHIBIT INDEX

Number                               Description


 2.1        Form of Distribution Agreement between GP Strategies
            Corporation and the Registrant. Incorporated herein by
            reference to Exhibit 2.1 of the Registrant's Form S-1,
            Registration No. 333-118568.

 3.1        Form of Amended and Restated Certificate of Incorporation of
            National Patent Development Corporation. Incorporated herein
            by reference to Exhibit 3.1 of the Registrant's Form S-1,
            Registration No. 333-118568.

 3.2        Amended and Restated Bylaws of National Patent Development
            Corporation. Incorporated herein by reference to Exhibit 3.2
            of the Registrant's Form S-1, Registration No. 333-118568.

 4.1        Form of certificate representing shares of common stock, par
            value $0.01 per share, of National Patent Development
            Corporation. Incorporated herein by reference to Exhibit 4.1
            of the Registrant's Form S-1, Registration No. 333-118568.

 4.2        Form of National Patent Development Corporation Warrant
            Certificate dated August 14, 2003. Incorporated herein by
            reference to Exhibit 10.03 of GP Strategies Corporation
            Form10-Q for the quarter ended June 30, 2003.

 10.1       Form of Management Agreement between GP Strategies
            Corporation and the Registrant. Incorporated herein by
            reference to Exhibit 10.1 of the Registrant's Form S-1,
            Registration No. 333-118568.

 10.2       Form of Management Agreement between the Registrant and GP
            Strategies Corporation. Incorporated herein by reference to
            Exhibit 10.2 of the Registrant's Form S-1, Registration No.
            333-118568.

 10.3       Financing and Security Agreement dated August 13, 2003 by and
            between General Physics Corporation, MXL Industries, Inc. and
            Wachovia Bank, National Association. Incorporated herein by
            reference to Exhibit 10.10 of GP Strategies Corporation Form
            10-Q for the quarter ended June 30, 2003.

 10.4       Form of Tax Sharing Agreement between GP Strategies
            Corporation and the Registrant. Incorporated herein by
            reference to Exhibit 10.2 of the Registrant's Form S-1,
            Registration No. 333-118568.

 10.5       Note and Warrant Purchase Agreement, dated as of August 8,
            2003, among GP Strategies Corporation, the Registrant, MXL
            Industries, Inc., Gabelli Funds, LLC, as Agent, and the
            Purchasers listed in Schedule 1.2 thereof. Incorporated
            herein by reference to Exhibit 10 of GP Strategies Form 10-Q
            for the quarter ended June 30, 2003.

77

10.6       Registration Rights Agreement dated August 14, 2003 between
           the Registrant and Gabelli Funds, LLC. Incorporated herein by
           reference to Exhibit 10.06 to GP Strategies' Form 10-Q for
           the quarter ended June 30, 2003.

10.7       Mortgage, Security Agreement and Assignment of Leases dated
           August 14, 2003, between GP Strategies Corporation and
           Gabelli Funds, LLC. Incorporated herein by reference to
           Exhibit 10.04 of GP Strategies Corporation Form 10-Q for the
           quarter ended June 30, 2003.

10.8       Indemnity Agreement dated August 14, 2003 by GP Strategies
           Corporation for the benefit of the Registrant and MXL
           Industries, Inc. Incorporated herein by reference to Exhibit
           10.07 of GP Strategies Corporation Form 10-Q for the quarter
           ended June 30, 2003.

10.9       National Patent Development Corporation 2003 Incentive Stock
           Plan. Incorporated herein by reference to Exhibit 10.8 of the
           Registrant's Form S-1, Registration No. 333-118568.

10.10      Employment Agreement, dated as of November 28, 2001, between
           Charles Dawson and Five Star Group, Inc. Incorporated herein
           by reference to Exhibit 10.12 of Five Star Products, Inc.
           Form 10-K for the year ended December 31, 2001.

10.11      Loan and Security Agreement dated as of June 20, 2003 by and
           between Five Star Group, Inc. and Fleet Capital Corporation.
           Incorporated herein by reference to Exhibit 10.1 of Five Star
           Products, Inc. Form 10-Q for the quarter ended June 30, 2003.

10.12      First Modification Agreement dated as of May 28, 2004 by and
           between Five Star Group, Inc. as borrower and Fleet Capital
           Corporation, as Lender. Incorporated herein by reference to
           Exhibit 10.11 of Five Star Products, Inc. Form 10-K for the
           year ended December 31, 2004.

10.13      Second Modification Agreement dated as of March 22, 2005 by
           and between Five Star Group, Inc. as borrower and Fleet
           Capital Corporation, as Lender. Incorporated herein by
           reference to Exhibit 10.12 of Five Star Products, Inc. Form
           10-K for the year ended December 31, 2004.

10.14      Agreement of Subordination & Assignment dated as of June 20,
           2003, by JL Distributors, Inc. in favor of Fleet Capital
           Corporation as Lender to Five Star Group, Inc. Incorporated
           herein by reference to Exhibit 10.1 of Five Star Products,
           Inc. Form 10-Q for the quarter ended June 30, 2003.

10.15      Amended Note in the amount of $2,800,000 dated December 19,
           2003, between the Five Star Products, Inc. and GP Strategies
           Corporation. Incorporated herein by reference to Exhibit
           10.11 of Five Star Products, Inc. Form 10-K for the year
           ended December 31, 2003.

78

10.16      Agreement dated as of January 22, 2004, between Five Star
           Products, Inc. and GP Strategies Corporation. Incorporated
           herein by reference to Exhibit 99(d) of Five Star Products,
           Inc. Schedule TO filed on February 6, 2004.

10.17      Tax Sharing Agreement dated as of February 1, 2004 between
           Five Star Products, Inc. and GP Strategies Corporation.
           Incorporated herein by reference to Exhibit 10.19 of Five
           Star Products, Inc. Form 10-K for the year ended December 31,
           2003.

10.18      Lease dated as of February 1, 1986 between Vernel Company and
           Five Star Group, Inc., as amended on July 25, 1994.
           Incorporated herein by reference to Exhibit 10.6 of Five Star
           Products, Inc. Form 10-K for the year ended December 31,
           1998.

10.19      Lease dated as of May 4, 1983 between Vornado, Inc., and Five
           Star Group, Inc. Incorporated herein by reference to Exhibit
           10.7 of Five Star Products, Inc. Form 10-K for the year ended
           December 31, 1998.

10.20      Credit Agreement dated March 8, 2001 by and between Allfirst
           Bank and MXL Industries, Inc. Incorporated herein by
           reference to Exhibit 10.14 of the Registrant's Form S-1,
           Registration No. 333-118568.

10.21      Mortgage, Security Agreement, Assignment of Leases and Rents
           and Fixture Filing dated June 26, 2001 by MXL Industries,
           Inc. to LaSalle Bank National Association. Incorporated
           herein by reference to Exhibit 10.15 of the Registrant's Form
           S-1, Registration No. 333-118568.

10.22      Credit Agreement dated March 1, 2005 by and between M&T Bank
           and MXL Industries, Inc. *

10.23      Continuing Guaranty Agreement dated March 1, 2005 by the
           Registrant for the benefit of M&T Bank. *

10.24      Amended and Restated Investor Rights Agreement dated as of
           May 30, 2003 by and among Hydro Med Sciences and certain
           Institutional Investors. Incorporated herein by reference to
           Exhibit 10.34 of GP Strategies' Form 10-K for the year ended
           December 31, 2003.

10.25      Amended and Restated Investor Right of First Refusal and
           Co-Sale Agreement dated as of May 30, 2003 by and among Hydro
           Med Sciences, Inc. and certain Institutional Investors.
           Incorporated herein by reference to Exhibit 10.35 of the GP
           Strategies' Form 10-K for the year ended December 31, 2003.

10.26      Stock Purchase Option Agreement dated as of June 30, 2004 by
           and among GP Strategies Corporation, National Patent
           Development Corporation, Valera Pharmaceuticals Inc. and
           certain Institutional Investors. Incorporated herein by
           reference to Exhibit 10.17 of the Registrant's Form S-1,
           Registration No. 333-118568.

10.27      Note Purchase Agreement dated as of November 12, 2004 by and
           between the Registrant, Bedford Oak Partners L.P. and Jerome
           Feldman. *

79

10.28      The Registrant's 6% Secured Note due 2009 dated as of
           November 12, 2004. *

10.29      Consulting and Severance Agreement dated as of July 1, 2004
           between MXL Industries, Inc. and Steve Cliff *

10.30      Consulting and Severance Agreement dated as of September 20,
           2004 between MXL Industries, Inc. and Frank Yohe *

14.1       Code of Ethics Policy. *

18         Not Applicable

19         Not Applicable

20         Not Applicable

21.1       Subsidiaries of the Registrant *

23.1       Not Applicable

28         Not Applicable

31.1       Certification of Chief Executive Officer *

31.2       Certification of Chief Financial Officer *

32.1       Certification Pursuant to 18 U.S.C. Section 1350 *

* Filed herewith

80

Exhibit 14.1

Code of Business Conduct and Ethics

For Chief Executive Officer and Senior Financial Officers

of National Patent Development Corporation and its Subsidiaries

It is the policy of National Patent Development Corporation that the Chief Executive Officer, the Director of Finance and the senior officers in the Accounting and Finance Department of each of National Patent Development Corporation and its subsidiaries (hereinafter sometimes collectively referred to as the "Company") adhere to and advocate the following principles governing their professional and ethical conduct in the fulfillment of their responsibilities:

1. Act with honesty and integrity, avoiding actual or apparent conflicts between his or her personal, private interests and the interests of the Company, including receiving improper personal benefits as a result of his or her position.

2. Perform responsibilities with a view to causing periodic reports filed or otherwise submitted to the SEC to contain information which is accurate, complete, fair, timely and understandable.

3. Comply with laws of federal, state, and local governments applicable to the Company, and the rules and regulations of private and public regulatory agencies having jurisdiction over the Company.

4. Promptly report any violations of the Company's Code of Ethics to the appropriate person(s) identified herein.

5. Act in good faith, responsibly, with due care, and diligence, without misrepresenting or omitting material facts or allowing independent judgment to be compromised.

6. Respect the confidentiality of information acquired in the course of the performance of his or her responsibilities except when authorized or otherwise legally obligated to disclose. Do not use confidential information acquired in the course of the performance of his or her responsibilities for personal advantage.

7. Proactively promote ethical behavior among subordinates and peers.

8. Use corporate assets and resources employed or entrusted in a responsible manner.

9. Do not use corporate information, corporate assets, corporate opportunities or one's position with the Company for personal gain or take personally opportunities that are discovered through the use of corporate property, information or position. Do not compete directly or indirectly with the Company.


10. Comply in all respects with the Company's Conduct of Business policy, and the Company's Policy Regarding Trading in Securities and Protection of Confidential Information.

11. Advance the Company's legitimate interests when the opportunity arises.

12. Act in a manner that shows accountability for adherence to the Company's Code of Ethics by certifying to the foregoing annually and filing a copy of such certification with the Audit Committee.

13. Deal fairly with the Company's customers, suppliers, competitors and employees.

Reporting Violations

If you have any concerns about a possible violation of the Company's Code of Ethics, it is your responsibility to promptly report any such violations to either the Company's Chairman of the Board or the Audit Committee or the Ethics Compliance Officer set forth in Section 4.0 "Ethics Program" of the Company's Conduct of Business. Requests for confidentiality will be honored to the greatest extent possible, consistent with the Company's legal obligations. If an investigation confirms the allegation, prompt corrective action will be taken. The "Ethics Program" contained in the Company's Conduct of Business is hereby incorporated by reference into this policy. The Business Conduct Hotline, 866-423-5994, provides a means for receiving confidential questions concerning any ethics-related issues of Company employees. The Company will not tolerate retaliation against persons making a report in good faith under this policy.

Amendments/Waivers to Code of Ethics

Any amendment to or waiver of, the Code of Ethics must be approved by the Board of Directors or a committee of the Board of Directors responsible for corporate governance matters. The Company is required to promptly disclose amendments to, and waivers of, the Code of Ethics for its executive officers or directors. The Company will within five business days after such amendment or waiver disclose the nature of such amendment or waiver on its website at www.npdc.com or in a Form 8-K filed with the SEC.

Availability on Web Site

The Code of Ethics and Code of Conduct of Business is available on the Company's web site at www.npdc.com and in print for any stockholder who requests it by writing to the Corporate Secretary, National Patent Development Corporation, 777 Westchester Avenue, White Plains, NY 10604.


Exhibit 10.22

CREDIT AGREEMENT
Pennsylvania

March 1, 2005

Borrower: MXL INDUSTRIES, INC., a Delaware corporation, having its chief executive office at 1764 Rohrerstown Road, Lancaster, PA 17601

Bank: MANUFACTURERS AND TRADERS TRUST COMPANY, a New York banking corporation with its chief executive office at One M&T Plaza, Buffalo, NY 14240. Attention: Office of General Counsel.

The Bank and the Borrower agree, intending to be legally bound, as follows:

1. DEFINITIONS.

a. "Obligations" means any and all indebtedness or other obligations of the Borrower to the Bank in any capacity, now existing, however created or evidenced, regardless of kind, class or form, whether direct, indirect, absolute or contingent (including obligations pursuant to any guaranty, endorsement, other assurance of payment or otherwise of Borrower to Bank), whether joint or several, whether from time to time reduced and thereafter increased, or entirely extinguished and thereafter reincurred, together with all extensions, renewals and replacements thereof, and all interest, fees, charges, costs or reasonable expenses which accrue on or in connection with the foregoing, including any indebtedness or obligations (i) not yet outstanding but contracted for, or with regard to which any other commitment by the Bank exists; (ii) arising prior to, during or after any pendency of any bankruptcy, insolvency, receivership or other similar proceeding; (iii) owed by the Borrower to others and which the Bank obtained, by assignment or otherwise; and (iv) payable under this Agreement.

b. "Transaction Documents" means this Agreement and all documents, instruments or other agreements by the Borrower in favor of the Bank in connection (directly or indirectly) with the Obligations, now in existence, including promissory notes, security agreements, guaranties and letter of credit reimbursement agreements.

2. REPRESENTATIONS AND WARRANTIES. The Borrower makes the following representations and warranties and any "Additional Representations and Warranties" on the schedule attached hereto and made part hereof (the "Schedule"), all of which shall be deemed to be continuing representations and warranties as long as this Agreement is in effect:

a. Good Standing; Authority. The Borrower is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was formed. The Borrower is duly authorized to do business in each jurisdiction in which failure to be so qualified might have a material adverse effect on its business or assets and has the power and authority to own the Collateral used as security for the Obligations and to use it in the ordinary course of business now and in the future.

b. Compliance. The Borrower is not in violation of any material statute, regulation and other law, the violation of which could materially adversely affect the business of Borrower. There is no charter or bylaw provision of Borrower which would be contravened by the execution and delivery of this Agreement. The Borrower has notified and will notify verbally or in writing if it is not in compliance with each material agreement to which it is a party or by which it or any of its assets is bound and a default of which could have a materially adverse affect on Borrower's ability for repaying the Loan.


c. Legality. Neither the execution, delivery and performance by the Borrower of this Agreement and all related documents, including the Transaction Documents, will conflict with or violate Borrowers organizational or governing documents or any material applicable laws or, constitute a default under any material agreement binding on the Borrower or any Subsidiary except for any conflict which could not have a materially adverse effect on Borrower. This Agreement and the Transaction Documents have been duly authorized by Borrower.

d. Fiscal Year. The fiscal year of the Borrower is the calendar year ending December 31st.

e. Title to Assets. The Borrower and each Subsidiary has good and marketable title to the collateral for this Loan (which is only the accounts receivable, inventory and a certain parcel of real estate located in Lancaster, Pennsylvania), except as set forth on the Schedule titled "Permitted Liens" or pursuant to the Bank's prior written consent.

f. Judgments and Litigation. Except as otherwise disclosed, there is no pending or to the knowledge of Borrower threatened investigation, action or other legal proceeding or judgment, order or award of any court, agency or other governmental authority or arbitrator (any, an "Action") which if determined adversely to Borrower would have a material adverse effect upon the Borrower or any Subsidiary or threaten the validity of the Credit, any Transaction Document or any related document or action.

g. Full Disclosure. Neither this Agreement nor any certificate, financial statement or other writing provided to the Bank by or on behalf of the Borrower or any Subsidiary contains any statement of material fact that is incorrect or misleading in any material respect or omits to state any material fact necessary to make any such statement not incorrect or misleading. There is no fact known to Borrower which Borrower has not disclosed to the Bank any material fact that might have a material adverse effect on the Borrower or any Subsidiary.

3. AFFIRMATIVE COVENANTS. So long as this Agreement is in effect, the Borrower will comply with any "Additional Affirmative Covenant" contained in the Schedule and shall:

a. Financial Statements and Other Information. Promptly deliver to the Bank financial reports as provided in an Addendum to Line of Credit Note dated even date herewith.

b. Accounting; Tax Returns and Payment of Claims. The Borrower and each Subsidiary will maintain a system of accounting and reserves in accordance with generally accepted accounting principles, has filed and will file each tax return required of it and, except as disclosed in the Schedule, has paid and will pay when due each tax, assessment, fee, charge, fine and penalty imposed by any taxing authority upon it or any of its assets, income or franchises, unless and to the extent such taxes shall be contested in good faith, provided Borrower maintains a reserve therefore in accordance with GAAP, as well as all amounts owed to mechanics, materialmen, landlords, suppliers and the like in the normal course of business.

c. Inspections. After one day advance notice and during normal business hours, the Borrower will permit, and cause its Subsidiaries to permit, the Bank's officers, attorneys or other agents, to inspect its and its Subsidiary's premises, examine and copy its records and discuss its and its Subsidiary's business, operations and financial or other condition with its and its Subsidiary's responsible officers and independent accountants.

2

d. Operating Accounts. Maintain, and cause its Subsidiaries to maintain, such bank accounts with the Bank to make Bank its primary banking facility.

e. Changes in Management and Control. If the Borrower is not an individual, immediately upon any change in the identity of the Borrower's chief executive officers or in its beneficial ownership, the Borrower will provide to the Bank a certificate executed by its senior individual authorized to transact business on behalf of the Borrower, specifying such change.

f. Notice of Defaults and Material Adverse Changes. Immediately upon (i) any Event of Default, (ii) any event or condition that is reasonably calculated to have a material adverse effect upon the Borrower or any Subsidiary or (iii) any Action, the Borrower will provide to the Bank verbal or written notification specifying the date(s) and nature of the event or the Action and what action the Borrower or its Subsidiary has taken or proposes to take with respect to it.

g. Insurance. Maintain its, and cause its Subsidiaries to maintain, property in good repair and will on request provide the Bank with evidence of insurance coverage satisfactory to the Bank, including fire and hazard, liability, workers' compensation and business interruption insurance and flood hazard insurance as required.

h. Further Assurances. Promptly upon the request of the Bank, the Borrower will execute, and cause its Subsidiaries to execute, and deliver each writing and take each other action that the Bank deems necessary or desirable in connection with any transaction contemplated by this Agreement.

i. Unused Commitment Fee. At the end of each calendar quarter during which the Bank's commitment for the Line of Credit remains outstanding commencing with the calendar quarter ending March 31, 2005, Borrower shall pay a fee to Bank equal, on an annualized basis, to .25% of the average daily unused commitment balance of the Line of Credit for such quarter. The fee shall be determined for each quarter by taking .25% of the average daily unused commitment balance for such quarter and multiplying that amount by a fraction, the numerator which shall be the number of days in such quarter and the denominator of which shall be the number of days in that calendar year. The unused commitment balance shall be determined by subtracting from $1,000,000.00 the principal balance of all funds advanced and outstanding under the Line of Credit. The unused commitment fee shall be due within ten (10) days after it is billed to Borrower by Bank.

4. NEGATIVE COVENANTS. As long as this Agreement is in effect, the Borrower shall not violate, and shall not suffer or permit any of its Subsidiaries to violate, any of the following covenants and any "Additional Negative Covenant" on the Schedule. The Borrower shall not:

a. Indebtedness. Permit any indebtedness over $100,000 without providing notice to the Bank(including direct and contingent liabilities) or not described on the Schedule titled "Permitted Indebtedness" except for trade indebtedness or current liabilities for salary and wages incurred in the ordinary course of business and not substantially overdue.

b. Guaranties. Become a guarantor, a surety, or otherwise liable for the debts or other obligations of another, whether by guaranty or suretyship agreement, agreement to purchase indebtedness, agreement for furnishing funds through the purchase of goods, supplies or services

3

(or by way of stock purchase, capital contribution, advance or loan)
for the purpose of paying or discharging indebtedness, or otherwise, except as an endorser of instruments for the payment of money deposited to its bank account for collection in the ordinary course of business and except as may be specified in the Schedule titled "Permitted Guaranties".

c. Liens. Permit any of its assets used as collateral for this Loan to be subject to any security interest, mortgage or other lien or encumbrance, except as set forth on the Schedule titled "Permitted Liens" and except for liens for property taxes not yet due; pledges and deposits to secure obligations or performance for workers' compensation, bids, tenders, contracts other than notes, appeal bonds or public or statutory obligations; and materialmen's, mechanics', carriers' and similar liens arising in the normal course of business.

d. Investments. Make any investment with proceeds from this Loan other than in FDIC insured deposits or United States Treasury obligations of less than one year, or in money market or mutual funds administering such investments, except as set forth on the Schedule titled "Permitted Investments".

e. Loans. Make any loan, advance or other extension of credit except as disclosed on the Schedule titled "Permitted Loans", except for endorsements of negotiable instruments deposited to the Borrower's deposit account for collection, trade credit in the normal course of business and intercompany loans approved in writing by the Bank.

f. Distributions. If the Borrower is not an individual, declare or pay any distribution, except for (i) dividends payable solely in stock, (ii) cash dividends paid to the Borrower by its Subsidiary and (iii) distributions provided on the Schedule entitled Permitted Distributions.

g. Changes In Form. Transfer or dispose of substantially all of its assets.

5. DEFAULT.

a. Events of Default. Any of the following events or conditions shall constitute an "Event of Default": (i) failure by the Borrower to pay when due (whether at the stated maturity, by acceleration, or otherwise) the Obligations, or any part thereof, or there occurs any event or condition which after notice, lapse of time or after both notice and lapse of time will permit acceleration of any Obligation;
(ii) default by the Borrower in the performance of any obligation, term or condition of this Agreement, the other Transaction Documents or any other agreement with the Bank or any of its affiliates or subsidiaries (collectively, "Affiliates"); (iii) the Borrower is dissolved, becomes insolvent, generally fails to pay or admits in writing its inability generally to pay its debts as they become due; (iv) the Borrower makes a general assignment, arrangement or composition agreement with or for the benefit of its creditors or makes, or sends notice of any intended, bulk sale; the sale, assignment, transfer or delivery of all or substantially all of the assets of the Borrower to a third party; or the cessation by the Borrower as a going business concern; (v) the Borrower files a petition in bankruptcy or institutes any action under federal or state law for the relief of debtors or seeks or consents to the appointment of an administrator, receiver, custodian or similar official for the wind up of its business (or has such a petition or action filed against it and such petition action or appointment is not

4

dismissed or stayed within forty-five (45) days); (vi) the reorganization, merger, consolidation or dissolution of the Borrower (or the making of any agreement therefor); (vii) the entry of any judgment or order of any court, other governmental authority or arbitrator against the Borrower which would have a material adverse affect on the Borrower; (viii) falsity, omission or inaccuracy of material facts submitted to the Bank or any Affiliate (whether in a financial statement or otherwise) in any material respect; (ix) a material adverse change in the Borrower, its business, assets, operations, affairs or condition (financial or otherwise) from the status shown on any financial statement or other document submitted to the Bank or any Affiliate, and which change the Bank determines will have a material adverse affect on (a) the Borrower, its business, assets, operations or condition (financial or otherwise), or (b) the ability of the Borrower to pay or perform the Obligations; (x) any pension plan of the Borrower fails to comply with applicable law or has vested unfunded liabilities that, in the opinion of the Bank, might have a material adverse effect on the Borrower's ability to repay its debts; (xi) any indication or evidence received by the Bank that the Borrower may have directly or indirectly been engaged in any type of activity which, in the Bank's discretion, might result in the forfeiture or any property of the Borrower to any governmental authority; (xii) the occurrence of any event described in Section 5(a)(i) through and including 5(a)(xi) with respect to any Subsidiary or to any endorser, guarantor or any other party liable for, or whose assets or any interest therein secures, payment of any of the Obligations; or (xiii) the Bank in good faith deems itself insecure with respect to payment or performance of the Obligations.

b. Rights and Remedies Upon Default. Upon the occurrence of any Event of Default, the Bank without presentment, protest, advertisement (except any notice required by law) to or upon the Borrower, any Subsidiary or any other person (all and each of which presentments, protests, and advertisements are hereby waived), may exercise all rights and remedies under the Borrower's or its Subsidiaries' agreements with the Bank or its Affiliates, applicable law, in equity or otherwise and may declare all or any part of any Obligations to be immediately due and payable without demand or notice of any kind and terminate any obligation it may have to grant any additional loan, credit or other financial accommodation to the Borrower or any Subsidiary. All or any part of any Obligations whether or not payable on demand, shall be immediately due and payable automatically upon the occurrence of an Event of Default in
Section 5(a)(vi) above. The provisions hereof are not intended in any way to affect any rights of the Bank with respect to any Obligations which may now or hereafter be payable on demand.

6. EXPENSES. The Borrower shall pay to the Bank on demand all reasonable costs and expenses (including all reasonable fees and disbursements of counsel retained for advice, suit, appeal or other proceedings or purpose and of any experts or agents it may retain), which the Bank may incur in connection with (i) the administration of the Obligations, including any administrative fees the Bank may impose for the preparation of discharges, releases or assignments to third-parties; (ii) the enforcement and collection of any Obligations or any guaranty thereof; (iii) the exercise, performance, enforcement or protection of any of the rights of the Bank hereunder; or (iv) the failure of the Borrower or any Subsidiary to perform or observe any provisions hereof. After such demand for payment of any cost, expense or fee under this Section or elsewhere under this Agreement, the Borrower shall pay interest at the highest default rate specified in any instrument evidencing any of the Obligations from the date payment is demanded by the Bank to the date reimbursed by the Borrower. All such costs, expenses or fees under this Agreement shall be added to the Obligations.

7. TERMINATION. This Agreement shall remain in full force and effect until (i) all Obligations outstanding, or contracted or committed for (whether or not

5

outstanding), shall be finally and irrevocably paid in full and (ii) all Transaction Documents have been terminated by the Bank.

8. RIGHT OF SETOFF. If an Event of Default occurs, the Bank shall have the right to set off against the amounts owing under this Agreement and the other Transaction Documents any property held in a deposit or other account or otherwise with the Bank or its Affiliates or otherwise owing by the Bank or its Affiliates in any capacity to the Borrower, its Subsidiary or any guarantor of, or endorser of any of the Transaction Documents evidencing, the Obligations. Such setoff shall be deemed to have been exercised immediately at the time the Bank or such Affiliate elect to do so.

9. MISCELLANEOUS.

a. Notices. Any notice or demand hereunder or required under applicable law shall be duly given if delivered or mailed to the Borrower (at its address on the Bank's records) or to the Bank (at the address on page one and separately to the officer of the Bank responsible for the Borrower's relationship with the Bank). Such notice or demand shall be deemed effective if delivered, upon personal delivery or if mailed, three (3) business days after deposit in an official depository maintained by the United States Post Office for the collection of mail or one (1) business day after delivery to a nationally recognized overnight delivery service. Notice by e-mail is not valid notice under this or any other agreement between the Borrower and the Bank.

b. Generally Accepted Accounting Principles. Any financial calculation to be made, all financial statements and other financial information to be provided, and all books and records, system of accounting and reserves to be kept in connection with the provisions of this Agreement, shall be in accordance with generally accepted accounting principles consistently applied during each interval and from interval to interval; provided, however, that in the event changes in generally accepted accounting principles shall be mandated by the Financial Accounting Standards Board or any similar accounting body of comparable standing, or should be recommended by Borrower's certified public accountants, to the extent such changes would affect any financial calculations to be made in connection herewith, such changes shall be implemented in making such calculations only from and after such date as Borrower and the Bank shall have amended this Agreement to the extent necessary to reflect such changes in the financial and other covenants to which such calculations relate.

c. Indemnification. If after receipt of any payment of all, or any part of, the Obligations, the Bank is, for any reason, compelled to surrender such payment to any person or entity because such payment is determined to be void or voidable as a preference, an impermissible setoff, or a diversion of trust funds, or for any other reason, the Transaction Documents shall continue in full force and the Borrower shall be liable, and shall indemnify and hold the Bank harmless for, the amount of such payment surrendered, except with respect to the negligence or intentional misconduct of bank. The provisions of this
Section shall be and remain effective notwithstanding any contrary action which may have been taken by the Bank in reliance upon such payment, and any such contrary action so taken shall be without prejudice to the Bank's rights under the Transaction Documents and shall be deemed to have been conditioned upon such payment having become final and irrevocable. The provisions of this Section shall survive the termination of this Agreement and the Transaction Documents.

d. Further Assurances. From time to time, the Borrower shall take, and cause its Subsidiaries to take, such action and execute and deliver to the Bank such additional documents, instruments, certificates, and agreements as the Bank may reasonably request to effectuate the purposes of the Transaction Documents.

6

e. Cumulative Nature and Non-Exclusive Exercise of Rights and Remedies. All rights and remedies of the Bank pursuant to this Agreement and the Transaction Documents shall be cumulative, and no such right or remedy shall be exclusive of any other such right or remedy. In the event of any unreconcilable inconsistencies, this Agreement shall control. No single or partial exercise by the Bank of any right or remedy pursuant to this Agreement or otherwise shall preclude any other or further exercise thereof, or any exercise of any other such right or remedy, by the Bank.

f. Governing Law; Jurisdiction. This Agreement has been delivered to and accepted by the Bank and will be deemed to be made in the Commonwealth of Pennsylvania. Unless provided otherwise under federal law, this Agreement will be interpreted in accordance with laws of the Commonwealth of Pennsylvania, excluding its conflict of laws rules.
BORROWER HEREBY IRREVOCABLY CONSENTS TO THE EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT IN THE COMMONWEALTH OF PENNSYLVANIA IN A COUNTY OR JUDICIAL DISTRICT WHERE THE BANK MAINTAINS A BRANCH, AND CONSENTS THAT THE BANK MAY EFFECT ANY SERVICE OF PROCESS IN THE MANNER AND AT BORROWER'S ADDRESS AS SET FORTH IN THE ABOVE SECTION ENTITLED "NOTICES"; PROVIDED THAT NOTHING CONTAINED IN THIS AGREEMENT WILL PREVENT THE BANK FROM BRINGING ANY ACTION, ENFORCING ANY AWARD OR JUDGMENT OR EXERCISING ANY RIGHTS AGAINST BORROWER INDIVIDUALLY, AGAINST ANY SECURITY OR AGAINST ANY PROPERTY OF BORROWER WITHIN ANY OTHER COUNTY, STATE OR OTHER FOREIGN OR DOMESTIC JURISDICTION. Borrower acknowledges and agrees that the venue provided above is the most convenient forum for both the Bank and Borrower, and Borrower waives any objection to venue and any objection based on a more convenient forum in any action instituted under this Agreement.

g. Joint and Several; Successors and Assigns. If there is more than one Borrower, each of them shall be jointly and severally liable for all amounts, which become due, and the performance of all obligations under this Agreement, and the term "the Borrower" shall include each as well as all of them. This Agreement shall be binding upon the Borrower and upon its heirs and legal representatives, its successors and assignees, and shall inure to the benefit of, and be enforceable by, the Bank, its successors and assignees and each direct or indirect assignee or other transferee of any of the Obligations; provided, however, that this Agreement may not be assigned by the Borrower without the prior written consent of the Bank.

h. Waivers; Changes in Writing. No failure or delay of the Bank in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The Borrower expressly disclaims any reliance on any course of dealing or usage of trade or oral representation of the Bank (including representations to make loans to the Borrower) and agrees that none of the foregoing shall operate as a waiver of any right or remedy of the Bank. No notice to or demand on the Borrower in any case shall entitle the Borrower to any other or further notice or demand in similar or other circumstances. No waiver of any provision of this Agreement or consent to any departure by the Borrower therefrom shall in any event be effective unless made specifically in writing by the Bank and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. No modification to any provision of this Agreement shall be effective unless made in writing in an agreement signed by the Borrower and the Bank.

i. Interpretation. Unless the context otherwise clearly requires, references to plural includes the singular and references to the singular include the plural; references to "individual" shall mean a natural person and shall include a natural person doing business under

7

an assumed name (e.g., a "DBA"); the word "or" has the inclusive meaning represented by the phrase "and/or"; the word "including", "includes" and "include" shall be deemed to be followed by the words "without limitation"; and captions or section headings are solely for convenience and not part of the substance of this Agreement. Any representation, warranty, covenant or agreement herein shall survive execution and delivery of this Agreement and shall be deemed continuous. Each provision of this Agreement shall be interpreted as consistent with existing law and shall be deemed amended to the extent necessary to comply with any conflicting law. If any provision nevertheless is held invalid, the other provisions shall remain in effect. The Borrower agrees that in any legal proceeding, a photocopy of this Agreement kept in the Bank's course of business may be admitted into evidence as an original.

j. Waiver of Jury Trial. THE BORROWER AND THE BANK HEREBY KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVE ANY RIGHT TO TRIAL BY JURY THE BORROWER AND THE BANK MAY HAVE IN ANY ACTION OR PROCEEDING, IN LAW OR IN EQUITY, IN CONNECTION WITH THIS AGREEMENT OR ANY TRANSACTIONS RELATED HERETO. THE BORROWER REPRESENTS AND WARRANTS THAT NO REPRESENTATIVE OR AGENT OF THE BANK HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE BANK WILL NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THIS JURY TRIAL WAIVER. THE BORROWER ACKNOWLEDGES THAT THE BANK HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE PROVISIONS OF THIS SECTION.

Acknowledgment. Borrower acknowledges that it has read and understands all the provisions of this Agreement, including the Governing Law, Jurisdiction and Waiver of Jury Trial, and has been advised by counsel as necessary or appropriate.

MANUFACTURERS AND TRADERS TRUST COMPANY

By: __________________________________________

Name: ________________________________________

Title: _______________________________________

MXL INDUSTRIES, INC.

By: __________________________________________

Name: _______________________________________

Title: ______________________________________

8

ACKNOWLEDGMENT

COMMONWEALTH OF PENNSYLVANIA        )
                                    )SS:
COUNTY OF LANCASTER                 )

On the day of , 2005, before me, the undersigned officer, personally appeared , who acknowledged himself/herself to be the Vice President of MANUFACTURERS AND TRADERS TRUST COMPANY, and that he/she as such officer, being authorized to do so, executed the foregoing instrument for the purposes therein contained by signing the name of said corporation by himself/herself as such officer.

Notary Public

ACKNOWLEDGMENT

COMMONWEALTH OF PENNSYLVANIA   )
                               )SS:
COUNTY OF LANCASTER            )

On this day of 2005, before me, the undersigned officer, personally appeared , who acknowledged himself to be the of MXL INDUSTRIES, INC., and that as such officer, being authorized to do so, executed the foregoing instrument for the purposes therein contained by signing the name of said corporation by himself as such officer.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

Notary Public

9

BANK USE ONLY

Authorization Confirmed:______________________________________________________


SCHEDULE

SCHEDULE

Additional Representations and Warranties (ss.2)

Additional Affirmative Covenants (ss.3)

Permitted Indebtedness (ss.4(a))

Permitted Guaranties (ss.4(b))

Permitted Liens (ss.4(c))

Permitted Investments (ss.4(d))

The following investments are permitted and excluded from this agreement:

o Investment in the Pawling property in NY o Investment in Valera Pharmaceutical stock o Investment in Millennium Cell stock
o Proceeds from the litigation and arbitration claim against MCI Communications Corporation and Electronic Data Systems Corporation

Permitted Loans (ss.4(e))

Permitted Distributions (ss.4(f))

The following distributions are permitted under this agreement:

o Proceeds from the investment in the Pawling property in NY o Proceeds from the investment in Valera Pharmaceutical stock o Proceeds from the investment in Millennium Cell stock
o Proceeds from the litigation and arbitration claim against MCI Communications Corporation and Electronic Data Systems Corporation
o Proceeds from the sale of the property in Downer's Grove Illinois

Additional Financial Covenants (ss.5)


Exhibit 10.23

CONTINUING GUARANTY
(Business Organization)

                                  Pennsylvania

GUARANTOR:        National Patent Development Corporation
                  777 Westchester Avenue, 4th Floor, White Plains, NY 10604, a
                  Delaware corporation

BORROWER:         MXL Industries, Inc.
                  1764 Rohrerstown Road, Lancaster, PA 17601

BANK:             Manufacturers and Traders Trust Company, a New York banking
                  corporation,  with banking offices located at One M&T
                  Plaza, Buffalo, New York 14240  Attention: Office of the
                  General Counsel.

1. Guaranty.

(a) Guarantor, intending to be legally bound, hereby unconditionally guarantees the full and prompt payment and performance of any and all of Borrower's Obligations (as defined below) to the Bank when due, whether at stated maturity, by acceleration or otherwise in the maximum amount provided in
Section 2 below. As used in this Guaranty, the term "Obligations" shall mean obligations, indebtedness and other liabilities of Borrower to the Bank arising from a Standard LIBOR Grid Note in the face amount of $1,000,000.00 dated and all related loan documents (the "Loan Documents") and all accrued and unpaid interest thereon and all Expenses (as defined below). Guarantor will pay or perform its obligations under this Guaranty upon demand after an Event of Default under the Loan Documents. This Guaranty is and is intended to be a continuing guaranty of payment (not collection) of the Obligations. Guarantor understands that the Bank can bring an action under this Guaranty without being required to exhaust other remedies or demand payment first from other parties.

(b) Guarantor acknowledges the receipt of valuable consideration for this Guaranty and acknowledges that the Bank is relying on this Guaranty in making a financial accommodation to Borrower, whether a commitment to lend, extension, modification or replacement of, or forbearance with respect to, any Obligation, cancellation of another guaranty, purchase of Borrower's assets, or other valuable consideration.

2. Continuing, Absolute, Unconditional. This Guaranty is irrevocable, absolute, continuing, unconditional. This Guaranty is limited in amount to (1) $ 1,000,000.00 of the principal amount of the Obligations plus (2) a proportionate share (i.e., in the same proportion as the amount in (1) above bears to the total principal amount of the obligations) of all accrued and unpaid interest, and Expenses (as defined below) incurred with respect to the Obligations and (3) all of the Expenses incurred with respect to this Guaranty (collectively, the "Guaranteed Amount").

3. Guarantor's Waivers & Authorizations.

(a) Guarantor's obligations shall not be released, impaired or affected in any way including by any of the following, all of which Guarantor hereby waives (i) any bankruptcy, reorganization or insolvency under any law of Borrower or that of any other party, or by any action of a trustee in any such proceeding; (ii) the existence or nonexistence or order of any filings, exchanges, releases, impairment or sale of, or failure to perfect or continue the perfection of a security interest in any collateral for the Obligations;
(iii) any failure of Guarantor to receive notice of any intended disposition of such collateral; (iv) any fictitiousness, incorrectness, invalidity or unenforceability, for any reason, of any instrument or other agreement which may evidence any Obligation; (v) any composition, extension, stay or other statutory relief granted to Borrower including, without limitation, the expiration of the


period of any statute of limitations with respect to any lawsuit or other legal proceeding against Borrower or any person in any way related to the Obligations or a part thereof or any collateral therefor; (vi) any change in form of organization, name, membership or ownership of Borrower or Guarantor; (vii) any refusal or failure of the Bank or any other person prior to the date hereof or hereafter to grant any additional loan or other credit accommodation to Borrower or the Bank's or any other party's receipt of notice of such refusal or failure;
(viii) any setoff, defense or counterclaim of Borrower with respect to the obligations or otherwise arising, either directly or indirectly, in regard to the Obligations.

(b) The Guarantor waives acceptance, assent and all rights of notice or demand including without limitation (i) notice of acceptance of this Guaranty, of Borrower's default or nonpayment of any Obligation, and of changes in Borrower's financial condition; (ii) presentment, protest, notice of protest and demand for payment; (iii) notice that any Obligations has been incurred or of the reliance by the Bank upon this Guaranty; and (iv) any other notice, demand or condition to which Guarantor might otherwise be entitled prior to the Bank's reliance on or enforcement of this Guaranty. Guarantor further authorizes the Bank, without notice, demand or additional reservation of rights against Guarantor and without affecting Guarantor's obligations hereunder, from time to time: (i) to accept and hold collateral from any party for the payment of any or all of the Obligations, and to exchange, enforce or refrain from enforcing, or release any or all of such collateral; (ii) to accept any indorsement or guaranty of any or all of the Obligations or any negotiable instrument or other writing intended to create an accord and satisfaction with respect to any or all of the Obligations; (iii) to release, replace or modify the obligation of any indorser or guarantor, or any party who has given any collateral for any of all of the Obligations, or any other party in any way obligated to pay any or all of the Obligations, and to enforce or refrain from enforcing, or compromise or modify, the terms of any obligation of any such indorser, guarantor or party;
(iv) to dispose of any and all collateral securing the Obligations in any manner as the Bank, in its sole discretion, may deem appropriate, and to direct the order and the enforcement of any and all indorsements and guaranties relating to the Obligations in the Bank's sole discretion; and (v) to determine the manner, amount and time of application of payments and credits, if any, to be made on all or any part of the Obligations including, without limitation, if this Guaranty is limited in amount, to make any such application to Obligations, if any, in excess of the amount of this Guaranty, provided that such applications are made in a commercially reasonable manner.

(c) Notwithstanding any other provision in this Guaranty, Guarantor irrevocably waives, without notice, any right he or she may have at law or in equity (including without limitation any law subrogating Guarantor to the rights of the Bank) to seek contribution, indemnification or any other form of reimbursement from Borrower or any other obligor or guarantor of the Obligations for any disbursement made under this Guaranty or otherwise, until such time as the Bank has been paid in full for all principal, interest and fees due under the Note..

4. Termination. This Guaranty shall remain in full force and effect until all Obligations outstanding shall be paid in full. Guarantor agrees that, to the extent that Borrower makes a payment or payments to the Bank on the Obligations, or the Bank receives any proceeds of collateral to be applied to the Obligations, which payment or payments or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside or otherwise are required to be repaid to Borrower, its estate, trustee, receiver or any other party, including, without limitation, under any bankruptcy law, state or federal law, common law or equitable cause, then to the extent of such repayment, the obligation or part thereof which has been paid, reduced or satisfied by such amount shall be reinstated and continued in full force and effect as of the date such initial payment, reduction or satisfaction occurred, notwithstanding any contrary action which may have been taken by the Bank in reliance upon such payment or payments.

5. Expenses. Guarantor agrees to reimburse the Bank on demand for all the

2

Bank's expenses, including without limitation costs of collection and actual attorneys' fees and disbursements incurred by the Bank in attempting to enforce this Guaranty, collect any of the Obligations (collectively, "Expenses"). Expenses will accrue interest at the Default Rate as defined in Note evidencing the Obligations until payment is actually received by the Bank.

6. Financial and Other Information. Guarantor shall promptly deliver to the Bank copies of all annual reports, proxy statements and similar information distributed to shareholders, partners or members and of all filings with the Securities and Exchange Commission and the Pension Benefit Guaranty Corporation. Guarantor understands this Guaranty and has satisfied itself as to its meaning and consequences and acknowledges that it has made its own arrangements for keeping informed of changes or potential changes affecting the Borrower including the Borrower's financial condition.

7. No Transfer of Assets. Guarantor shall not transfer, reinvest or otherwise dispose of its assets in a manner or to an extent that would materially impair Guarantor's ability to perform its obligations under this Guaranty.

8. Nonwaiver by the Bank; Miscellaneous. This Guaranty is intended by Guarantor to be the final, complete and exclusive expression of the agreement between Guarantor and the Bank. This Guaranty may be assigned by the Bank, shall inure to the benefit of the Bank and its successors and assigns, and shall be binding upon Guarantor and his or her legal representative, successors and assigns and any participation may be granted by the Bank herein in connection with the assignment or granting of a participation by the Bank in the Obligations or any part thereof. All rights and remedies of the Bank are cumulative, and no such right or remedy shall be exclusive of any other right or remedy. This Guaranty does not supersede any other guaranty or security granted to the Bank by Guarantor or others (except as to Guarantor's Waiver of Subrogation rights above). No single, partial or delayed exercise by the Bank of any right or remedy shall preclude exercise by the Bank at any time at its sole option of the same or any other right or remedy of the Bank without notice. Guarantor expressly disclaims any reliance on any course of dealing or usage of trade or oral representation of the Bank including, without limitation, representations to make loans to Borrower or enter into any other agreement with Borrower or Guarantor. No course of dealing or other conduct, no oral agreement or representation made by the Bank or usage of trade shall operate as a waiver of any right or remedy of the Bank. No waiver or amendment of any right or remedy of the Bank or release by the Bank shall be effective unless made specifically in writing by the Bank. Each provision of this Guaranty shall be interpreted as consistent with existing law and shall be deemed amended to the extent necessary to comply with any conflicting law. If any provision nevertheless is held invalid, the other provisions shall remain in effect. Guarantor agrees that in any legal proceeding, a copy of this Guaranty kept in the Bank's course of business may be admitted into evidence as an original. Captions are solely for convenience and not part of the substance of this Guaranty. Payments made to the Bank by Guarantor after maturity of the Obligations, by acceleration or otherwise, shall reduce the Guaranteed Amount.

9. Authorization. Guarantor certifies that it is an entity in the form described above duly organized and in good standing under the laws of the State of its organization and duly authorized to do business in each State material to the conduct of its business. Guarantor has determined that the execution of this Guaranty will be in its best interests. Execution of this Guaranty by the persons signing below has been authorized by all necessary corporate action. Guarantor's chief executive office is located at the above address.

10. Notices. Any demand or notice hereunder or under any applicable law pertaining hereto shall be in writing and duly given if delivered to Guarantor (at its address on the Bank's records) or to the Bank (at the address on page one and separately to the Bank officer responsible for Borrower's relationship with the Bank). Such notice or demand shall be deemed sufficiently given for all purposes when delivered (i) by personal delivery and shall be deemed effective when delivered, or (ii) by mail or courier and shall be deemed effective three

3

(3) business days after deposit in an official depository maintained by the United States Post Office for the collection of mail or one (1) business day after delivery to a nationally recognized overnight courier service (e.g., Federal Express). Notice by e-mail is not valid notice under this or any other agreement between Guarantor and the Bank.

11. Governing Law and Jurisdiction. This Guaranty has been delivered to and accepted by the Bank and will be deemed to be made in the Commonwealth of Pennsylvania. Except as otherwise provided under federal law, this Guaranty will be interpreted in accordance with the laws of the Commonwealth of Pennsylvania excluding its conflict of laws rules. GUARANTOR HEREBY IRREVOCABLY CONSENTS TO THE EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT IN THE COMMONWEALTH OF PENNSYLVANIA IN A COUNTY OR JUDICIAL DISTRICT WHERE THE BANK MAINTAINS A BRANCH AND CONSENTS THAT THE BANK MAY EFFECT ANY SERVICE OF PROCESS IN THE MANNER AND AT GUARANTOR'S ADDRESS SET FORTH ABOVE FOR PROVIDING NOTICE OR DEMAND; PROVIDED THAT NOTHING CONTAINED IN THIS GUARANTY WILL PREVENT THE BANK FROM BRINGING ANY ACTION, ENFORCING ANY AWARD OR JUDGMENT OR EXERCISING ANY RIGHTS AGAINST GUARANTOR INDIVIDUALLY, AGAINST ANY SECURITY OR AGAINST ANY PROPERTY OF GUARANTOR WITHIN ANY OTHER COUNTY, STATE OR OTHER FOREIGN OR DOMESTIC JURISDICTION. Guarantor acknowledges and agrees that the venue provided above is the most convenient forum for both the Bank and Guarantor. Guarantor waives any objection to venue and any objection based on a more convenient forum in any action instituted under this Guaranty.

12. Waiver of Jury Trial. GUARANTOR AND THE BANK HEREBY KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVE ANY RIGHT TO TRIAL BY JURY GUARANTOR AND THE BANK MAY HAVE IN ANY ACTION OR PROCEEDING, IN LAW OR IN EQUITY, IN CONNECTION WITH THIS GUARANTY OR THE TRANSACTIONS RELATED HERETO. GUARANTOR REPRESENTS AND WARRANTS THAT NO REPRESENTATIVE OR AGENT OF THE BANK HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE BANK WILL NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THIS JURY TRIAL WAIVER. GUARANTOR ACKNOWLEDGES THAT THE BANK HAS BEEN INDUCED TO ENTER INTO THIS GUARANTY BY, AMONG OTHER THINGS, THE PROVISIONS OF THIS SECTION.

4

13. Guarantor acknowledges that it has read and understands all the provisions of this Guaranty, including the Governing Law, Jurisdiction and Waiver of Jury Trial, and has been advised by counsel as necessary or appropriate.

GUARANTOR:
NATIONAL PATENT DEVELOPMENT CORPORATION

DATE                                   By:
     ----------------------            ----------------------------------------

TIN #
      --------------------------------------

5

ACKNOWLEDGMENT

COMMONWEALTH OF PENNSYLVANIA)

: SS.

COUNTY OF ________________________)

On the ___________ day of __________________, in the year 20_______, before me, the undersigned, a Notary Public in and for said Commonwealth, personally appeared ______________________________________________, personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies), and that by his/her/their signature(s) on the instrument, the individual(s), or the person upon behalf of which the individual(s) acted, executed the instrument.

Notary Public

6

Exhibit 10.27

NOTE PURCHASE AGREEMENT

Agreement, dated November 12, 2004, among National Patent Development Corporation, a Delaware corporation ("NPDC"), MXL Industries, Inc., a Delaware corporation ("MXL"), and the purchasers set forth on the signature pages hereto (the "Purchasers").

The Purchasers desire to acquire NPDC's 6% Secured Notes due 2009 from NPDC in exchange for cash as hereinafter provided, and NPDC desires to sell such Notes to the Purchasers.

I. The Purchase

1.1. Authorization of Notes. NPDC has authorized the issue and sale of $1,590,000 aggregate principal amount of its 6% Secured Notes due 2009. Such 6% Secured Notes due 2009 shall be substantially in the form set forth in Exhibit A (references to a "Schedule" or an "Exhibit" are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement) and are herein referred to individually as a "Note" and collectively as the "Notes," which terms shall also include any notes delivered in exchange or replacement therefor.

1.2. Terms of the Purchase(a) . On the basis of the representations, warranties, covenants, and agreements contained in this Agreement and subject to the terms and conditions of this Agreement, at the Closing (as defined below), NPDC shall issue and sell to each of the Purchasers, and each of the Purchasers will purchase from NPDC, a Note in the principal amount specified opposite such Purchaser's name in Schedule 1.2, at a purchase price for such Note equal to 100% of the principal amount of such Note. The obligations of each Purchaser hereunder are several and not joint obligations and no Purchaser shall have any obligation or liability to any person for the performance or non-performance by any other Purchaser hereunder.

1.3. Closing.

(a) The closing of the transactions contemplated by Section 1.2 (the "Closing") shall take place at the offices of Duane Morris LLP, 380 Lexington Avenue, New York, New York, at 10:00 a.m. local time on the date hereof (the "Closing Date"). The Closing may occur at such different place, different time, or different date as NPDC, MXL, and the Purchasers agree in writing.

(b) At the Closing, (i) NPDC shall deliver to each Purchaser, against delivery by such Purchaser to NPDC or its order, by wire transfer of immediately available funds, of payment of the full purchase price for the Note to be purchased by such Purchaser, a Note in the principal amount to be purchased by such Purchaser, dated the Closing Date, and registered in the name of such Purchaser, and (ii) MXL shall deliver a Pledge Agreement (the "Pledge"), substantially in the form set forth in Exhibit B.


1.4. Use of Proceeds; Transfer of Shares. NPDC shall use the proceeds of the issue and sale of the Notes to exercise its option to purchase 2,068,966 Series B Convertible Preferred Shares (the "Shares") of Valera Pharmaceuticals, Inc. ("Valera"). Immediately upon exercise of such option, NPDC shall contribute the Shares to MXL. If MXL shall sell or otherwise transfer any or all of the Shares, MXL shall pay to the Purchasers or their respective assignees, pro rata in accordance with the amounts of the Notes they are purchasing hereunder, an aggregate amount equal to 50% of the excess, if any, of (i) the proceeds of such sale or other transfer of such Shares over (ii) the aggregate exercise price paid by NPDC for such Shares.

II. Representations and Warranties of NPDC

NPDC represents and warrants to the Purchasers as follows:

2.1. Organization and Qualification. NPDC is a corporation duly organized, validly existing, and in good standing under the laws of the State of Delaware, with all requisite power and authority to own, lease, license, and use its properties and assets and to carry on the business in which it is engaged. NPDC is duly qualified to transact the business in which it is engaged and is in good standing as a foreign corporation in every jurisdiction in which its ownership, leasing, licensing, or use of property or assets or the conduct of its business makes such qualification necessary.

2.2. Authority to Sell; Enforceability. NPDC has all requisite power and authority to execute, deliver, and perform this Agreement and the Notes. All necessary corporate proceedings of NPDC have been duly taken to authorize the execution, delivery, and performance by NPDC of this Agreement and the Notes. Each of this Agreement and the Notes has been duly authorized by NPDC and this Agreement has been, and at the Closing the Notes will be, duly executed and delivered by NPDC. Each of this Agreement and the Notes constitutes or will constitute the legal, valid, and binding obligation of NPDC and is or will be enforceable as to NPDC in accordance with its terms, except as limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium, or other laws of general application affecting enforcement of creditors' rights, and for general principles of equity that restrict the availability of equitable remedies.

2.3. No Conflicts. No consent, authorization, approval, order, license, certificate, or permit of or from, or declaration or filing with, any federal, state, local, or other governmental authority or any court or other tribunal is required by NPDC for the execution, delivery, or performance by NPDC of this Agreement or the Notes, except as may be required under securities laws. No consent of any party to any contract, agreement, instrument, lease, or license (collectively, "Contracts") to which NPDC or any of its subsidiaries (each, an "NPDC Subsidiary") is a party, or to which it or any of its businesses, properties, or assets are subject, is required for the execution, delivery, or performance of this Agreement or the Notes; and the execution, delivery, and performance by NPDC of this Agreement and the Notes will not violate, result in a breach of, conflict with, or (with or without the giving of notice or the passage of time or both) entitle any party to terminate or call a default under, entitle any party to rights and privileges that such party was not receiving or

2

entitled to receive immediately before this Agreement was executed under, or create any obligation on the part of NPDC or any NPDC Subsidiary that it was not paying or obligated to pay immediately before this Agreement was executed under, any term of any such Contract or violate or result in a breach of any term of the certificate of incorporation (or other charter document) or by-laws of NPDC or any NPDC Subsidiary, or violate, result in a breach of, or conflict with any law, rule, regulation, order, judgment, or decree binding on NPDC or any NPDC Subsidiary or to which it or any of its businesses, properties, or assets are subject, in each case except as would not be reasonably likely to have a material adverse effect on NPDC and its NPDC Subsidiaries taken as a whole.

2.4. No Registration Required. Assuming the continuing accuracy of the representations and warranties of the Purchasers contained in Article IV hereof, the offer, sale and issuance of the Notes will be exempt from the registration requirements of the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the "Securities Act").

III. Representations and Warranties of MXL

MXL represents and warrants to the Purchasers as follows:

3.1. Organization and Qualification. MXL is a corporation duly organized, validly existing, and in good standing under the laws of the State of Delaware, with all requisite power and authority to own, lease, license, and use its properties and assets and to carry on the business in which it is engaged. MXL is duly qualified to transact the business in which it is engaged and is or will be in good standing as a foreign corporation in every jurisdiction in which its ownership, leasing, licensing, or use of property or assets or the conduct of its business makes such qualification necessary.

3.2. Authority; Enforceability. MXL has all requisite power and authority to execute, deliver, and perform this Agreement and the Pledge. All necessary corporate proceedings of MXL have been duly taken to authorize the execution, delivery, and performance by MXL of this Agreement and the Pledge. Each of this Agreement and the Pledge has been duly authorized by MXL and this Agreement has been, and at the Closing the Pledge will be, duly executed and delivered by MXL. Each of this Agreement and the Pledge constitutes or will constitute the legal, valid, and binding obligation of MXL and is or will be enforceable as to MXL in accordance with its terms, except as limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws of general application affecting enforcement of creditors' rights, and for general principles of equity that restrict the availability of equitable remedies.

3.3. No Conflicts. No consent, authorization, approval, order, license, certificate, or permit of or from, or declaration or filing with, any federal, state, local, or other governmental authority or any court or other tribunal is required by MXL for the execution, delivery, or performance by MXL of this Agreement or the Pledge. No consent of any party to any Contract to which MXL or any of its subsidiaries (each, an "MXL Subsidiary") is a party, or to which it or any of its businesses, properties, or assets are subject, is required for the execution, delivery, or performance of this Agreement or the Pledge; and the

3

execution, delivery, and performance by MXL of this Agreement and the Pledge will not violate, result in a breach of, conflict with, or (with or without the giving of notice or the passage of time or both) entitle any party to terminate or call a default under, entitle any party to rights and privileges that such party was not receiving or entitled to receive immediately before this Agreement was executed under, or create any obligation on the part of MXL or any MXL Subsidiary that it was not paying or obligated to pay immediately before this Agreement was executed under, any term of any such Contract or violate or result in a breach of any term of the certificate of incorporation (or other charter document) or by-laws of MXL or any MXL Subsidiary, or violate, result in a breach of, or conflict with any law, rule, regulation, order, judgment, or decree binding on MXL or any MXL Subsidiary or to which it or any of its businesses, properties, or assets are subject, in each case except as would not be reasonably likely to have a material adverse effect on MXL and its MXL Subsidiaries taken as a whole.

IV. Representations and Warranties of the Purchasers

Each Purchaser, severally and not jointly, represents and warrants to the other parties hereto as follows:

4.1. Organization. Such Purchaser, if an entity, is duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation, with all requisite power and authority to own, lease, license, and use its properties and assets and to carry on the business in which it is engaged.

4.2. Authority to Buy. Such Purchaser, if an entity, has all requisite power and authority to execute, deliver, and perform this Agreement; all necessary proceedings of such Purchaser have been duly taken to authorize the execution, delivery, and performance of this Agreement by such Purchaser; and this Agreement has been duly executed and delivered by such Purchaser, is the legal, valid, and binding obligation of such Purchaser, and is enforceable as to such Purchaser in accordance with its terms. Such Purchaser, if an individual, has reached the age of majority in the jurisdiction in which he resides; is a bona fide resident of the jurisdiction contained in the address set forth on Schedule 1.2; is legally competent to execute this Agreement; and does not intend to change residence to another jurisdiction.

4.3. Non-Distributive Intent. Such Purchaser is acquiring the Note to be acquired by it for its own account (and not for the account of others) for investment and not with a view to the distribution thereof. The Purchaser will not sell or otherwise dispose of the Note to be acquired by it (whether pursuant to a liquidating distribution or otherwise) without registration under the Securities Act or an exemption therefrom, and such Note may contain a legend to the foregoing effect. The Purchaser understands that it may not sell or otherwise dispose of the Note to be acquired by it in the absence of either a registration statement under the Securities Act or an exemption from the registration provisions of the Securities Act.

4.4. Purchaser Status. Such Purchaser is an accredited investor within the definition set forth in Rule 501(a) under the Securities Act.

4

V. Miscellaneous

5.1. Transfer Restrictions. Each Purchaser acknowledges and agrees that the Notes are subject to restrictions on transfer as set forth therein.

5.2. Further Actions. At any time and from time to time, each party agrees, at its expense, to take such actions and to execute and deliver such documents as may be reasonably necessary to effectuate the purposes of this Agreement.

5.3. Entire Understanding. This Agreement and the Exhibits and Schedules hereto set forth the entire understanding of the parties with respect to the subject matter hereof and supersede all existing agreements among them concerning such subject matter.

5.4. Amendments and Waivers. Any provisions of this Agreement or the Notes may be modified, amended, or waived if, but only if, such modification, amendment or waiver is in writing and is signed by NPDC and the Purchasers.

5.5. Notices. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by Federal Express, Express Mail, or similar overnight delivery or courier service, or delivered (in person or by telecopy, telex, or similar telecommunications equipment) against receipt to the party to whom it is to be given,

(a) if to NPDC:

National Patent Development Corporation 777 Westchester Avenue White Plains, NY 10604 Attn: General Counsel Facsimile No. (914) 249-9745

(b) if to MXL:

c/o National Patent Development Corporation 777 Westchester Avenue White Plains, NY 10604 Attn: General Counsel Facsimile No. (914) 249-9745
(c) if to any Purchaser:

to the address set forth for such Purchaser on Schedule 1.2.

or to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 5.5. Any notice shall be deemed given at the time of receipt thereof.

5

5.6. No Waiver; Remedies Cumulative. Any waiver by any party of a breach of any term of this Agreement shall not operate as or be construed to be a waiver of any other breach of that term or of any breach of any other term of this Agreement. The failure of a party to insist upon strict adherence to any term of this Agreement on one or more occasions will not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. The rights, powers, and remedies of the Purchasers provided in this Agreement, the Notes, and the Pledge are cumulative and not exclusive of any right, power, or remedy provided by law or equity.

5.7. Binding Effect. No party may sell, assign, transfer, or otherwise convey any of its rights or delegate any of its duties under this Agreement, except as hereinafter provided, and this Agreement shall be binding upon and inure to the benefit of the parties hereto and the respective permitted successors, assigns, and personal representatives of the parties. Any attempted sale, assignment, transfer, conveyance, or delegation in violation of this Section 5.7 shall be void. The provisions of this Agreement shall inure to the benefit of each indemnified party and its successors and assigns (if not a natural person) and his assigns, heirs, and personal representatives (if a natural person).

5.8. No Third Party Beneficiaries. This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement (except as provided in Section 5.7).

5.9. Separability. If any provision of this Agreement is invalid, illegal, or unenforceable, the balance of this Agreement shall remain in effect, and if any provision is inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons and circumstances.

5.10. Headings. The headings in this Agreement are solely for convenience of reference and shall be given no effect in the construction or interpretation of this Agreement.

5.11. Counterparts; Governing Law. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. It shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to conflict of laws.

6

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first written above.

NATIONAL PATENT DEVELOPMENT CORPORATION

By

Name:


Title:

MXL INDUSTRIES, INC.

By

Name:


Title:

Purchasers

BEDFORD OAK PARTNERS, L.P.

By

Name:


Title:

Jerome Feldman

7

2

SCHEDULE 1.2 PURCHASERS

                                                       Principal Amount of Note
  Purchaser and Address

Bedford Oak Partners, L.P.                                    $1,060,000
100 South Bedford Road
Mt. Kisco, NY 10549

Jerome Feldman                                                $  530,000
c/o GP Strategies Corporation
777 Westchester Avenue
White Plains, New York 10604


Exhibit 10.28

THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO CERTAIN RESTRICTIONS ON

TRANSFER AND, AMONG OTHER RESTRICTIONS, HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS NATIONAL PATENT DEVELOPMENT CORPORATION ("NPDC") HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE SATISFACTORY TO NPDC AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

NATIONAL PATENT DEVELOPMENT CORPORATION
6% Secured Note due 2009

No.__________ Original Issue Date: November 12, 2004

NATIONAL PATENT DEVELOPMENT CORPORATION, a Delaware corporation ("NPDC"), for value received, hereby promises to pay to ______________________________, with an address at _________________________________________, or registered assigns (the "Holder"), the principal amount of __________________________ Dollars ($______________) on the Maturity Date (as defined below), and, subject to the terms and conditions hereof, to pay interest on the unpaid principal balance hereof at the rate
(calculated on the basis of a 360-day year consisting of twelve 30-day months)
of 6% per annum from the date hereof until the Maturity Date. Accrued interest on the unpaid principal balance hereof shall be payable semi-annually on the 30th day of April and the 31st day of October in each year, commencing on April 30, 2005 (each such date and the Maturity Date being an "Interest Payment Date"). In no event shall any interest to be paid hereunder exceed the maximum rate permitted by law. In any such event, this Note shall automatically be deemed amended to permit interest charges at an amount equal to, but no greater than, the maximum rate permitted by law.

1. Offering. This Note was issued by NPDC in an offering of $1,590,000 principal amount of 6% Secured Notes due 2009 (collectively, the "Notes") pursuant to the Note Purchase Agreement, dated November 12, 2004 (the "Purchase Agreement"), among NPDC, its wholly-owned subsidiary MXL Industries, Inc., a Delaware corporation ("MXL"), and the purchasers named therein. Capitalized terms used and not otherwise defined herein have the meanings as defined in the Purchase Agreement.

2. Payments.

(a) Principal of, and any accrued and unpaid interest on, this Note shall be due and payable in full on October 31, 2009 (the "Maturity Date").

(b) Interest on this Note shall accrue from the most recent Interest Payment Date to which interest has been paid or, if no interest has


been paid on this Note, from the Original Issue Date, to, but excluding, the next Interest Payment Date, and, subject to the terms and conditions hereof, shall be payable in arrears on each Interest Payment Date.

(c) If any Interest Payment Date falls on a day that is not a Business Day (as defined below), the payment (of principal or interest or both) due on such Interest Payment Date will be made on the next succeeding Business Day with the same force and effect as if made on the Interest Payment Date. "Business Day" means any day which is not a Saturday or Sunday and is not a day on which banking institutions are generally authorized or obligated to close in the City of New York, New York.

(d) Payments of principal and interest on this Note to be made on any Interest Payment Date shall be made by check sent to the Holder of record of this Note on the Record Date (as defined below) relating to such Interest Payment Date. All payments will be delivered to the address set forth therefor on the note register described below, and will be in such coin or currency of the United States of America as at the time of payment shall be legal tender for the payment of public and private debts. For purposes of determining the holders of record entitled to receive payment on any Interest Payment Date, NPDC may fix a record date (the "Record Date"), which shall be not more than five Business Days prior to such Interest Payment Date. If NPDC does not otherwise establish a Record Date relating to any Interest Payment Date, the Record Date shall be the Business Day prior to such Interest Payment Date. Notwithstanding the foregoing, the Record Date relating to the Maturity Date shall be the Maturity Date.

(e) NPDC may, at its option, at any time and from time to time, prepay all or any part of the principal of and accrued interest on this Note, without payment of any premium or penalty.

(f) If MXL shall sell or otherwise dispose of all or any of the Shares (as defined below), NPDC shall cause MXL to distribute to NPDC the lesser of (i) the amount of proceeds of such sale or disposition (net of taxes and any amounts required to be paid by MXL to the Purchasers or their respective assignees pursuant to Section 1.4 of the Purchase Agreement) and (ii) the aggregate of the then outstanding principal of and accrued interest on all outstanding Notes. Upon receipt of such distribution from MXL, NPDC shall prepay, without payment of any premium or penalty, the then outstanding principal of and accrued interest on this Note in an amount equal to the Pro Rata Portion of such distribution. The "Pro Rata Portion" means a fraction, the numerator of which is the then outstanding principal of and accrued interest on this Note and the denominator of which is the aggregate of the then outstanding principal of and accrued interest on all outstanding Notes.

(g) If GP Strategies Corporation ("GP") shall receive any proceeds from the Claim and, out of such proceeds, make a capital contribution to NPDC, NPDC shall, upon receipt of such capital contribution, prepay, without payment of any premium or penalty, the outstanding principal of and accrued interest on this Note in an amount equal to the lesser of (i) the Pro Rata Portion of such capital contribution and (ii) the then outstanding principal of and accrued interest on this Note. The "Claim" means GP's pending claims against MCI Communications Corporation, Electronic Data Systems Corporation and the Systemhouse subsidiaries MCI Communications Corporation sold to Electronic Data Systems Corporation.

2

(h) All payments on this Note shall be applied first to accrued interest hereon and the balance to the payment of principal hereof.

(i) The obligations to make the payments provided for in this Note are absolute and unconditional and not subject to any defense, set-off, counterclaim, rescission, recoupment or adjustment whatsoever. NPDC hereby expressly waives demand and presentment for payment, notice of non-payment, notice of dishonor, protest, notice of protest, bringing of suit and diligence in taking any action to collect any amount called for hereunder, and shall be directly and primarily liable for the payment of all sums owing and to be owing hereon, regardless of and without any notice, diligence, act or omission with respect to the collection of any amount called for hereunder.

3. Security. This Note is secured by the Pledge Agreement, dated the Original Issue Date, executed by MXL for the benefit of the holders of the Notes, pursuant to which MXL has pledged to the holders of the Notes all of the shares of capital stock, including 2,068,966 Series B Convertible Preferred Shares (the "Shares"), of Valera Pharmaceuticals, Inc. ("Valera") held by MXL.

4. Forced Sale. If this Note remains outstanding on December 31, 2005 and MXL owns Shares on such date, the holders of Notes constituting a majority of the then outstanding principal of and accrued interest on all outstanding Notes may, by written notice to NPDC, require NPDC to cause MXL to take reasonable efforts to sell as promptly as practicable such number of Shares as may be necessary to prepay all of the Notes in full (or, if a sale of all of the Shares shall not be sufficient to prepay all of the Notes, all of the Shares).

5. Events of Default. The occurrence of any of the following events shall constitute an event of default (an "Event of Default"):

(a) A default in the payment of the principal on this Note, when and as the same shall become due and payable, which default shall continue for a period of five Business Days after the date fixed for the making of such principal payment.

(b) A default in the payment of any interest on this Note, when and as the same shall become due and payable, which default shall continue for a period of 30 Business Days after the date fixed for the making of such interest payment.

(c) A failure to perform or observe any material covenant or agreement contained in the Purchase Agreement or this Note within 30 Business Days after the giving of notice by the Holder of such failure (or, if such failure is not capable of being remedied within such period, for such longer period as it is reasonably necessary to effect a remedy so long as NPDC continues to diligently pursue remedy of such failure).

(d) The occurrence of a default by MXL under the Pledge.

(e) The entry of a decree or order by a court having jurisdiction adjudging NPDC a bankrupt or insolvent, or approving a petition seeking reorganization, arrangement, adjustment, or composition of or in respect of NPDC, under federal bankruptcy law, as now or hereafter constituted, or any other applicable federal or state bankruptcy, insolvency or other similar law, and the continuance of any such decree

3

or order unstayed and in effect for a period of 60 consecutive days; or the commencement by NPDC of a voluntary case under federal bankruptcy law, as now or hereafter constituted, or any other applicable federal or state bankruptcy, insolvency or other similar law, or the consent by it to the institution of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under federal bankruptcy law or any other applicable federal or state law, or the consent by it to the filing of such petition or to the appointment of a receiver, liquidator, assignee, trustee, sequestration or similar official of NPDC or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the admission by it in writing of its inability to pay its debts generally as they become due, or the taking of corporate action by NPDC in furtherance of any such action.

6. Remedies Upon Default.

(a) Upon the occurrence, and during the continuance, of an Event of Default specified in Section 5(a), (b), (c), or (d), the Holder of this Note may declare all or any part of the unpaid principal amount of this Note, and all interest accrued and unpaid thereon, to be immediately due and payable, without presentment, demand, protest or other formalities of any kind, all of which are hereby expressly waived by NPDC.

(b) Upon the occurrence of an Event of Default specified in Section 5(e), all of the principal amount then outstanding of, and all interest accrued and unpaid on, the Notes shall automatically become immediately due and payable without presentment, demand, protest or other formalities of any kind, all of which are hereby expressly waived by NPDC.

(c) The Holder may institute such actions or proceedings in law or equity as it shall deem expedient for the protection of its rights and may prosecute and enforce its claims against all assets of NPDC.

7. Registration and Transfer.

(a) NPDC shall maintain books for the registration and transfer of the Notes.

(b) Prior to due presentment for registration of transfer of this Note, NPDC may deem and treat the registered Holder as the absolute owner thereof. NPDC shall be entitled to treat the registered holder of any Note on the note register as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in such Note on the part of any other person, and shall not be liable for any registration or transfer of the Notes which are registered or to be registered in the name of a fiduciary or the nominee of a fiduciary unless made with the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration or transfer, or with the knowledge of such facts that its participation therein amounts to bad faith. In all cases of transfer by an attorney, executor, administrator, guardian, or other legal representative, duly authenticated evidence of his or its authority shall be produced.

(c) This Note has not been registered under the Securities Act of 1933, as amended (the "Securities Act"). Without limiting the foregoing, the Holder shall not make any disposition of this Note unless:

4

(i) Each transferee is an affiliate or family member of the initial Holder; and

(ii) (A) each transferee has agreed in writing to be bound by the terms of this Note and the Purchase Agreement, (B) the Holder shall have notified NPDC of the proposed disposition and shall have furnished NPDC with a detailed statement of the circumstances surrounding the proposed disposition, and (C) the Holder shall have furnished NPDC with an opinion of counsel, which counsel and opinion are reasonably satisfactory to NPDC, that such disposition will not require registration of this Note under the Securities Act.

(d) Each Note shall be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under other applicable securities laws):

THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND, AMONG OTHER RESTRICTIONS, HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS NATIONAL PATENT DEVELOPMENT CORPORATION ("NPDC") HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE SATISFACTORY TO NPDC AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

(e) NPDC shall register upon its books any permitted transfer of this Note, upon surrender of same to NPDC with a written instrument of transfer, in the form attached as Exhibit A, duly executed by the registered Holder or by a duly authorized attorney thereof and (unless being transferred to NPDC) by the transferee or by a duly authorized attorney thereof, together with such other documents as may be required for such transfer as provided above. Upon any such registration of transfer, new Note(s) shall be issued to the transferee(s) and the surrendered Note shall be canceled by NPDC. This Note may also be exchanged, at the option of the Holder, for new Notes representing in the aggregate the principal amount of this Note then outstanding.

(f) Upon receipt by NPDC of reasonable evidence of the ownership of and the loss, theft, destruction, or mutilation of this Note and, in the case of loss, theft, or destruction, of indemnity reasonably satisfactory to NPDC, or, in the case of mutilation, upon surrender and cancellation of the mutilated Note, NPDC shall execute and deliver in lieu thereof a new Note representing the principal amount of such Note then outstanding.

8. Miscellaneous.

(a) This Note shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to principles governing conflicts of law.

(b) Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by Federal Express, Express

5

Mail or similar overnight delivery or courier service or delivered (in person or by telecopy, telex or similar telecommunications equipment) against receipt to the party to whom it is to be given, (i) if to NPDC, at its address at 777 Westchester Avenue, Fourth Floor, White Plains, New York 10604, Attention: Chief Executive Officer, (ii) if to the Holder, at its address set forth on the first page hereof, or (iii) in either case, to such other address as the party shall have furnished in writing in accordance with the provisions of this Section
8(b). Any notice shall be deemed given at the time of receipt thereof.

(c) No course of dealing and no delay or omission on the part of the Holder in exercising any right or remedy shall operate as a waiver thereof or otherwise prejudice the Holder's rights, powers or remedies. No right, power or remedy conferred by this Note upon the Holder shall be exclusive of any other right, power or remedy referred to herein or now or hereafter available at law, in equity, by statute or otherwise, and all such remedies may be exercised singly or concurrently.

IN WITNESS WHEREOF, NPDC has caused this Note to be executed and dated the day and year first above written.

NATIONAL PATENT DEVELOPMENT CORPORATION

By: ___________________________
Name:
Title:

6

EXHIBIT A

FORM OF ASSIGNMENT

(To be executed by the registered holder if such holder desires to transfer the attached Note)

FOR VALUE RECEIVED, ______________________ (the "Holder") hereby sells, assigns, and transfers unto

Name ________________________________

Address_______________________________



Social Security or Tax Identification Number


______ Notes, together with all right, title, and interest therein, and does hereby irrevocably constitute and appoint _______________ attorney to transfer such Note on the books of National Patent Development Corporation ("NPDC"), with full power of substitution.

Dated: _________________


Name of Holder


Signature


If executed in a representative or fiduciary capacity, print name and title of individual executing this notice on behalf of the Holder.

NOTE: The above signature should correspond exactly with the name on the first page of the attached Note.


Social Security or Tax Identification Number of Holder

Address of Holder:




The undersigned transferee, by execution hereof, (i) represents and warrants to NPDC that (a) such transferee is family member or affiliate of the initial Holder, (b) the undersigned is acquiring the Note, and will acquire any shares of NPDC Common Stock (as defined in the Note) issued in payment of any interest thereon, for investment and without a view to a distribution other than pursuant to a registration statement under the Securities Act of 1933, as amended, and applicable state securities laws, or an exemption therefrom, and
(c) the name, address, and social security or tax identification number of the undersigned is as set forth above, and (ii) agrees to be bound by the terms of the Note and the Purchase Agreement (as defined in the Note).

Dated: _________________


Name of Transferee


Signature


If executed in a representative or fiduciary capacity, print name and title of individual executing this notice on behalf of the transferee.

NOTE: The above signature should correspond exactly with the name set forth above.


Exhibit 10.29

CONSULTING AND SEVERANCE AGREEMENT

AGREEMENT, dated as of July 1, 2004, between MXL Industries, Inc., a Delaware corporation with principal executive offices at 1764 Rohrerstown Road, Lancaster, PA 17601 (the "Company") and Steve Cliff, residing at 1054 Ladderback Drive, Lancaster, PA 17601 ("Consultant").

W I T N E S S E T H

WHEREAS, Consultant desires to terminate his employment with the Company; and

WHEREAS, the Company desires to offer severance payments to Consultant in appreciation for Consultant's past loyal service; and

WHEREAS, the parties wish to settle fully and finally any claims, disputes and obligations relating to Consultant's employment with the Company and the termination thereof; and

WHEREAS, the Company desires to engage Consultant to perform consulting services for the Company, and Consultant desires to perform such services, on the terms and conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the premises, the mutual promises, covenants, and conditions herein contained and for other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, the parties hereto intending to be legally bound hereby agree as follows:

Section 1. Consultant's Services.

The Company hereby retains Consultant, and Consultant hereby agrees to perform for the Company, consulting and advisory services, upon the terms and conditions set forth in this Agreement. Consultant shall devote such time and effort to the performance of Consultant's duties under this Agreement as shall be reasonably necessary for the performance thereof. The manner in which the consulting services are to be performed shall be determined by Consultant in consultation with the Company.

Section 2. Term.

The term of this Agreement (the "Term") shall commence on the Effective Date (as hereinafter defined) and end on the second anniversary of the Effective Date, unless earlier terminated as provided in Section 5(g). Consultant acknowledges and agrees that his relationship with the Company, whether as a consultant or otherwise, shall terminate at the end of the Term.


Section 3. Compensation.

During the Term, subject to all the terms and conditions of this Agreement, the Company shall pay to or provide Consultant with the following:

(a) Fees. The Company shall pay Consultant, as compensation for all services to be rendered by Consultant under this Agreement, a consulting fee of $4,357.97, less applicable federal, state, local and other legally required withholdings, payable bi-weekly (the "Fees").

(c) Benefit Plans. Consultant shall be entitled to participate in the Company's benefit plans as follows:

(i) Consultant will be permitted to participate in the Company's medical plan, to the extent eligible; provided that if Consultant becomes eligible to participate in a health insurance plan of another employer or Medicare, the Company shall have the option to terminate his health insurance coverage then in effect. The Company may at any time, terminate any of the plans or benefits with respect to its employees, to the extent permitted by law, without any obligation to Consultant.

(ii) the Company shall maintain the group life insurance policy covering Consultant on the date hereof.

The Company shall bear the cost of such benefits to the same extent (which shall be subject to change from time to time) as the Company bears the cost of such benefits for management personnel of the Company, and Consultant shall bear any balance of such cost.

(d) 401(k) Plan. During the Term, Consultant shall have the option to maintain any investments held by Consultant through the Company's 401(k) Plan.

Section 4. Expenses.

The Company shall reimburse Consultant promptly for any out-of-pocket expense incurred by him in connection with rendering services hereunder upon submission of a bill therefor, provided that the Company gave its prior written approval for such expense.

Section 5. Nondisclosure and Noncompetition.

(a) Confidentiality.

(i) Consultant will, during the Term and thereafter, treat all Confidential Information (as defined below) of the Company and its respective Customers (as defined below) and affiliates confidentially.

2

Consultant will not discuss or disclose such Confidential Information, directly or indirectly, with or to any person who is not an authorized officer or authorized employee of the Company. Consultant will not use any Confidential Information of the Company or its Customers or affiliates, or any other property of the Company, other than as is necessary in connection with his performance of consulting services hereunder or as specifically directed by the Company, or in any way which is detrimental to the Company. Consultant will not use any Confidential Information of GP Strategies ("GP") or its Customers or affiliates, or any other property of GP, in any manner not specifically directed by GP, or in any way which is detrimental to GP.

(ii) Consultant agrees that all Confidential Information, together with all notes, drawings, and records relating thereto, all computer disks containing any Confidential Information, and all copies or facsimiles of any of the foregoing (in any media), in Consultant's possession are the exclusive property of the Company or GP, as the case may be. Consultant will not remove from the Company's premises any notes or records relating to Confidential Information of the Company or copies or facsimiles thereof (on any media) or any other property of the Company or any Customer or affiliate of the Company, except in the furtherance of the business of the Company. Consultant will promptly, upon termination of this Agreement for any reason and the request of the Company, deliver to the Company without retaining a copy thereof and will not keep in Consultant's possession, or recreate or deliver to anyone else, any or all of such Confidential Information or other property. Consultant will not remove from GP's premises any notes or records relating to Confidential Information of GP or copies or facsimiles thereof (on any media) or any other property of GP or any Customer or affiliate of GP. Consultant will promptly deliver to GP without retaining a copy thereof and will not keep in Consultant's possession, or recreate or deliver to anyone else, any or all of such Confidential Information or other property.

(iii) Notwithstanding the foregoing, Consultant may use Confidential Information as is necessary to enforce Consultant's rights under this Agreement, provided that, in the event of litigation concerning any such matter, Consultant will stipulate to entry of a protective order limiting Consultant's use of Confidential Information to the litigation or as otherwise permitted hereunder, prohibiting its dissemination to the public or otherwise for reasons not permitted hereunder and requiring its return at the conclusion of such proceedings.

(iv) The term "Confidential Information" means all confidential information in any way concerning the activities, business, or affairs of the Company or GP, as the case may be, or their respective Customers or affiliates. Confidential Information includes, without limitation, information, observations and data concerning trade secrets, inventions, or know-how of proprietary processes, together with all marketing, sales, financial, and research information; information concerning projects in research and development, or marketing plans for any products or projects; information concerning the technology, designs, or computer systems and programs of the Company or GP, as the case may be; and other information not generally known to the public

3

concerning the business practices, activities, and business affairs of the Company or GP, as the case may be, or their respective Customers or affiliates. The term "Customer" means all past, present and prospective customers of the Company or GP, as the case may be.

(b) Trademarks, Etc. During and after the Term, Consultant will have no right, title, or interest in any trademark, trade name, or character names belonging to or used by the Company or GP or any material or matter of any sort prepared for or used in connection with advertising, broadcasting, or promotion of the services provided by the Company or GP, whether produced, prepared, published, or broadcast in whole or in part by Consultant, nor will Consultant make any claims with respect thereto. Consultant recognizes that the Company or GP, as the case may be, has and will continue to have and retain the sole and exclusive rights in any and all of the aforementioned trademarks, trade names, character names, material, or matter.

(c) Non-competition and No Disparagement. Consultant will not, during the Term and thereafter, directly or indirectly disparage the Company or GP, any of the Company's or GP's products or services, or any of the Company's or GP's then current or former directors, officers, or employees. During the period ending twenty-four (24) months after the Effective Date, Consultant will not:

(i) solicit the employment of any employee of the Company or GP for one year after termination of such person's employment with the Company or GP;

(ii) encourage or induce any employee of the Company or GP to terminate his or her employment with the Company or GP;

(iii) contact or solicit, or direct or assist others to contact or solicit, any Customers, suppliers, or other business associates of the Company or GP;

(iv) engage in a diversion of good-will regarding the business conducted by the Company or GP;

(v) otherwise interfere in any way with the relationships between the Company or GP and their respective Customers, suppliers, lenders, or business associates; or

(vi) compete with the Company in the business of optical molding, including by: (A) serving as a consultant to any person if Consultant knows or should have known that such consulting services would help such person compete against the Company or GP, (B) having any interest (as owner, principal, general or limited partner, agent, employee, officer, director, or stockholder) in any person which competes with the Company or GP, other than a passive interest of less than 5% of the voting stock of a publicly traded company, (C) establishing an entity that engages in the business of the Company or GP, (D) acquiring an existing entity that engages in such business, (E) otherwise engaging

4

in such business; (F) participating in the management of any entity that engages in such business, or (G) serving (or having a nominee serve) with a competing entity as an officer, director, manager, or employee having duties dealing with such competing business.

(d) Inventions. Consultant hereby assigns to the Company Consultant's entire right to all Company Inventions (as hereinafter defined), which will be the sole and exclusive property of the Company whether or not subject to patent, copyright, trademark, or trade secret protection. Consultant also acknowledges that all original works of authorship that are made by Consultant (solely or jointly with others), within the scope of Consultant's services hereunder, and that are protectable by copyright, are "works made for hire," as that term is defined in the United States Copyright Act (17 U.S.C. ss.ss. 101, et seq.). To the extent that any such works, by operation of law, cannot be "works made for hire," Consultant hereby assigns to the Company all right, title and interest in and to such works and to any related copyrights. "Company Inventions" means all ideas, processes, trademarks and service marks, inventions, discoveries, and improvements to any of the foregoing, that Consultant learned or learned of, conceived or conceives of, developed or develops, or created or creates, alone or with others during Consultant's employment with the Company or any predecessor, affiliate, or successor thereof
(whether or not conceived, developed, or created during regular working hours) that directly or indirectly arise from or relate to (i) the business, products, or services of the Company or any predecessor, affiliate, or successor thereof,
(ii) work performed for the Company by Consultant or any other employee, agent, or contractor of the Company or any predecessor, affiliate, or successor thereof, (iii) the use of the time of the Company or any predecessor, affiliate, or successor thereof, or (iv) access to the Confidential Information of the Company or any predecessor, affiliate, or successor thereof. Consultant will promptly execute, acknowledge and deliver to the Company all additional instruments or documents deemed at any time by the Company in its reasonable discretion to be necessary to carry out the intentions of this Section 6(d).

(e) Acknowledgments. Consultant acknowledges and agrees that
(i) the Confidential Information of the Company and Company Inventions have substantial value to the Company, (ii) the Confidential Information of the Company and Company Inventions would be susceptible to immediate competitive application by those outside of the Company, (iii) the Confidential Information of GP has substantial value to GP, and (iv) the Confidential Information of GP would be susceptible to immediate competitive application by those outside of GP, and that, under these circumstances, the provisions of this Section 6 are fair and reasonable.

(f) Survival. Consultant's obligations under this Section 5 will survive the termination of this Agreement and will thereafter be enforceable.

(g) Remedies. Consultant acknowledges that, if Consultant breaches any obligation under this Section 5, the Company and GP will suffer immediate and irreparable harm and damage for which money alone cannot fully compensate the Company and GP. Consultant therefore agrees that, upon such breach or threatened breach of any obligation under this Section 5, the Company

5

and GP will be entitled to a temporary restraining order, preliminary injunction, permanent injunction or other injunctive relief, without posting any bond or other security, compelling Consultant to comply with any or all such provisions. In addition, if Consultant breaches any obligation under this
Section 5, the Company or GP may terminate this Agreement and the Term, and upon such termination, the Company and GP will have no further obligation or liability hereunder except that the Company will pay to Consultant the portion, if any, of the Fees and any other amounts due and unpaid hereunder for the period through the date of such termination. This Section 5 will not be construed as an election of any remedy, or as a waiver of any right available to the Company or GP under this Agreement or law, including the right to seek damages from Consultant for a breach of any provision of this Agreement, nor will this Section 5 be construed to limit the rights or remedies available under applicable law for any violation of any provision of this Agreement.

(h) The Company. As used in this Section 5, the term "Company" shall include the Company and any subsidiary or affiliate of the Company, and the term "GP" shall include GP and any subsidiary or affiliate of GP.

Section 7. Death.

If Consultant shall die during the Term, his services hereunder shall terminate, and in such case:

(a) the Company will have no further obligation or liability hereunder except that the Company shall pay to Consultant's spouse (or if he leaves no spouse, to his estate or designated beneficiary), the Fees, and shall maintain the benefits set forth in Section 3, for the benefit of Consultant's spouse, each through the second anniversary of the Effective Date.

Section 8. Disability.

If, as a result of Consultant's incapacity due to physical or mental illness, Consultant shall not have performed the services hereunder for 90 consecutive days or for an aggregate of more than 180 days in any 12 month period, and within 90 days after the Company has notified Consultant of such non-performance, he shall not have resumed performance of the services hereunder which shall continue for a minimum of eight consecutive weeks thereafter, the Company may terminate Consultant's services hereunder. In the case of such termination, the Company will have no further obligation or liability hereunder except that the Company shall pay to Consultant the Fees, and shall maintain the benefits set forth in Section 3(d) for the benefit of Consultant and his spouse, each through the second anniversary of the Effective Date.

Section 9. Benefits Not Otherwise Entitled To.

Consultant acknowledges that the payment and benefits specified above are in addition to and otherwise exceed any payment, benefit or other thing of

6

value to which he might otherwise be entitled.

Section 10. General Releases.

(a) Consultant, in consideration of this Agreement, releases and forever discharges the Company, GP, and their respective parents, affiliates and subsidiaries, and each of their respective current, former, and future, officers, directors, trustees, employees, agents, attorneys, successors, and assigns (hereinafter collectively "Releasees"), from all actions, causes of action, suits, debts, sums of money, covenants, agreements, promises, claims, and demands whatsoever, whether known or unknown, in law or equity, whether statutory or common law, whether federal, state, local, or otherwise (collectively "Claims"), including, but not limited to, any claims relating to, or arising out of any aspect of Consultant's employment with the Company, or the termination of such employment, including, but not limited to:

(i) any and all claims of wrongful discharge, breach of the contract or equitable estoppel;

(ii) any and all claims for wages or employee benefits, including, but not limited to, any and all claims under the Employee Retirement Income Security Act, the Fair Labor Standards Act, or any federal, state or local labor or benefits law;

(iii) any and all claims of employment discrimination on any basis, including, but not limited to, all claims under the following statutes and the amendments thereto, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act of 1967 ("ADEA"), the Civil Rights Act of 1866, 42 U.S.C. ss. 1981, the Civil Rights Act of 1991, the Americans with Disabilities Act of 1990, the Immigration Reform and Control Act of 1986, the New York State Executive Law, the New York City Human Rights Law, any and all claims under any other federal, state, or local civil or human rights law; and

(iv) any and all claims for monetary recovery, including, but not limited to, severance pay, back pay, front pay, liquidated, compensatory and punitive damages, and attorneys' fees, disbursements and costs;

which against the Releasees, Consultant or Consultant's heirs, executors or administrators, ever had, now have, or hereinafter can, shall, or may have, for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time to the Effective Date, other than Claims ("Unreleased Claims") relating to the enforcement of the provisions of this Agreement or of Consultant's rights to indemnification under the Company's certificate of incorporation and by-laws.

(b) The Company and GP, in consideration of this Agreement, releases and forever discharges Consultant from all Claims, including, but not

7

limited to, any claims relating to, or arising out of any aspect of Consultant's employment with the Company, or the termination of such employment, which against Consultant the Company or GP ever had, now has, or hereinafter can, shall, or may have, for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time to the Effective Date, other than Claims relating to the enforcement of the provisions of this Agreement.

Section 11. No Suits.

Consultant represents and warrants that he has never commenced or filed and covenants and agrees never to commence, file or in any way prosecute or cause to be commenced or prosecuted against the Releasees or any of them, any action, charge, complaint or other proceedings, whether administrative, judicial, legislative or otherwise, including, but not limited to, any action or proceeding for damages, attorney's fees, disbursements, costs or equitable relief based upon or seeking relief on account of actions or failures to act by the Releasees which may have occurred or failed to occur prior to the Effective Date, other than in connection with Unreleased Claims. Consultant agrees that in the event he files any charge, complaint or commences any litigation of any kind that is covered by this Agreement, he shall pay all of the reasonable attorneys' fees, expenses and costs incurred by Releasees in responding to such action, including, but not limited to, any consequential damages that Releasees, or any of them, may suffer or incur. Consultant further represents that he will not aid, abet or assist in any manner whatsoever any other third party in filing, pursuing or maintaining any lawsuit, complaint, or charge against any of the Releasees, except if compelled to do so by valid legal process or if otherwise required to do so by law. The provisions of this Paragraph 11 shall be inapplicable in any matters regarding the ADEA, should Consultant allege in good faith that the waiver herein of his right to file an ADEA claim was not knowing and voluntary.

Section 12. Knowing and Voluntary Waiver.

(a) Consultant agrees that this Agreement constitutes a knowing and voluntary waiver of all Claims, other than the Unreleased Claims, Consultant may have against the Releasees, or any of them, including, but not limited to, all rights or claims arising under the ADEA, including, but not limited to, all claims of age discrimination in employment and all claims of retaliation in violation of the ADEA.

(b) This Agreement shall not affect the rights and responsibilities of the Equal Employment Opportunity Commission (the "EEOC") to enforce the ADEA and other laws. Notwithstanding paragraph 11 above, this Agreement shall not be used to justify interfering with Consultant's right to file a charge with the EEOC or participate in an investigation or proceeding by the EEOC. However, should any charge be filed with the EEOC, Consultant expressly waives all rights or claims which arose prior to his execution of this Agreement that he may have against the Releasees, or any of them, to receive any benefit or remedial relief (including, but not limited to, reinstatement, back pay, front pay, damages, and attorneys' fees) as a consequence of such EEOC filing, and of any litigation concerning any facts alleged in any such charge.

8

(c) The Company, GP, and Consultant agree that, for a period of seven days following his execution of this Agreement ("Revocation Period"), Consultant has the right to revoke this Agreement by delivering notice in writing of such revocation to the Company and GP. If Consultant gives such notice of revocation within the Revocation Period, this Agreement shall be null and void. If no such notice of revocation is delivered by Consultant within the Revocation Period, this Agreement will be deemed fully effective and enforceable on the eighth day after its execution by Consultant ("Effective Date").

(d) The Company and GP hereby advise Consultant to consult with his attorney prior to executing this Agreement. Consultant further acknowledges that the Company and GP have given him a period of at least 21 days in which to consider this Agreement before executing this Agreement.

(e) Consultant's acceptance of the payments and benefits described above, at any time subsequent to seven days after his execution of this Agreement, shall constitute an admission by Consultant that he did not revoke this Agreement during the Revocation Period of seven days, and shall further constitute an admission by Consultant that this Agreement has become effective and enforceable.

(f) If Consultant executed this Agreement at any time prior to the end of the 21 day period that the Company and GP gave him in which to consider this Agreement, such early execution was a knowing and voluntary waiver of Consultant's right to consider this Agreement for at least 21 days, and was due to Consultant's belief that he had ample time in which to consider and understand this Agreement, and in which to review this Agreement with his attorney.

Section 13. Non-Admission of Wrongdoing.

This Agreement shall not in any way be construed as an admission by the Company or GP of any liability, or of any unlawful, discriminatory, or otherwise wrongful acts whatsoever against the Consultant or any other person.

Section 14. Acknowledgment of Full Payments.

Consultant agrees that the Company has paid to him all of the wages, commissions, bonuses and accrued vacation pay through the date of his execution of this Agreement and that neither the Company nor GP owes no other wages, commissions, bonuses, vacation pay, employee benefits, severance payments or other compensation or payments of any kind or nature, other than as provided in this Agreement.

Section 15. Binding Agreement.

9

Except as expressly permitted hereby, Consultant's rights and obligations under this Agreement shall not be transferable by assignment or otherwise, such rights shall not be subject to commutation, encumbrance, or the claims of Consultant's creditors, and any attempt to do any of the foregoing shall be void. The provisions of this Agreement shall be binding upon and inure to the benefit of Consultant and his personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, and legatees, shall be binding upon and inure to the benefit of the Company and its successors, and shall be binding upon and inure to the benefit of GP and its successors. If Consultant should die while any amounts would still be payable to him hereunder if he had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Consultant's devisee, legatee, or other designee or, if there be no such designee, to Consultant's estate. Notwithstanding anything to the contrary contained herein, GP shall have no responsibility for the obligations of the Company hereunder.

Section 16. No Third Party Beneficiaries.

This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement (except as provided in Section 15).

Section 17. Modification.

This Agreement sets forth the entire understanding of the parties with respect to the subject matter hereof, supersedes all existing agreements between them concerning such subject matter, and may be modified only by a written instrument duly executed by each party.

Section 18. Notices.

Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified mail, return receipt requested, or by Federal Express, Express Mail, or similar overnight delivery or courier service or delivered (in person or by telecopy, telex, or similar telecommunications equipment) against receipt to the party to whom it is to be given at the address of such party set forth in the preamble to this Agreement (or to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 18). Notice to the estate of Consultant shall be sufficient if addressed to Consultant as provided in this
Section 18. Any notice or other communication given by certified mail shall be deemed given at the time of certification thereof, except for a notice changing a party's address which shall be deemed given at the time of receipt thereof. Any notice given by other means permitted by this Section 18 shall be deemed given at the time of receipt thereof.

Section 19. Waiver.

10

Any waiver by any party of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a party to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. Any waiver must be in writing.

Section 20. Headings.

The headings in this Agreement are solely for the convenience of reference and shall be given no effect in the construction or interpretation of this Agreement.

Section 21. Counterparts; Governing Law.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. It shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to conflict of laws.

Section 22. Acknowledgment.

CONSULTANT EXPRESSLY ACKNOWLEDGES, REPRESENTS, AND WARRANTS THAT HE HAS CAREFULLY READ THIS AGREEMENT; THAT HE FULLY UNDERSTANDS THE TERMS, CONDITIONS, AND SIGNIFICANCE OF THIS AGREEMENT; THAT HE HAS HAD AMPLE TIME TO CONSIDER AND NEGOTIATE THIS AGREEMENT; THAT THE COMPANY AND GP HAVE ADVISED HIM TO CONSULT WITH AN ATTORNEY CONCERNING THIS AGREEMENT; THAT HE HAS HAD A FULL OPPORTUNITY TO AND HAS IN FACT REVIEWED THIS AGREEMENT WITH HIS ATTORNEY, AND THAT HE HAS EXECUTED THIS AGREEMENT VOLUNTARILY, KNOWINGLY, AND WITH SUCH ADVICE OF COUNSEL AS HE HAS DEEMED APPROPRIATE.

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first above written.

NATIONAL PATENT DEVELOPMENT CORPORATION              MXL INDUSTRIES, INC.
(As to Sections 3, 4 7 and 8 hereunder)

By: _______________________                          By: ______________________
Name:                                                    Name:
Title                                                    Title

Steve Cliff

11

Exhibit 21.1

Subsidiaries of the Registrant

Name                                                            Jurisdiction

MXL Industries, Inc.                                            Delaware
Five Star Products, Inc.                                        Delaware
JL Distributors                                                 Delaware


Exhibit 31.1

CERTIFICATION

I, Jerome I. Feldman, Chief Executive Officer, certify that:

1. I have reviewed this annual report on Form 10-K of National Patent Development Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating

to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial


reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 14, 2005

Jerome I. Feldman
Chief Executive Officer


Exhibit 31.2

CERTIFICATION

I, Scott N. Greenberg, Chief Financial Officer, certify that:

1. I have reviewed this annual report on Form 10-K of National Patent Development Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial


reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 14, 2005

Scott N. Greenberg
Chief Financial Officer


Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of National Patent Development Corporation (the "Company") for the year ended December 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 14, 2005

Jerome I. Feldman Scott N. Greenberg Chief Executive Officer Chief Financial Officer


Exhibit 10.30

CONSULTING AND SEVERANCE AGREEMENT

AGREEMENT, dated as of September 20, 2004, between MXL Industries, Inc., a Delaware corporation with principal executive offices at 1764 Rohrerstown Road, Lancaster, PA 17601 (the "Company") and Frank Yohe, residing at 226 Dogwood Drive, Elizabethtown, PA 17022 ("Consultant").

W I T N E S S E T H

WHEREAS, Consultant desires to terminate his employment with the Company; and

WHEREAS, the Company desires to offer severance payments to Consultant in appreciation for Consultant's past loyal service; and

WHEREAS, the parties wish to settle fully and finally any claims, disputes and obligations relating to Consultant's employment with the Company and the termination thereof; and

WHEREAS, the Company desires to engage Consultant to perform consulting services for the Company, and Consultant desires to perform such services, on the terms and conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the premises, the mutual promises, covenants, and conditions herein contained and for other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, the parties hereto intending to be legally bound hereby agree as follows:

Section 1. Consultant's Services.

The Company hereby retains Consultant, and Consultant hereby agrees to perform for the Company, consulting and advisory services, upon the terms and conditions set forth in this Agreement. Consultant shall devote such time and effort to the performance of Consultant's duties under this Agreement as shall be reasonably necessary for the performance thereof. The manner in which the consulting services are to be performed shall be determined by Consultant in consultation with the Company.

Section 2. Term.

The term of this Agreement (the "Term") shall commence on the Effective Date (as hereinafter defined) and end on the second anniversary of the Effective Date, unless earlier terminated as provided in Section 5(g). Consultant acknowledges and agrees that his relationship with the Company, whether as a consultant or otherwise, shall terminate at the end of the Term.


Section 3. Compensation.

During the Term, subject to all the terms and conditions of this Agreement, the Company shall pay to or provide Consultant with the following:

(a) Fees. The Company shall pay Consultant, as compensation for all services to be rendered by Consultant under this Agreement, a consulting fee of $2,209.38, less applicable federal, state, local and other legally required withholdings, payable bi-weekly (the "Fees"), commencing Friday October 15, 2004. In addition, Consultant acknowledges that he was paid his full salary at the bi-weekly rate of $4,418.76 through October 14, 2004, which includes full payment for the 19 earned and unused vacation days.

(c) Benefit Plans. Consultant shall be entitled to participate in the Company's benefit plans as follows:

(i) Consultant will be permitted to participate in the Company's medical plan, to the extent eligible; provided that if Consultant becomes eligible to participate in a health insurance plan of another employer or Medicare, the Company shall have the option to terminate his health insurance coverage then in effect. The Company may at any time, terminate any of the plans or benefits with respect to its employees, to the extent permitted by law, without any obligation to Consultant.

(ii) the Company shall maintain the group life insurance policy covering Consultant on the date hereof, to the extent eligible.

The Company shall bear the cost of such benefits to the same extent (which shall be subject to change from time to time), to the extent eligible, as the Company bears the cost of such benefits for management personnel of the Company, and Consultant shall bear any balance of such cost.

(d) 401(k) Plan. During the Term, Consultant shall have the option to maintain any investments held by Consultant through the Company's 401(k) Plan, to the extent eligible.

Section 4. Expenses.

The Company shall reimburse Consultant promptly for any out-of-pocket expense incurred by him in connection with rendering services hereunder upon submission of a bill therefor, provided that the Company gave its prior written approval for such expense.

Section 5. Nondisclosure and Noncompetition.

(a) Confidentiality.

2

(i) Consultant will, during the Term and thereafter, treat all Confidential Information (as defined below) of the Company and its respective Customers (as defined below) and affiliates confidentially. Consultant will not discuss or disclose such Confidential Information, directly or indirectly, with or to any person who is not an authorized officer or authorized employee of the Company. Consultant will not use any Confidential Information of the Company or its Customers or affiliates, or any other property of the Company, other than as is necessary in connection with his performance of consulting services hereunder or as specifically directed by the Company, or in any way which is detrimental to the Company. Consultant will not use any Confidential Information of GP Strategies ("GP") or its Customers or affiliates, or any other property of GP, in any manner not specifically directed by GP, or in any way which is detrimental to GP.

(ii) Consultant agrees that all Confidential Information, together with all notes, drawings, and records relating thereto, all computer disks containing any Confidential Information, and all copies or facsimiles of any of the foregoing (in any media), in Consultant's possession are the exclusive property of the Company or GP, as the case may be. Consultant will not remove from the Company's premises any notes or records relating to Confidential Information of the Company or copies or facsimiles thereof (on any media) or any other property of the Company or any Customer or affiliate of the Company, except in the furtherance of the business of the Company. Consultant will promptly, upon termination of this Agreement for any reason and the request of the Company, deliver to the Company without retaining a copy thereof and will not keep in Consultant's possession, or recreate or deliver to anyone else, any or all of such Confidential Information or other property. Consultant will not remove from GP's premises any notes or records relating to Confidential Information of GP or copies or facsimiles thereof (on any media) or any other property of GP or any Customer or affiliate of GP. Consultant will promptly deliver to GP without retaining a copy thereof and will not keep in Consultant's possession, or recreate or deliver to anyone else, any or all of such Confidential Information or other property.

(iii) Notwithstanding the foregoing, Consultant may use Confidential Information as is necessary to enforce Consultant's rights under this Agreement, provided that, in the event of litigation concerning any such matter, Consultant will stipulate to entry of a protective order limiting Consultant's use of Confidential Information to the litigation or as otherwise permitted hereunder, prohibiting its dissemination to the public or otherwise for reasons not permitted hereunder and requiring its return at the conclusion of such proceedings.

(iv) The term "Confidential Information" means all confidential information in any way concerning the activities, business, or affairs of the Company or GP, as the case may be, or their respective Customers or affiliates. Confidential Information includes, without limitation, information, observations and data concerning trade secrets, inventions, or know-how of proprietary processes, together with all marketing, sales, financial, and research information; information concerning projects in

3

research and development, or marketing plans for any products or projects; information concerning the technology, designs, or computer systems and programs of the Company or GP, as the case may be; and other information not generally known to the public concerning the business practices, activities, and business affairs of the Company or GP, as the case may be, or their respective Customers or affiliates. The term "Customer" means all past, present and prospective customers of the Company or GP, as the case may be.

(b) Trademarks, Etc. During and after the Term, Consultant will have no right, title, or interest in any trademark, trade name, or character names belonging to or used by the Company or GP or any material or matter of any sort prepared for or used in connection with advertising, broadcasting, or promotion of the services provided by the Company or GP, whether produced, prepared, published, or broadcast in whole or in part by Consultant, nor will Consultant make any claims with respect thereto. Consultant recognizes that the Company or GP, as the case may be, has and will continue to have and retain the sole and exclusive rights in any and all of the aforementioned trademarks, trade names, character names, material, or matter.

(c) Non-competition and No Disparagement. Consultant will not, during the Term and thereafter, directly or indirectly disparage the Company or GP, any of the Company's or GP's products or services, or any of the Company's or GP's then current or former directors, officers, or employees. During the period ending twenty-four (24) months after the Effective Date, Consultant will not:

(i) solicit the employment of any active employee of the Company or GP;

(ii) encourage or induce any employee of the Company or GP to terminate his or her employment with the Company or GP;

(iii) contact or solicit, or direct or assist others to contact or solicit, any Customers, suppliers, or other business associates of the Company or GP;

(iv) engage in a diversion of good-will regarding the business conducted by the Company or GP;

(v) otherwise interfere in any way with the relationships between the Company or GP and their respective Customers, suppliers, lenders, or business associates; or

(vi) compete with the Company in the business of optical molding, including by: (A) serving as a consultant to any person if Consultant knows or should have known that such consulting services would help such person compete against the Company or GP, (B) having any interest (as owner, principal, general or limited partner, agent, employee, officer, director, or stockholder) in any person which competes with the Company or GP, other than a passive interest of less than 5% of the voting stock of a publicly traded company, (C) establishing an entity that engages in the business of the Company or GP, (D) acquiring an existing entity that engages in such

4

business, (E) otherwise engaging in such business; (F) participating in the management of any entity that engages in such business, or (G) serving (or having a nominee serve) with a competing entity as an officer, director, manager, or employee having duties dealing with such competing business.

(d) Inventions. Consultant hereby assigns to the Company Consultant's entire right to all Company Inventions (as hereinafter defined), which will be the sole and exclusive property of the Company whether or not subject to patent, copyright, trademark, or trade secret protection. Consultant also acknowledges that all original works of authorship that are made by Consultant (solely or jointly with others), within the scope of Consultant's services hereunder, and that are protectable by copyright, are "works made for hire," as that term is defined in the United States Copyright Act (17 U.S.C. ss.ss. 101, et seq.). To the extent that any such works, by operation of law, cannot be "works made for hire," Consultant hereby assigns to the Company all right, title and interest in and to such works and to any related copyrights. "Company Inventions" means all ideas, processes, trademarks and service marks, inventions, discoveries, and improvements to any of the foregoing, that Consultant learned or learned of, conceived or conceives of, developed or develops, or created or creates, alone or with others during Consultant's employment with the Company or any predecessor, affiliate, or successor thereof (whether or not conceived, developed, or created during regular working hours) that directly or indirectly arise from or relate to (i) the business, products, or services of the Company or any predecessor, affiliate, or successor thereof, (ii) work performed for the Company by Consultant or any other employee, agent, or contractor of the Company or any predecessor, affiliate, or successor thereof, (iii) the use of the time of the Company or any predecessor, affiliate, or successor thereof, or (iv) access to the Confidential Information of the Company or any predecessor, affiliate, or successor thereof. Consultant will promptly execute, acknowledge and deliver to the Company all additional instruments or documents deemed at any time by the Company in its reasonable discretion to be necessary to carry out the intentions of this Section 6(d).

(e) Acknowledgments. Consultant acknowledges and agrees that (i) the Confidential Information of the Company and Company Inventions have substantial value to the Company, (ii) the Confidential Information of the Company and Company Inventions would be susceptible to immediate competitive application by those outside of the Company, (iii) the Confidential Information of GP has substantial value to GP, and (iv) the Confidential Information of GP would be susceptible to immediate competitive application by those outside of GP, and that, under these circumstances, the provisions of this Section 5 are fair and reasonable.

(f) Survival. Consultant's obligations under this Section 5 will survive the termination of this Agreement and will thereafter be enforceable.

(g) Remedies. Consultant acknowledges that, if Consultant breaches any obligation under this Section 5, the Company and GP will suffer immediate and irreparable harm and damage for which money alone cannot fully compensate the Company and GP. Consultant therefore agrees that, upon such breach or threatened breach of any obligation under this Section 5, the Company and GP will be

5

entitled to a temporary restraining order, preliminary injunction, permanent injunction or other injunctive relief, without posting any bond or other security, compelling Consultant to comply with any or all such provisions. In addition, if Consultant breaches any obligation under this Section 5, the Company or GP may terminate this Agreement and the Term, and upon such termination, the Company and GP will have no further obligation or liability hereunder except that the Company will pay to Consultant the portion, if any, of the Fees and any other amounts due and unpaid hereunder for the period through the date of such termination. This Section 5 will not be construed as an election of any remedy, or as a waiver of any right available to the Company or GP under this Agreement or law, including the right to seek damages from Consultant for a breach of any provision of this Agreement, nor will this
Section 5 be construed to limit the rights or remedies available under applicable law for any violation of any provision of this Agreement. (h) The Company. As used in this Section 5, the term "Company" shall include the Company and any subsidiary or affiliate of the Company, and the term "GP" shall include GP and any subsidiary or affiliate of GP.

Section 6. Death.

If Consultant shall die during the Term, his services hereunder shall terminate, and in such case:

(a) the Company will have no further obligation or liability hereunder except that the Company shall pay to Consultant's spouse (or if he leaves no spouse, to his estate or designated beneficiary), the Fees, and shall maintain the benefits set forth in Section 3, for the benefit of Consultant's spouse, each through the second anniversary of the Effective Date.

Section 7. Disability.

If, as a result of Consultant's incapacity due to physical or mental illness, Consultant shall not have performed the services hereunder for 90 consecutive days or for an aggregate of more than 180 days in any 12 month period, and within 90 days after the Company has notified Consultant of such non-performance, he shall not have resumed performance of the services hereunder which shall continue for a minimum of eight consecutive weeks thereafter, the Company may terminate Consultant's services hereunder. In the case of such termination, the Company will have no further obligation or liability hereunder except that the Company shall pay to Consultant the Fees, and shall maintain the benefits set forth in Section 3(b) for the benefit of Consultant and his spouse, each through the second anniversary of the Effective Date.

Section 8. Benefits Not Otherwise Entitled To.

Consultant acknowledges that the payment and benefits specified above

6

are in addition to and otherwise exceed any payment, benefit or other thing of value to which he might otherwise be entitled.

Section 9. General Releases.

(a) Consultant, in consideration of this Agreement, releases and forever discharges the Company, GP, and their respective parents, affiliates and subsidiaries, and each of their respective current, former, and future, officers, directors, trustees, employees, agents, attorneys, successors, and assigns (hereinafter collectively "Releasees"), from all actions, causes of action, suits, debts, sums of money, covenants, agreements, promises, claims, and demands whatsoever, whether known or unknown, in law or equity, whether statutory or common law, whether federal, state, local, or otherwise (collectively "Claims"), including, but not limited to, any claims relating to, or arising out of any aspect of Consultant's employment with the Company, or the termination of such employment, including, but not limited to:

(i) any and all claims of wrongful discharge, breach of the contract or equitable estoppel;

(ii) any and all claims for wages or employee benefits, including, but not limited to, any and all claims under the Employee Retirement Income Security Act, the Fair Labor Standards Act, or any federal, state or local labor or benefits law;

(iii) any and all claims of employment discrimination on any basis, including, but not limited to, all claims under the following statutes and the amendments thereto, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act of 1967 ("ADEA"), the Civil Rights Act of 1866, 42 U.S.C. ss. 1981, the Civil Rights Act of 1991, the Americans with Disabilities Act of 1990, the Immigration Reform and Control Act of 1986, the New York State Executive Law, the New York City Human Rights Law, any and all claims under any other federal, state, or local civil or human rights law; and

(iv) any and all claims for monetary recovery, including, but not limited to, severance pay, back pay, front pay, liquidated, compensatory and punitive damages, and attorneys' fees, disbursements and costs;

which against the Releasees, Consultant or Consultant's heirs, executors or administrators, ever had, now have, or hereinafter can, shall, or may have, for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time to the Effective Date, other than Claims ("Unreleased Claims") relating to the enforcement of the provisions of this Agreement or of Consultant's rights to indemnification under the Company's certificate of incorporation and by-laws.

(b) The Company and GP, in consideration of this Agreement, releases

7

and forever discharges Consultant from all Claims, including, but not limited to, any claims relating to, or arising out of any aspect of Consultant's employment with the Company, or the termination of such employment, which against Consultant the Company or GP ever had, now has, or hereinafter can, shall, or may have, for, upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time to the Effective Date, other than Claims relating to the enforcement of the provisions of this Agreement.

Section 10. No Suits.

Consultant represents and warrants that he has never commenced or filed and covenants and agrees never to commence, file or in any way prosecute or cause to be commenced or prosecuted against the Releasees or any of them, any action, charge, complaint or other proceedings, whether administrative, judicial, legislative or otherwise, including, but not limited to, any action or proceeding for damages, attorney's fees, disbursements, costs or equitable relief based upon or seeking relief on account of actions or failures to act by the Releasees which may have occurred or failed to occur prior to the Effective Date, other than in connection with Unreleased Claims. Consultant agrees that in the event he files any charge, complaint or commences any litigation of any kind that is covered by this Agreement, he shall pay all of the reasonable attorneys' fees, expenses and costs incurred by Releasees in responding to such action, including, but not limited to, any consequential damages that Releasees, or any of them, may suffer or incur. Consultant further represents that he will not aid, abet or assist in any manner whatsoever any other third party in filing, pursuing or maintaining any lawsuit, complaint, or charge against any of the Releasees, except if compelled to do so by valid legal process or if otherwise required to do so by law. The provisions of this Paragraph 11 shall be inapplicable in any matters regarding the ADEA, should Consultant allege in good faith that the waiver herein of his right to file an ADEA claim was not knowing and voluntary.

Section 11. Knowing and Voluntary Waiver.

(a) Consultant agrees that this Agreement constitutes a knowing and voluntary waiver of all Claims, other than the Unreleased Claims, Consultant may have against the Releasees, or any of them, including, but not limited to, all rights or claims arising under the ADEA, including, but not limited to, all claims of age discrimination in employment and all claims of retaliation in violation of the ADEA.

(b) This Agreement shall not affect the rights and responsibilities of the Equal Employment Opportunity Commission (the "EEOC") to enforce the ADEA and other laws. Notwithstanding paragraph 10 above, this Agreement shall not be used to justify interfering with Consultant's right to file a charge with the EEOC or participate in an investigation or proceeding by the EEOC. However, should any charge be filed with the EEOC, Consultant expressly waives all rights or claims which arose prior to his execution of this Agreement that he may have against the Releasees, or any of them, to receive any benefit or remedial relief (including, but not limited to, reinstatement, back pay, front pay, damages, and attorneys' fees) as a consequence of such EEOC filing, and of any litigation concerning any facts alleged in any such charge.

8

(c) The Company, GP, and Consultant agree that, for a period of seven days following his execution of this Agreement ("Revocation Period"), Consultant has the right to revoke this Agreement by delivering notice in writing of such revocation to the Company and GP. If Consultant gives such notice of revocation within the Revocation Period, this Agreement shall be null and void. If no such notice of revocation is delivered by Consultant within the Revocation Period, this Agreement will be deemed fully effective and enforceable on the eighth day after its execution by Consultant ("Effective Date").

(d) The Company and GP hereby advise Consultant to consult with his attorney prior to executing this Agreement. Consultant further acknowledges that the Company and GP have given him a period of at least 21 days in which to consider this Agreement before executing this Agreement.

(e) Consultant's acceptance of the payments and benefits described above, at any time subsequent to seven days after his execution of this Agreement, shall constitute an admission by Consultant that he did not revoke this Agreement during the Revocation Period of seven days, and shall further constitute an admission by Consultant that this Agreement has become effective and enforceable.

(f) If Consultant executed this Agreement at any time prior to the end of the 21 day period that the Company and GP gave him in which to consider this Agreement, such early execution was a knowing and voluntary waiver of Consultant's right to consider this Agreement for at least 21 days, and was due to Consultant's belief that he had ample time in which to consider and understand this Agreement, and in which to review this Agreement with his attorney.

Section 12. Non-Admission of Wrongdoing.

This Agreement shall not in any way be construed as an admission by the Company or GP of any liability, or of any unlawful, discriminatory, or otherwise wrongful acts whatsoever against the Consultant or any other person.

Section 13. Acknowledgment of Full Payments.

Consultant agrees that the Company has paid to him all of the wages, commissions, bonuses and accrued vacation pay through the date of his execution of this Agreement and that neither the Company nor GP owes no other wages, commissions, bonuses, vacation pay, employee benefits, severance payments or other compensation or payments of any kind or nature, other than as provided in this Agreement.

Section 14. Binding Agreement.

9

Except as expressly permitted hereby, Consultant's rights and obligations under this Agreement shall not be transferable by assignment or otherwise, such rights shall not be subject to commutation, encumbrance, or the claims of Consultant's creditors, and any attempt to do any of the foregoing shall be void. The provisions of this Agreement shall be binding upon and inure to the benefit of Consultant and his personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, and legatees, shall be binding upon and inure to the benefit of the Company and its successors, and shall be binding upon and inure to the benefit of GP and its successors. If Consultant should die while any amounts would still be payable to him hereunder if he had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Consultant's devisee, legatee, or other designee or, if there be no such designee, to Consultant's estate. Notwithstanding anything to the contrary contained herein, GP shall have no responsibility for the obligations of the Company hereunder.

Section 15. No Third Party Beneficiaries.

This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement (except as provided in Section 14).

Section 16. Modification.

This Agreement sets forth the entire understanding of the parties with respect to the subject matter hereof, supersedes all existing agreements between them concerning such subject matter, and may be modified only by a written instrument duly executed by each party.

Section 17. Notices.

Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified mail, return receipt requested, or by Federal Express, Express Mail, or similar overnight delivery or courier service or delivered (in person or by telecopy, telex, or similar telecommunications equipment) against receipt to the party to whom it is to be given at the address of such party set forth in the preamble to this Agreement (or to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 17). Notice to the estate of Consultant shall be sufficient if addressed to Consultant as provided in this
Section 17. Any notice or other communication given by certified mail shall be deemed given at the time of certification thereof, except for a notice changing a party's address which shall be deemed given at the time of receipt thereof. Any notice given by other means permitted by this Section 18 shall be deemed given at the time of receipt thereof.

Section 18. Waiver.

10

Any waiver by any party of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a party to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. Any waiver must be in writing.

Section 19. Headings.

The headings in this Agreement are solely for the convenience of reference and shall be given no effect in the construction or interpretation of this Agreement.

Section 20. Counterparts; Governing Law.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. It shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to conflict of laws.

Section 21. Acknowledgment.

CONSULTANT EXPRESSLY ACKNOWLEDGES, REPRESENTS, AND WARRANTS THAT HE HAS CAREFULLY READ THIS AGREEMENT; THAT HE FULLY UNDERSTANDS THE TERMS, CONDITIONS, AND SIGNIFICANCE OF THIS AGREEMENT; THAT HE HAS HAD AMPLE TIME TO CONSIDER AND NEGOTIATE THIS AGREEMENT; THAT THE COMPANY AND GP HAVE ADVISED HIM TO CONSULT WITH AN ATTORNEY CONCERNING THIS AGREEMENT; THAT HE HAS HAD A FULL OPPORTUNITY TO AND HAS IN FACT REVIEWED THIS AGREEMENT WITH HIS ATTORNEY, AND THAT HE HAS EXECUTED THIS AGREEMENT VOLUNTARILY, KNOWINGLY, AND WITH SUCH ADVICE OF COUNSEL AS HE HAS DEEMED APPROPRIATE.

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first above written.

MXL INDUSTRIES, INC.

By:

Name:


Title:

Frank Yohe

GUARANTY OF CONSULTING AND SEVERANCE AGREEMENT

The undersigned guarantees the obligations of MXL Industries, Inc. solely with respect to its obligations under Sections 3, 4, 6 and 7 of this Agreement.

NATIONAL PATENT DEVELOPMENT CORPORATON

By:

Name:


Title: